0001144204-12-062448.txt : 20121114 0001144204-12-062448.hdr.sgml : 20121114 20121114154524 ACCESSION NUMBER: 0001144204-12-062448 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121114 DATE AS OF CHANGE: 20121114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 121204139 BUSINESS ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 v326313_10q.htm

FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission file number 0-21617

ProPhase Labs, Inc.

(Exact name of registrant as specified in its charter)

Nevada		23-2577138
(State or other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

621 N. Shady Retreat Road, Doylestown, Pennsylvania 18901

(Address of principal executive office) (Zip Code)

(215) 345-0919

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (See definition of “large accelerated filer”, "accelerated filer”, “non-accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer ¨ Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at November 13, 2012
Common Stock, $0.0005 par value		14,836,340

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

		PAGE
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of September 30, 2012 (unaudited) and December 31, 2011	3

	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2012 and 2011 (unaudited)	4

	Condensed Consolidated Statement of Stockholders’ Equity for the Nine Months Ended September 30, 2012 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2012 and 2011 (unaudited)	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30

Item 4.	Controls and Procedures	30

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	32

Signatures		33

Certifications

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	September 30, 2012			December 31, 2011
	(unaudited)
ASSETS
Cash and cash equivalents (Note 2)	$	1,815		$	5,541
Accounts receivable (net of $37 and zero, respectively)		4,172			3,219
Inventory, net (Note 2)		3,414			2,688
Prepaid expenses and other current assets		1,104			1,747
Total current assets		10,505			13,195

Intangible asset, licensed technology (Note 3)		3,577			3,577

Property, plant and equipment, net of accumulated depreciation of $3,796 and $3,608, respectively (Note 2)		2,452			2,307
	$	16,534		$	19,079

LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES:
Accounts payable	$	537		$	885
Accrued royalties (Note 4)		3,524			3,524
Accrued advertising and other allowances		2,143			2,959
Other current liabilities		439			485
Total current liabilities		6,643			7,853

Commitments and contingencies (Note 4)		-			-

STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000; issued: 20,172,393 and 20,161,636 shares, respectively		10			10
Additional paid-in-capital		41,760			41,552
Accumulated deficit		(6,242	)		(4,699	)
Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively		(25,637	)		(25,637	)
Total stockholders' equity		9,891			11,226
	$	16,534		$	19,079

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended				Nine Months Ended
	September 30, 2012		September 30, 2011		September 30, 2012			September 30, 2011

Net sales (Note 2)	$	5,415	$	5,083	$	13,328		$	9,992

Cost of sales (Note 2)		2,016		1,487		4,763			3,508

Gross profit		3,399		3,596		8,565			6,484

Operating expenses:
Sales and marketing		1,035		1,158		5,032			3,376
Administration		1,126		1,134		4,027			3,417
Research and development		165		198		1,055			594
		2,326		2,490		10,114			7,387

Income (loss) from operations		1,073		1,106		(1,549	)		(903	)

Interest and other income		1		4		6			26

Income (loss) before income taxes		1,074		1,110		(1,543	)		(877	)

Income tax (benefit) (Note 6)		-		-		-			-

Net income (loss)	$	1,074	$	1,110	$	(1,543	)	$	(877	)

Basic income (loss) per share:
Net income (loss)	$	0.07	$	0.07	$	(0.10	)	$	(0.06	)

Diluted income (loss) per share:
Net income (loss)	$	0.07	$	0.07	$	(0.10	)	$	(0.06	)

Weighted average common shares outstanding:
Basic		14,836		15,113		14,804			14,901
Diluted		14,981		15,113		14,804			14,901

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of

Stockholders’ Equity

(in thousands, except share data)

(unaudited)

	Common Stock				Additional
	Shares		Par		Paid-In		Accumulated			Treasury
	Outstanding		Value		Capital		Deficit			Stock			Total

Balance at December 31, 2011		14,825,583	$	10	$	41,552	$	(4,699	)	$	(25,637	)	$	11,226

Net loss		-		-		-		(1,543	)		-			(1,543	)

Share-based compensation expense		-		-		115		-			-			115

Common stock granted pursuant to employment agreements		10,757		-		93		-			-			93

Balance at September 30, 2012		14,836,340	$	10	$	41,760	$	(6,242	)	$	(25,637	)	$	9,891

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Nine Months Ended
	September 30, 2012			September 30, 2011
Cash flows from operating activities:
Net loss	$	(1,543	)	$	(877	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization		188			297
Share-based compensation expense		208			316
Bad debt expense		37			-
Gain on sale of asset		-			(28	)
Changes in operating assets and liabilities:
Accounts receivable		(990	)		402
Inventory		(726	)		(1,836	)
Accounts payable		(348	)		237
Accrued advertising and other allowances		(816	)		(605	)
Other operating assets and liabilities, net		597			(951	)
Net cash used in operating activities		(3,393	)		(3,045	)

Cash flows from investing activities:
Capital expenditures		(333	)		(288	)
Proceeds from the sale of fixed assets		-			166
Net cash flows used in investing activities		(333	)		(122	)

Cash flows from financing activities:
Purchase of treasury stock		-			(449	)
Net cash used in financing activities		-			(449	)

Net decrease in cash and cash equivalents		(3,726	)		(3,616	)

Cash and cash equivalents at beginning of period		5,541			8,232

Cash and cash equivalents at end of period	$	1,815		$	4,616

Supplemental disclosures of cash flow information:
Common stock issued in lieu of cash, as payment of accrued compensation	$	-		$	294

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Business

ProPhase Labs, Inc (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplements, personal care and cosmeceutical products.

Our primary business is currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZE^Ò is an established product in the health care and cold remedy market. For the three and nine months ended September 30, 2012 and 2011, our revenues from operations have come principally from our OTC cold remedy products.

We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2012 shall be the term “Fiscal 2012” and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term the “we”, “us: or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines and retail customers’ balance their inventory positions as cold season consumer demand subsides. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Òlozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® lozenges, we market and distribute Cold-EEZE^®Oral Spray, Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelts^® and Kids-EEZE^® soft chew children’s OTC cold remedies (“Kids-EEZE^® Products”). We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Oral Spray products, Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelts^®, Kids-EEZE^® Products and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At September 30, 2012 and December 31, 2011, inventory included raw material, work in progress and packaging amounts of $1.4 million and $981,000 respectively, and finished goods of $2.0 million and $1.7 million, respectively.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - fifteen to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Concentration of Risks

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedyproducts are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2012, our cash balance was $1.8 million and our bank balance was $2.4 million. Of the total bank balance, $766,000 was covered by federal depository insurance and $1.6 million was uninsured at September 30, 2012.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large wholesalers, mass merchandisers and multi-outlet pharmacy and chain drug stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Our largest accounts receivable balances are with five customers representing approximately 68.3% and 52.7% of total trade receivable balances at September 30, 2012 and December 31, 2011, respectively. Three of such customers represented approximately 56.2% of total trade receivable balances at September 30, 2012. Two of such customers represented approximately 34.4% of total trade receivable balances at December 31, 2011, respectively.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 92% and 95% of total revenues for the nine months ended September 30, 2012 and 2011, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and nine months ended September 30, 2012 and 2011, our net sales were principally related to domestic markets.

Raw materials used in the production of our products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE^® products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable to supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of fair value of related party payables, if any, is not practicable due to their related party nature.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

As of September 30, 2012 and December 31, 2011, we included a provision for sales allowances of $93,000 and $101,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of $37,000 and zero as of September 30, 2012 and December 31, 2011, respectively. Additionally, accrued advertising and other allowances as of September 30, 2012 included $1.3 million for estimated future sales returns and $822,000 for cooperative incentive promotion costs. As of December 31, 2011 accrued advertising and other allowances included $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions.

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended September 30, 2012 and 2011, we charged to operations $45,000 and $125,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the nine months ended September 30, 2012 and 2011, we charged to operations $208,000 and $316,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest Entity

On March 22, 2010, the Company, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010. Expenses incurred to date by the Joint Venture have been principally for certain product research and development activities which have been charged to research and development expense by the Company.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense, cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for the three months ended September 30, 2012 and 2011 were $1.3 million and $1.7 million, respectively. Advertising and incentive promotion costs incurred for the nine months ended September 30, 2012 and 2011 were $5.5 million and $3.9 million, respectively. Included in prepaid expenses and other current assets was $947,000 and $1.2 million at September 30, 2012 and December 31, 2011, respectively, relating to prepaid advertising and promotion expenses.

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended September 30, 2012 and 2011 were $165,000 and $198,000, respectively. Research and development costs for the nine months ended September 30, 2012 and 2011 were $1.0 million and $594,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 6).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2004 through 2011 remain open to examination by the major taxing jurisdictions to which we are subject.

Recently Issued Accounting Standards

In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,” (“ASU 2011-05”) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders’ equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal periods beginning after December 15, 2011. The adoption of ASU 2011-05 did not have a material impact on our consolidated financial position, results of operations or cash flows.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other Topics” (“ASU 2011-08”) which provides authoritative guidance on testing goodwill for impairment that became effective beginning January 1, 2012, with earlier adoption permitted. The revised standards are intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of ASU 2011-08 did not have a material impact on our consolidated financial position, results of operations or cash flows.

In July 2012, the FASB provided further guidance pertaining to the testing of goodwill for impairment with the issuance of Accounting Standards Update No. 2012-05, “Intangibles – Goodwill and Other Topics” (“ASU 2012-02”). The new guidance gives the option to first assess qualitative factors to determine if it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative valuation test. The new standard is effective for fiscal years beginning on or after September 15, 2012. We will adopt this accounting standard in the fourth quarter of Fiscal 2012 and we do not anticipate that this adoption will have a significant impact on our financial position, results of operations or cash flows.

Note 3 – Investment in Phusion Laboratories, LLC.

Our Joint Venture was formed to develop and commercialize for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM. Pursuant to a License Agreement, dated March 22, 2010, as amended (the “Amended License Agreement”), with PSI Parent, our Joint Venture obtained, (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug. Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent and made a one-time payment to PSI Parent of $1.0 million. In September 2011, PSI Parent sold, with our consent, an aggregate of 750,000 shares of our Common Stock to various third parties. Contemporaneously, we entered into a redemption agreement with PSI Parent. Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by PSI Parent for the aggregate redemption price of $448,500 in cash. The redemption price was equal to $0.65 per share and the 690,000 shares were added to our treasury stock.

Pursuant to the LLC Agreement, PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and product analysis. At September 30, 2012, cash and equivalents includes $388,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Investment in Phusion Laboratories, LLC. – continued

The $3.6 million payment made in March 2010 represents the estimated fair value to acquire the product license and is recorded as an intangible asset. We currently estimate the expected useful life of the product license to be approximately 10 years which we will begin amortizing the cost of intangible asset once product commercialization is completed with PSI Parent and the OTC drug products begin to ship to our retail customers.

The product development effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi) retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These studies are expected to be completed later in Fiscal 2012. For Fiscal 2011 and through September 30, 2012, expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of September 30, 2012, we have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any specific OTC product covered under the product license but we do not project that any such OTC products will be available for shipment within the next twelve months.

Note 4 – Commitments and Contingencies

We had maintained a separate representation and distribution agreement relating to the development of the zinc gluconate product formulation. In return for exclusive distribution rights, we agreed to pay the developer a 3% royalty and a 2% consulting fee based on sales collected, less certain deductions, throughout the term of this agreement, which expired in May 2007. However, we and the developer are in litigation and as such no potential offset from such litigation for these fees have been recorded. The amount accrued for this expense at each of September 30, 2012 and December 31, 2011 is $3.5 million.

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2012, as follows (in thousands):

Fiscal Year	Employment Contracts
2012	$	256
2013		1,025
2014		1,025
2015		555
2016		-
2017		-
Total	$	2,861

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 5 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was amended effective May 23, 2008 and further amended effective August 18, 2009. The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is September 25, 2018.

The 1997 Option Plan

On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the three month or nine month period ended September 30, 2012 or September 30, 2011, respectively.

As of December 31, 2011, we are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At September 30, 2012, there are 99,000 options outstanding under the 1997 Plan with various expiration dates ranging from October 2013 through December 2015, depending upon the date of grant.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 5 – Transactions Affecting Stockholders’ Equity – continued

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 (the “2010 Equity Compensation Plan”). The 2010 Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options (defined below) but unissued under the 1997 Plan, an aggregate of 1.8 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made; however, as of March 31, 2010, there remained 1,449,750 shares subject to vested options that were authorized for issuance (the “Issued Options”) but were unissued under the 1997 Plan. As of September 30, 2012, 1,350,750 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the “Expired Options”). As a consequence, these options are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 450,750 options are deemed cancelled. For the three months and nine months ended September 30, 2012, no options were granted pursuant to the 2010 Equity Compensation Plan. For the three months and nine months ended September 30, 2011, we granted 524,329 options, to employees pursuant to the 2010 Equity Compensation Plan. At September, 30, 2012, there are 13,659 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 250,000. No shares were granted under this plan for the three months and nine months ended September 30, 2012. For the three months and nine months ended September 30, 2011 we issued 49,160 and 114,010 shares, respectively, of our Common Stock valued at $41,000 and $122,000, respectively, for share-based director compensation expense. At September 30, 2012, there are 17,605 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

Stock Option Exercises and Other Grants

Pursuant to the terms of Robert V. Cuddihy, Jr.’s, our Chief Operating Officer and Chief Financial Officer, initial employment agreement dated August 19, 2009 which terminated effective January 1, 2012, Mr. Cuddihy received an annual grant of shares of Common Stock that is equal to $50,000, payable quarterly, promptly following the close of each quarter calculated based on the average closing price of our Common Stock for the last five (5) trading days of the quarter. For the three months and nine months ended September 30, 2011 Mr. Cuddihy earned 15,665 shares and 40,885 shares, respectively, valued at $12,500 and $37,500, respectively, as share-based compensation. In January 2012, we issued to Mr. Cuddihy 10,757 shares valued at $12,500 that were earned in Fiscal 2011 as share-based compensation pursuant to the terms of the initial employment agreement.

There were no stock options exercised for the three months or nine months ended September 30, 2012 or September 30, 2011.

Note 6 – Income Taxes

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 6 – Income Taxes - continued

Certain exercises of options and warrants, and restricted stock issued for services that became unrestricted resulted in reductions to taxes currently payable and a corresponding increase to additional-paid-in-capital for prior years. In addition, certain tax benefits for option and warrant exercises totaling $6.3 million are deferred and will be credited to additional-paid-in-capital when our net operating loss carry-forward attributable to these exercises are utilized. Consequently, these net operating loss carryforward will not be available to offset our current income tax expense. As of December 31, 2011, we had net operating loss carry-forwards of approximately $31.6 million for federal purposes that will expire beginning in Fiscal 2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes that will expire beginning Fiscal 2018 through 2031. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, we have recorded a full valuation allowance equaling the total deferred tax asset at September 30, 2012 and December 31, 2011. As of September 30, 2012 and December 31, 2011, we have no unrecognized tax benefits.

The major jurisdiction for which we file income tax returns is the United States. The Internal Revenue Service (“IRS”) has examined our tax year ended September 30, 2005 and has made no changes to the filed tax returns. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.

Note 7 – Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilizes the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at September 30, 2012 and 2011 were 1,293,000 and 1,281,250, respectively.

For the nine months ended September 30, 2012 and 2011, dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the nine months ended September 30, 2012 and 2011, there were 86,328 and 53,517 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation. For the three months ended September 30, 2012, there were 144,943 Common Stock Equivalents, which were in the money, that were included in the earnings per share computation. For the three months ended September 30, 2011, there were zero Common Stock Equivalents which were in the money, that were excluded from the earnings per share computation.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 7 – Earnings (Loss) Per Share – continued

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

	Three Months Ended						Three Months Ended						Nine Months Ended								Nine Months Ended
	September 30, 2012						September 30, 2011						September 30, 2012								September 30, 2011
	Income		Shares		EPS		Income		Shares		EPS		Loss			Shares		EPS			Loss			Shares		EPS
Basic earnings (loss) per share	$	1,074		14,836	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,804	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

Dilutives:
Options		-		145		-		-		-		-		-			-		-			-			-		-

Diluted loss per share	$	1,074		14,981	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,804	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations.

General

ProPhase Labs, Inc. (“we”, “us”, “ProPhase” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplements, personal care and cosmeceutical products.

Our primary business is currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of the common cold symptoms by nearly half. Cold-EEZE^Ò is an established product in the health care and cold remedy market. For the nine months ended September 30, 2012 and 2011, our revenues from operations have come principally from our OTC cold remedy products.

Recent Developments

In a letter dated May 29, 2012, ProPhase received an expression of interest and a non-binding proposal to be acquired by a to-be-formed affiliate of Matrixx Initiatives, Inc. ("Matrixx"). At a meeting of the Board of Directors held on June 28, 2012, the Company’s Board of Directors, after careful consideration and consultation with its advisors, unanimously voted to reject the Matrixx proposal. Matrixx is the owner of the Zicam^® brand of cold and allergy products and is a direct competitor to ProPhase's Cold-EEZE^® Cold Remedy product line.

In a letter to ProPhase dated September 6, 2012, Matrixx then repeated its non-binding proposal on the same terms as its May 29, 2012 letter to ProPhase. Matrixx repeated the identical non-binding proposal in a September 14, 2012 letter. The Matrixx September 14, 2012 letter was attached to the report on Schedule 13D filed by Matrixx on September 14, 2012.

On September 4, 2012, Matrixx purchased for $200,000 a three year option to acquire 1,453,427 shares of the Company’s common stock for $1.40 per share from Guy J. Quigley, ProPhase’s former Chairman and Chief Executive Officer. Matrixx also acquired from Mr. Quigley a voting proxy to vote the shares subject to the option. The Company learned of Matrixx’s transactions with Mr. Quigley through the filing by Mr. Quigley of reports on Form 4 and Schedule 13-D filed with the SEC.

On October 9, 2012, ProPhase received a revised non-binding proposal, on essentially the same terms as Matrixx's earlier offer, except that in this latest proposal Matrixx raised the proposed price by $0.20 per share. In response, the Company again sought advice from its independent financial advisors. At a meeting held on October 24, 2012, the Company's Board of Directors unanimously voted to reject this latest Matrixx proposal after careful consideration and consultation with its advisors.

In evaluating the Matrixx revised proposal, the Board unanimously determined, among other things, that:

The non-binding Matrixx proposal undervalues ProPhase’s current business and future prospects.

The Matrixx proposal does not adequately reflect the true value of ProPhase’s unique market position, business opportunities and new product launches. The Board believes that the Company’s recent and potential future revenue growth will result in superior value to that offered by Matrixx in a sale transaction.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

The Matrixx proposal is conditioned upon Matrixx being permitted access to non-public and confidential ProPhase information. Even if Matrixx were to sign a confidentiality agreement, there is undue risk to ProPhase in disclosing confidential information to one of its largest and most aggressive competitors.

The interests of ProPhase’s stockholders will be best served by the Company continuing to pursue its independent strategic plan. The Company has made substantial investments in its Cold-EEZE^® brand and believes that shareholders should be given the opportunity to realize a return on these investments.

Furthermore, we have implemented a business and marketing strategy designed to deliver superior results to our stockholders over the long term. First, we preserved the Cold-EEZE^® brand, then we repositioned the brand, and now we are growing and leveraging the brand. As we have consistently explained to our shareholders, it remains our view that by investing in our Cold-EEZE^® brand, we are building our distribution platform and pipeline, which has led to securing increased shelf space with our retailers for the upcoming cold season, and which has provided us with the opportunity to introduce new and improved products, including the national launch of Cold-EEZE^® Oral Spray and Cold-EEZE^® Daytime/Nighttime QuickMelts^® for the upcoming cold season. The extra $0.20 per share that Matrixx has tacked on to its prior inadequate offer does not alter our Board’s view that the current shareholders of the Company should benefit from the upside created by our current strategies, not the private equity owners of one of our primary competitors

It is understood that Matrixx’s goal, like that of any suitor, is to buy our shares at the lowest possible price, which is why Matrixx has acquired the right to buy 1,453,427 shares at $1.40 per share from another shareholder. Nevertheless, our Board of Directors and management are disappointed that Matrixx resorted to publishing faulty arguments in their October 9, 2012 press release as to why the Company should be sold. The Matrixx tactic appears to be an attempt to coerce our shareholders, our Board and our management to accept an inadequate offer from Matrixx. Matrixx's fundamental assertion that ProPhase supposedly 'lacks the scale to effectively compete…' is demonstrably false, as evidenced by the most recent 52 week industry retail sales data (based on reported industry data for the cough cold category through the end of Q3 2012), which shows that even without including ProPhase's new products, our core Cold-EEZE^® Cold Remedy products continue to grow at double digit rates while sales of many of our competitor’s products, including Matrixx’s Zicam^® brand core cough/cold products, declined by double digits during the same time period. Matrixx’s desire to acquire ProPhase is therefore not surprising.

Management believes we are now beginning to realize the rewards for our efforts and clearly one of our competitors has taken notice. However, our Board continues to believe that the timing is not right to sell the Company for a number of reasons. Sales and shelf space of our flagship Cold-EEZE^® brand were in significant decline when new management took the helm in mid-2009, and now, after implementing a broad range of carefully developed strategies, our brand is gaining market share and growing nicely. Our new product introductions have been well received by the retail trade and we look forward to further expanding our product line next season. Our management team is committed to achieving our well planned and outlined longer term goals. If we stay the course, we believe that our shareholders will be well rewarded for their patience.

Certain Risk Factors

Our business is regulated by various agencies of the states and localities where our products are sold. Governmental regulations in foreign countries where we plan to commence or expand sales may prevent or delay entry into a market or prevent or delay the introduction, or require the reformulation of certain of our products. In addition, no prediction can be made as to whether new domestic or foreign legislation regulating our activities will be enacted. Any new legislation could have a material adverse effect on our business, financial condition and operations. Non-compliance with any applicable requirements may subject us or the manufacturers of our products to agency action, including warning letters, fines, product recalls, seizures and injunctions.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

The manufacturing, processing, formulation, packaging, labeling and advertising of our OTC cold remedy products are subject to regulation by several federal agencies, including (i) the Food and Drug Administration (“FDA”), (ii) the Federal Trade Commission (“FTC”), (iii) the Consumer Product Safety Commission, (iv) the United States Department of Agriculture, (v) the United States Postal Service, (vi) the United States Environmental Protection Agency and (vii) the United States Occupational Safety and Health Administration.

In addition to OTC and prescription drug products, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements, including vitamins, minerals and herbs, food additives, food supplements and cosmetics. The FTC also has overlapping jurisdiction with the FDA to regulate the promotion and advertising of vitamins, OTC drugs, cosmetics and foods. In addition, certain of our OTC cold remedy products are homeopathic remedies which are subject to standards established by the Homeopathic Pharmacopoeia of the United States (“HPUS”). HPUS sets the standards for source, composition and preparation of homeopathic remedies which are officially recognized under the Federal Food, Drug and Cosmetics Act, as amended.

Preclinical development, clinical trials, product manufacturing, labeling, distribution and marketing of potential new products are also subject to federal and state regulation in the United States and other countries. Clinical trials and product marketing and manufacturing are subject to the rigorous review and approval processes of the FDA and foreign regulatory authorities. To obtain approval of a new drug product, a company must demonstrate through adequate and well-controlled clinical trials that the drug product is safe and effective for its intended use. Obtaining FDA and other required regulatory approvals is lengthy and expensive. Typically, obtaining regulatory approval for pharmaceutical products requires substantial resources and takes several years. The length of this process depends on the type, complexity and novelty of the product and the nature of the disease or other indication to be treated. Preclinical studies must comply with FDA regulations. Clinical trials must also comply with FDA regulations to ensure safety of the human subjects in the trial and may require large numbers of test subjects, complex protocols and possibly lengthy follow-up periods. Consequently, satisfaction of government regulations may take several years, may cause delays in introducing potential new products for considerable periods of time and may require imposing costly procedures upon our activities. If regulatory approval of new products is not obtained in a timely manner or not at all, we could be materially adversely affected. Even if regulatory approval of new products is obtained, such approval may impose limitations on the indicated uses for which the products may be marketed which could also materially adversely affect our business, financial condition and future operations.

The Joint Venture is at its early stage of development where product and market research has been initiated and new product initiatives are being evaluated and prioritized for future development and commercialization. Prior to any new product being available for sale, substantial resources will have to be committed to commercialize a product which may include research, development, preclinical testing, clinical trials, manufacturing scale-up and regulatory approval. The Joint Venture may disrupt our ongoing operations, divert management from day-to-day responsibilities and increase our expenses.

We face significant technological risks inherent in developing these products. The Joint Venture may be subject to delays and/or ultimately unable to successfully implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented and proprietary TPM^TM that exploit certain compounds that embody the TPM^TM for use in a product combining one or more of such compounds with an OTC drug. The commercialization and ultimate product market acceptance is subject to, among other influences, consumer purchasing trends, demand for our OTC drug, health and wellness trends, regulatory factors, retail acceptance and overall economic and market conditions. As a consequence, we may suspend or abandon some or all of our proposed new products before they become commercially viable. Even if we develop and obtain approval of a new product, if we cannot successfully commercialize it in a timely manner, our business and financial condition may be materially adversely affected.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capability and the requirements associated with the development of potential OTC drug and other medicinal products in order to continue to compete on a national and international level. Our business development is dependent on continued conformity with government regulations, a reliable information technology system capable of supporting continued growth and continued reliable sources for product and materials to satisfy consumer demand. Many of our competitors have substantially greater capital resources, technical staffs, facilities, marketing resources, product development, distribution and experience than we do. As a consequence, our competitors may have certain advantages, including the ability to allocate greater resources for new product development, marketing and other purposes.

Readers should carefully review the risk factors described in other sections of this filing as well as in other documents we file from time to time with the Securities and Exchange Commission.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Our significant accounting policies are described in Note 2 of Notes to Condensed Consolidated Financial Statements included under Item 1 of this Part I. However, certain accounting policies are deemed “critical”, as they require management’s highest degree of judgment, estimates and assumptions. These accounting estimates and disclosures have been discussed with Audit Committee of our Board of Directors. A discussion of our critical accounting policies, the judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions are as follows:

Revenue Recognition – Sales Allowances

When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Òlozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® lozenges we market and distribute Cold-EEZE^®Oral Spray, Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelts^® and Kids-EEZE^® soft chew children’s OTC cold remedies (“Kids-EEZE^® Products”). We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Oral Spray products, Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelts^®, Kids-EEZE^® Products and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such item that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

We classify product returns into principally three categories, (i) non-routine returns, (ii) obsolete product and (iii) product mix realignment by certain of our customers. “Non-routine” returns are defined as product returned to us as a consequence of unanticipated circumstances principally due to (i) retail store closings or (ii) unexpected poor retail sell through to consumers causing us to discontinue the product. “Obsolete” returns are defined as product returned to us as a consequence of product shelf-life “use by” expiration date. “Product mix realignment” returns are defined as product returned to us due to initiatives by the trade to discontinue purchasing certain of our products. Product mix realignment returns are generally nominal and are frequently related to discontinued or soon to be discontinued products.

A one percent deviation for these Sales Allowance provisions for the three months ended September 30, 2012 and 2011 would affect net sales by approximately $66,000 and $68,000, respectively. A one percent deviation for these Sales Allowance provisions for the nine months ended September 30, 2012 and 2011 would affect net sales by approximately $162,000 and $127,000, respectively.

Income Taxes

As of December 31, 2011, we have net operating loss carry-forwards of approximately $31.6 million for federal purposes that will expire beginning in Fiscal 2020 through Fiscal 2031. Additionally, there are net operating loss carry-forwards of approximately $20.0 million for state purposes that will expire beginning in Fiscal 2018 through Fiscal 2031. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock are assured, a valuation allowance equaling the total deferred tax asset is being provided. Management believes that this allowance is required due to the uncertainty of realizing these tax benefits in the future. The uncertainty arises largely due to substantial marketing and research and development costs.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Seasonality of the Business

Our sales are derived principally from our OTC cold remedy products. As a consequence, a significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for our OTC cold remedy products with a corresponding increase in marketing and advertising expenditures designed to promote our products during the Cold Season (as defined below). In addition, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined in our industry as the period of September to March (“Cold Season”) when the incidence of the common cold rises as a consequence of the change in weather and other factors. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Financial Condition and Results of Operations

Results from Operations for the Three Months Ended September 30, 2012

as Compared to the Three Months Ended September 30, 2011

For the three months ended September 30, 2012, net sales were $5.4 million as compared to $5.1 million for the three months ended September 30, 2011. For the three months ended September 30, 2012, net sales of OTC cold remedy products were $5.1 million as compared to net sales of $4.9 million for three months ended September 30, 2011. For the three months ended September 30, 2012 and 2011, our contract manufacturing operations generated net sales to third party customers of $316,000 and $192,000, respectively.

Net sales of OTC cold remedy products remained stable for the three months ended September 30, 2012 as compared to the three months ended September 30, 2011 due to similar timing of shipments to retailers from period to period. The timing, stocking and ultimate level of demand of retailer purchases of our OTC cold remedy products are affected by the change in the timing and the comparative severity of the respective Cold Season as well as the effects of the timing and scope of our marketing and promotional efforts to increase consumer awareness and to influence purchase decisions.

Cost of sales for the three months ended September 30, 2012 were $2.0 million as compared to $1.5 million for the three months ended September 30, 2011. For the three months ended September 30, 2012 as compared to the three months ended September 30, 2011, we realized a gross margin of 62.8% and 70.7%, respectively. The decrease of 7.9% in gross margin is principally due (i) an increase in ingredient commodity costs incurred and (ii) an unfavorable variance in our manufacturing operations overhead absorption rate as a consequence of the timing of production and the product mix shipped to retailers during the three months ended September 30, 2012 as compared to the three months ended September 30, 2011. Gross margins are principally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, retail cooperative incentive promotion and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the three months ended September 30, 2012 decreased $123,000 to $1.0 million as compared to $1.2 million for the three months ended September 30, 2011. The decrease in sales and marketing expense for the three months ended September 30, 2012 as compared to the three months ended September 30, 2011 was due to a decrease in advertising expenditures.

General and administration expense for the three months ended September 30, 2012 were $1.1 million as compared to $1.1 million for the three months ended September 30, 2011 as we continued to control our general and administration expenses from period to period.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Research and development costs during the three months ended September 30, 2012 decreased $33,000 to $165,000, as compared to $198,000 for the three months ended September 30, 2011. The decrease in research and development costs for the three months ended September 30, 2012 as compared to the three months ended September 30, 2011 was due principally to a decrease in outside research expenditures. Additionally, we continue to engage in other market analysis, research and development activities that we determine are appropriate and we may increase our research and development activities in future periods as a consequence of the Joint Venture.

Interest and other income for the three months ended September 30, 2012 was $1,000 as compared to $4,000 for the three months ended September 30, 2011. The decrease of $3,000 for the three months ended September 30, 2012 as compared to the three months ended September 30, 2011 was the result of decreased bank balance and lower interest rates.

As a consequence of the effects of the above, the net income for the three months ended September 30, 2012, was $1.1 million or $0.07 per share, as compared to net income of $1.1 million or $0.07 per share, for the three months ended September 30, 2011.

Financial Condition and Results of Operations

Results from Operations for the Nine Months Ended September 30, 2012

as Compared to the Nine Months Ended September 30, 2011

For the nine months ended September 30, 2012, net sales were $13.3 million as compared to $10.0 million for the nine months ended September 30, 2011. For the nine months ended September 30, 2012, net sales of OTC cold remedy products were $12.3 million as compared to net sales of $9.5 million for nine months ended September 30, 2011. For the nine months ended September 30, 2012 and 2011, our contract manufacturing operations generated net sales to third party customers of $1.0 million and $536,000, respectively. Net sales of OTC cold remedy products increased $2.8 million for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011 due to the timing of shipments to retailers from period to period principally as a result of an increase in consumer demand during the 2011-2012 Cold Season as compared to the 2010-2011 Cold Season. We believe that consumer demand for our products increased as a consequence of our increased, targeted marketing investment in our Cold-EEZE^® Cold Remedy products during the 2011-2012 Cold Season as compared to 2010-2011 Cold Season. The timing, stocking and ultimate level of demand of our retailer purchases of our OTC cold remedy products are affected by the change in the timing and the comparative severity of the respective Cold Season as well as the effects of the timing and scope of our marketing and promotional efforts to increase consumer awareness and to influence purchase decisions.

Cost of sales for the nine months ended September 30, 2012 were $4.8 million as compared to $3.5 million for the nine months ended September 30, 2011. For the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011, we realized a gross margin of 64.3% and 64.9%, respectively. As a consequence of the increased sales volume, we realized certain production efficiencies and improved overhead expense absorption while our raw ingredient and packaging costs increase slightly from period to period. Gross margins are principally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, retail cooperative incentive promotion and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Sales and marketing expense for the nine months ended September 30, 2012 increased $1.7 million to $5.0 million as compared to $3.4 million for the nine months ended September 30, 2011. The increase in sales and marketing expense for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011 was principally due to an increase in advertising expenditures as we expanded the scope and timing of our media and product promotion advertising campaigns with the cold season from period to period as we continue to make significant, strategic marketing investments in an effort to build and grow the sales of our OTC cold remedy products.

General and administration expense for the nine months ended September 30, 2012 increased $610,000 to $4.0 million as compared to $3.4 million for the nine months ended September 30, 2011. The increase in general and administration expense for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011 was principally due to an increase in personnel expense and legal fees.

Research and development costs during the nine months ended September 30, 2012 increased $461,000 to $1.0 million, as compared to $594,000 for the nine months ended September 30, 2011. The increase in research and development costs for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011 was due principally to an increase in personnel expense and outside research expenditures. Additionally, we continue to engage in other market analysis, research and development activities that we determine are appropriate and we may increase our research and development activities in future periods as a consequence of the Joint Venture.

Interest and other income for the nine months ended September 30, 2012 was $6,000 as compared to $26,000 for the nine months ended September 30, 2011. The decrease of $20,000 for the nine months ended September 30, 2012 as compared to the nine months ended September 30, 2011 was the result of decreased bank balance and lower interest rates.

As a consequence of the effects of the above, the net loss for the nine months ended September 30, 2012, was $ 1.5 million or ($0.10) per share, as compared to a net loss of $877,000 or ($0.06) per share, for the nine months ended September 30, 2011.

Liquidity and Capital Resources

Our aggregate cash and cash equivalents as of September 30, 2012 were $1.8 million as compared to $5.5 million at December 31, 2011. Our working capital was $3.9 million and $5.3 million as of September 30, 2012 and December 31, 2011, respectively. Changes in working capital for the nine months ended September 30, 2012 were principally due to (i) the net loss of $1.5 million, (ii) our increase in amounts carried as accounts receivable of $990,000 and inventory of $726,000 as a consequence of the seasonality of our business and (ii) our reduction in accrued advertising and other allowances of $816,000.

As a consequence of our research and development initiatives, in July 2012 we launched our first-ever Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelt^® tablets. Each QuickMelt^® tablet dissolves quickly in your mouth without water and delivers the same amount of cold remedy (active ingredient zinc gluconate) found in our Cold-EEZE^® lozenges. The Cold-EEZE^Ò Daytime QuickMelts^® shorten your cold and are non-drowsy. The Cold-EEZE^Ò Nighttime QuickMelts^® are a combination product formulated to shorten your cold and also help you fall asleep faster, naturally and are non-habit forming. Retail acceptance for QuickMelts^®has been strong and we commenced shipments in July 2012. In addition to the QuickMelts’ nationwide availability, the Cold-EEZE^® Oral Spray, launched in August 2011, has gone from an initial distribution in the 2011-2012 Cold Season to full national distribution for the upcoming 2012-2013 Cold Season. Two sprays deliver the same amount of cold remedy (active ingredient zinc gluconate) as in one Cold-EEZE^® lozenge.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Management believes that its strategy to maintain Cold-EEZE^Ò as a recognized brand name, its broader range of products, its adequate manufacturing capacity, together with its current working capital, should provide an internal source of capital to fund normal business operations.

Our operations support the current research and development expenditures related to new products. In addition to the funding from operations, we may in the short and long term raise capital through the issuance of securities or secure other financing sources to support such product development research, new product acquisitions or a venture investment or acquisition. Such funding through the issuance of equity securities would result in the dilution of current stockholders’ ownership in the Company. Should our product development initiatives progress on certain formulations, additional development expenditures may require substantial financial support and may necessitate the consideration of alternative approaches such as licensing, joint venture, or partnership arrangements that we determine will meet our long term goals and objectives. Ultimately, should internal working capital be insufficient and external funding methods or other business arrangements become unattainable, it would likely result in the deferral or abandonment of future development relative to current and prospective product development initiatives and formulations.

Management is not aware of any trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity or (ii) net sales or income from continuing operations. Our business is subject to (i) seasonal variations, (ii) changes in the scope, timing and cost of our marketing campaigns and (iii) the retail and consumer acceptance of our new products such as the Cold-EEZE^® Cold Remedy Daytime/Nighttime QuickMelt^® tablets launched July 2012, thereby impacting liquidity and working capital during the course of our fiscal year.

Management believes that cash generated from operations, along with our current cash balances, will be sufficient to finance working capital and capital expenditure requirements to fund normal business operations for at least the next twelve months. However, we may require additional capital to support, among other items, (i) new product introductions, (ii) expansion of our product marketing and promotion activities, (iii) additional research development activities, (iv) further investment in our Joint Venture, (v) venture investments or acquisitions, and/or (vi) support current operations. Since late Fiscal 2008, there has been volatility in the capital and financial markets due at least in part to the constricted global economic environment resulting in uncertainty and access to financing is uncertain. Moreover, consumer and as a consequence, customer spending habits may be adversely affected by the current uncertain economic environment. These conditions could have an adverse effect on our industry and business, including our financial condition, results of operations and cash flows.

To the extent that we do not generate sufficient cash from operations, we may need to incur indebtedness to finance plans for growth. Volatility in the credit markets and the liquidity of major financial institutions may have an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly created instruments in the public or private markets on terms that we believe to be reasonable, if at all.

Capital Expenditures

Capital expenditures during the remainder of Fiscal 2012 are not expected to be material.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Recently Issued Accounting Standards

In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other Topics” (“ASU 2011-08”) which provides authoritative guidance on testing goodwill for impairment that became effective beginning January 1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of ASU 2011-08 did not have a material impact on our consolidated financial position, results of operations or cash flows.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward looking statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict. Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Report may contain forward-looking statements attributed to third parties relating to their estimates regarding the growth of our markets. You are cautioned that such forward looking statements are not guarantees of future performance and that all forward-looking statements address matters that involve risk and uncertainties, and there are many important risks, uncertainties and other factors that could cause our actual results, levels of activity, performance, achievements and prospects, as well as those of the markets we serve, to differ materially from the forward-looking statements contained in this Report.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Such risks and uncertainties include, but are not limited to:

The ability of our management to successfully implement our business plan and strategy;

Our ability to fund our operations including the cost and availability of capital and credit;

Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;

Our dependence on sales from our main product, Cold-EEZE^Ò Cold Remedy and our ability to successfully develop and commercialize new products, including our Cold-EEZE^Ò Oral Spray and our Cold-EEZE^Ò Daytime/Nighttime QuickMelts^Ò;

The uncertain length and severity of the current general financial and economic downturn, the timing and strength of an economic recovery, if any, and their impacts on our business including demand for our products;

Our ability to protect our proprietary rights;

Our continued ability to comply with regulations relating to our current products and any new products we develop, including our ability to effectively respond to changes in laws and regulations or the interpretation thereof including changing market rules and evolving federal, state and regional laws and regulations;

Potential disruptions in our ability to manufacture our products or our access to raw materials;

Seasonal fluctuations in demand for our products;

Our ability to attract, retain and motivate key employees;

The ability of our Joint Venture to successfully implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented and proprietary technology; and

Other risks identified in this Report.

You should also consider carefully the statements under other sections of this Report and our Annual Report on Form 10-K for the year ended December 31, 2011, which address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including due to a reduction in the availability of credit, financial market volatility and recession.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the disclosure controls and procedures as of the end of the period covered by this report. Based on our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company’s disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Report.

Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting. Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Our internal control over financial reporting includes those policies and procedures that:

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;

provide reasonable assurance that our transactions are recorded as necessary to permit preparation of our financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the nine months ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. Further, because of changes in conditions, effectiveness of internal controls over financial reporting may vary over time. Our system contains self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified.

Our management conducted an evaluation of our effectiveness of the system of internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company’s internal controls over financial reporting were effective as of September 30, 2012.

Part II. Other Information

Item 1. Legal Proceedings.

None

Item 1A. Risk Factors.

Not applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

None

Item 6. Exhibits

(1)	Exhibit 31.1	Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(2)	Exhibit 31.2	Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(3)	Exhibit 32.1	Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(4)	Exhibit 32.2	Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ProPhase Labs, Inc.

	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

Date: November 13, 2012

	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer
		(Principal Accounting and Financial Officer)

Date: November 13, 2012

EX-31.1 2 v326313_ex31-1.htm EX-31.1

EXHIBIT 31.1

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Ted Karkus, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;

Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2012

	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 v326313_ex31-2.htm EX-31.2

EXHIBIT 31.2

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert V. Cuddihy, Jr., certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2012

	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 4 v326313_ex32-1.htm EX-32.1

EXHIBIT 32.1

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
	(Principal Executive Officer)
	November 13, 2012

EX-32.2 5 v326313_ex32-2.htm EX-32.2

EXHIBIT 32.2

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert V. Cuddihy, Jr., Chief Financial Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Robert V. Cuddihy, Jr.
	Robert V. Cuddihy, Jr.
	Chief Operating Officer and Chief Financial Officer
	(Principal Accounting and Financial Officer)
	November 13, 2012

EX-101.INS 6 prph-20120930.xml XBRL INSTANCE DOCUMENT 0000868278 prph:Plan1997Member 2010-03-31 0000868278 prph:LimitedLiabilityCompanyAgreementMember 2010-03-01 2010-03-31 0000868278 2010-12-31 0000868278 2011-07-01 2011-09-30 0000868278 us-gaap:StockOptionsMember 2011-07-01 2011-09-30 0000868278 prph:CommonStockEquivalentsMember 2011-07-01 2011-09-30 0000868278 prph:ChiefOperatingOfficerAndChiefFinancialOfficerMember 2011-07-01 2011-09-30 0000868278 prph:Plan2010Member 2011-07-01 2011-09-30 0000868278 prph:DirectorsPlan2010Member 2011-07-01 2011-09-30 0000868278 2011-01-01 2011-09-30 0000868278 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000868278 prph:CommonStockEquivalentsMember 2011-01-01 2011-09-30 0000868278 prph:ChiefOperatingOfficerAndChiefFinancialOfficerMember 2011-01-01 2011-09-30 0000868278 prph:Plan2010Member 2011-01-01 2011-09-30 0000868278 prph:DirectorsPlan2010Member 2011-01-01 2011-09-30 0000868278 us-gaap:SalesRevenueGoodsNetMember 2011-01-01 2011-09-30 0000868278 2011-09-30 0000868278 prph:PsiParentMember 2011-09-01 2011-09-30 0000868278 2011-01-01 2011-12-31 0000868278 us-gaap:AccountsReceivableMember prph:FiveCustomerMember 2011-01-01 2011-12-31 0000868278 us-gaap:AccountsReceivableMember prph:TwoCustomerMember 2011-01-01 2011-12-31 0000868278 2011-12-31 0000868278 prph:EstimatedFutureSalesReturnMember 2011-12-31 0000868278 prph:CooperativeIncentiveMember 2011-12-31 0000868278 prph:OtherAdvertisingAndMarketingPromotionsMember 2011-12-31 0000868278 prph:AdvertisingAndIncentivePromotionCostsMember 2011-12-31 0000868278 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000868278 us-gaap:RetainedEarningsMember 2011-12-31 0000868278 us-gaap:CommonStockMember 2011-12-31 0000868278 us-gaap:TreasuryStockMember 2011-12-31 0000868278 2012-07-01 2012-09-30 0000868278 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0000868278 prph:CommonStockEquivalentsMember 2012-07-01 2012-09-30 0000868278 prph:Plan2010Member 2012-07-01 2012-09-30 0000868278 prph:DirectorsPlan2010Member 2012-07-01 2012-09-30 0000868278 2012-01-01 2012-09-30 0000868278 prph:Plan1997Member 2012-01-01 2012-09-30 0000868278 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000868278 prph:CommonStockEquivalentsMember 2012-01-01 2012-09-30 0000868278 prph:ChiefOperatingOfficerAndChiefFinancialOfficerMember 2012-01-01 2012-09-30 0000868278 prph:Plan2010Member 2012-01-01 2012-09-30 0000868278 prph:DirectorsPlan2010Member 2012-01-01 2012-09-30 0000868278 us-gaap:SalesRevenueGoodsNetMember 2012-01-01 2012-09-30 0000868278 prph:PsiParentMember 2012-01-01 2012-09-30 0000868278 us-gaap:AccountsReceivableMember prph:FiveCustomerMember 2012-01-01 2012-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-09-30 0000868278 us-gaap:RetainedEarningsMember 2012-01-01 2012-09-30 0000868278 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000868278 us-gaap:TreasuryStockMember 2012-01-01 2012-09-30 0000868278 us-gaap:CorporateJointVentureMember 2012-01-01 2012-09-30 0000868278 us-gaap:SoftwareMember 2012-01-01 2012-09-30 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000868278 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000868278 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000868278 us-gaap:FurnitureAndFixturesMember 2012-01-01 2012-09-30 0000868278 us-gaap:AccountsReceivableMember prph:ThreeCustomerMember 2012-01-01 2012-09-30 0000868278 2012-09-30 0000868278 prph:Plan1997Member 2012-09-30 0000868278 prph:ChiefOperatingOfficerAndChiefFinancialOfficerMember 2012-09-30 0000868278 prph:Plan2010Member 2012-09-30 0000868278 prph:DirectorsPlan2010Member 2012-09-30 0000868278 prph:EstimatedFutureSalesReturnMember 2012-09-30 0000868278 prph:CooperativeIncentiveMember 2012-09-30 0000868278 prph:AdvertisingAndIncentivePromotionCostsMember 2012-09-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2012-09-30 0000868278 us-gaap:RetainedEarningsMember 2012-09-30 0000868278 us-gaap:CommonStockMember 2012-09-30 0000868278 us-gaap:TreasuryStockMember 2012-09-30 0000868278 us-gaap:CorporateJointVentureMember 2012-09-30 0000868278 us-gaap:EmploymentContractsMember 2012-09-30 0000868278 2012-11-13 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure ProPhase Labs, Inc. 0000868278 --12-31 Smaller Reporting Company prph 14836340 10-Q false 2012-09-30 Q3 2012

8232000

4616000

5541000

1815000

388000

3219000

4172000

2688000

3414000

1747000

1200000

1104000

947000

13195000

10505000

3577000

2307000

2452000

19079000

16534000

885000

537000

3524000

2959000

2143000

485000

439000

7853000

6643000

10000

41552000

41760000

-4699000

-6242000

25637000

11226000

41552000

-4699000

10000

-25637000

9891000

41760000

-6242000

10000

-25637000

19079000

16534000

3608000

3796000

0.0005

50000000

20161636

20172393

37000

5336053

5083000

9992000

5415000

13328000

1487000

3508000

2016000

4763000

3596000

6484000

3399000

8565000

1158000

3376000

1035000

5032000

1134000

3417000

1126000

4027000

198000

594000

165000

1055000

2490000

7387000

2326000

10114000

1106000

-903000

1073000

-1549000

4000

26000

1000

6000

1110000

-877000

1074000

-1543000

1110000

-877000

1074000

-1543000

0.07

-0.06

0.07

-0.10

15113 14901 14836 14804

14825583

14836340

115000

93000 93000 0 0 0 10757

297000

188000

125000

316000

45000

208000

28000

-402000

990000

1836000

726000

237000

-348000

-605000 -816000

951000

-597000

-3045000

-3393000

288000

333000

166000

-122000

-333000

449000

-449000

-3616000

-3726000

294000

Note 1 – Organization and Business   ProPhase Labs, Inc (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplements, personal care and cosmeceutical products.   Our primary business is currently the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZEÒ Cold Remedy and our principal product is Cold-EEZEÒ zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZEÒ is an established product in the health care and cold remedy market. For the three and nine months ended September 30, 2012 and 2011, our revenues from operations have come principally from our OTC cold remedy products.   We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2012 shall be the term “Fiscal 2012” and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term the “we”, “us: or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies   Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of operating results that may be achieved over the course of the full year.   Seasonality of the Business Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines and retail customers’ balance their inventory positions as cold season consumer demand subsides. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.     Use of Estimates The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.   Our primary product, Cold-EEZEÒ lozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE® lozenges we market and distribute Cold-EEZE® Oral Spray, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts® and Kids-EEZE® soft chew children’s OTC cold remedies (“Kids-EEZE® Products”). We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix®”). Each of the Cold-EEZE® Oral Spray products, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts®, Kids-EEZE® Products and Organix® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.   Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.   Inventory Valuation Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At September 30, 2012 and December 31, 2011, inventory included raw material, work in progress and packaging amounts of $1.4 million and $981,000 respectively, and finished goods of $2.0 million and $1.7 million, respectively.   Property, Plant and Equipment Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - fifteen to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.    Concentration of Risks Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC drug, personal care or other products in order to continue to compete on a national level and/or international level.   Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.   Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.   We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2012, our cash balance was $1.8 million and our bank balance was $2.4 million. Of the total bank balance, $766,000 was covered by federal depository insurance and $1.6 million was uninsured at September 30, 2012.   Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large wholesalers, mass merchandisers and multi-outlet pharmacy and chain drug stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Our largest accounts receivable balances are with five customers representing approximately 68.3% and 52.7% of total trade receivable balances at September 30, 2012 and December 31, 2011, respectively. Three of such customers represented approximately 56.2% of total trade receivable balances at September 30, 2012. Two of such customers represented approximately 34.4% of total trade receivable balances at December 31, 2011, respectively.   Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 92% and 95% of total revenues for the nine months ended September 30, 2012 and 2011, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and nine months ended September 30, 2012 and 2011, our net sales were principally related to domestic markets.   Raw materials used in the production of our products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE® products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable to supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.    Long-lived Assets We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.   Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.   Fair Value of Financial Instruments    Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of fair value of related party payables, if any, is not practicable due to their related party nature.   Revenue Recognition Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.   We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.   As of September 30, 2012 and December 31, 2011, we included a provision for sales allowances of $93,000 and $101,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of $37,000 and zero as of September 30, 2012 and December 31, 2011, respectively. Additionally, accrued advertising and other allowances as of September 30, 2012 included $1.3 million for estimated future sales returns and $822,000 for cooperative incentive promotion costs. As of December 31, 2011 accrued advertising and other allowances included $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions.   Shipping and Handling Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.   Stock Compensation We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.   Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended September 30, 2012 and 2011, we charged to operations $45,000 and $125,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the nine months ended September 30, 2012 and 2011, we charged to operations $208,000 and $316,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.   Variable Interest Entity On March 22, 2010, the Company, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010. Expenses incurred to date by the Joint Venture have been principally for certain product research and development activities which have been charged to research and development expense by the Company.   Advertising and Incentive Promotions Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense, cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for the three months ended September 30, 2012 and 2011 were $1.3 million and $1.7 million, respectively. Advertising and incentive promotion costs incurred for the nine months ended September 30, 2012 and 2011 were $5.5 million and $3.9 million, respectively. Included in prepaid expenses and other current assets was $947,000 and $1.2 million at September 30, 2012 and December 31, 2011, respectively, relating to prepaid advertising and promotion expenses.   Research and Development Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended September 30, 2012 and 2011 were $165,000 and $198,000, respectively. Research and development costs for the nine months ended September 30, 2012 and 2011 were $1.0 million and $594,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.   Income Taxes We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 6).   We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.   As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2004 through 2011 remain open to examination by the major taxing jurisdictions to which we are subject.   Recently Issued Accounting Standards In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,” (“ASU 2011-05”) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders’ equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal periods beginning after December 15, 2011. The adoption of ASU 2011-05 did not have a material impact on our consolidated financial position, results of operations or cash flows.    In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other Topics” (“ASU 2011-08”) which provides authoritative guidance on testing goodwill for impairment that became effective beginning January 1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of ASU 2011-08 did not have a material impact on our consolidated financial position, results of operations or cash flows.

Note 3 – Investment in Phusion Laboratories, LLC. Our Joint Venture was formed to develop and commercialize for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM. Pursuant to a License Agreement, dated March 22, 2010, as amended (the “Amended License Agreement”), with PSI Parent, our Joint Venture obtained, (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug. Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent and made a one-time payment to PSI Parent of $1.0 million. In September 2011, PSI Parent sold, with our consent, an aggregate of 750,000 shares of our Common Stock to various third parties.  Contemporaneously, we entered into a redemption agreement with PSI Parent. Under the terms of the redemption agreement, we redeemed 690,000 shares of our Common Stock held by PSI Parent for the aggregate redemption price of $448,500 in cash.  The redemption price was equal to $0.65 per share and the 690,000 shares were added to our treasury stock. Pursuant to the LLC Agreement, PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and product analysis. At September 30, 2012, cash and equivalents includes $388,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us. The $3.6 million payment made in March 2010 represents the estimated fair value to acquire the product license and is recorded as an intangible asset. We currently estimate the expected useful life of the product license to be approximately 10 years which we will begin amortizing the cost of intangible asset once product commercialization is completed with PSI Parent and the OTC drug products begin to ship to our retail customers. The product development effort of the Joint Venture is a multi-stage process that includes (i) market analysis and research, (ii) product formulation research and development, (iii) product evaluation, (iv) product commercialization, (v) production and distribution, and (vi) retail and consumer advertising and marketing. During Fiscal 2011, we conducted preliminary market analysis to identify market opportunities to develop differentiated, science-based, efficacious products that deliver results to consumers and worked with PSI and PSI Parent to provide initial formulations for certain identified OTC active ingredients. In December 2011, we initiated a study of these preliminary formulations to evaluate product attributes, performance and potential commercial viability. These studies are expected to be completed later in Fiscal 2012. For Fiscal 2011 and through September 30, 2012, expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. As of September 30, 2012, we have not established a formal commercialization program timeline, pending the results of the recently initiated studies, for any specific OTC product covered under the product license but we do not project that any such OTC products will be available for shipment within the next twelve months.

Note 4 – Commitments and Contingencies   We had maintained a separate representation and distribution agreement relating to the development of the zinc gluconate product formulation. In return for exclusive distribution rights, we agreed to pay the developer a 3% royalty and a 2% consulting fee based on sales collected, less certain deductions, throughout the term of this agreement, which expired in May 2007. However, we and the developer are in litigation and as such no potential offset from such litigation for these fees have been recorded. The amount accrued for this expense at each of September 30, 2012 and December 31, 2011 is $3.5 million.   We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2012, as follows (in thousands):   <table align="center" style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center;">Fiscal Year</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Employment Contracts</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: center; width: 73%;">2012</td> <td style="width: 3%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 22%;">256</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: center;">2013</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,025</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: center;">2014</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,025</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: center;">2015</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">555</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: center;">2016</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: center; padding-bottom: 1pt;">2017</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: right; padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">2,861</td> <td style="text-align: left; padding-bottom: 2.5pt;"></td> </tr> </table>

Note 5 – Transactions Affecting Stockholders’ Equity   Stockholder Rights Plan On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was amended effective May 23, 2008 and further amended effective August 18, 2009. The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is September 25, 2018.    The 1997 Option Plan On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the three month or nine month period ended September 30, 2012 or September 30, 2011.   As of December 31, 2011, we are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At September 30, 2012, there are 99,000 options outstanding under the 1997 Plan with various expiration dates ranging from October 2013 through December 2015, depending upon the date of grant.   The 2010 Equity Compensation Plan On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 (the “2010 Equity Compensation Plan”). The 2010 Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options (defined below) but unissued under the 1997 Plan, an aggregate of 1.8 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made; however, as of March 31, 2010, there remained 1,449,750 shares subject to vested options that were authorized for issuance (the “Issued Options”) but were unissued under the 1997 Plan. As of September 30, 2012, 1,331,000 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the “Expired Options”). As a consequence, these options are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 431,000 options are deemed cancelled. For the three months and nine months ended September 30, 2012, no options were granted pursuant to the 2010 Equity Compensation Plan. For the three months and nine months ended September 30, 2011, we granted 524,329 options, to employees pursuant to the 2010 Equity Compensation Plan. At September, 30, 2012, there are 13,659 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.   The 2010 Directors’ Equity Compensation Plan On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 250,000. No shares were granted under this plan for the three months and nine months ended September 30, 2012. For the three months and nine months ended September 30, 2011 we issued 49,160 and 114,010 shares, respectively, of our Common Stock valued at $41,000 and $122,000, respectively, for share-based director compensation expense. At September 30, 2012, there are 17,605 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.    Stock Option Exercises and Other Grants Pursuant to the terms of Robert V. Cuddihy, Jr.’s, our Chief Operating Officer and Chief Financial Officer, initial employment agreement dated August 19, 2009 which terminated effective January 1, 2012, Mr. Cuddihy received an annual grant of shares of Common Stock that is equal to $50,000, payable quarterly,promptly following the close of each quarter calculated based on the average closing price of our Common Stock for the last five (5) trading days of the quarter. For the three months and nine months ended September 30, 2011 Mr. Cuddihy earned 15,665 shares and 40,885 shares, respectively, valued at $12,500 and $37,500, respectively, as share-based compensation. In January 2012, we issued to Mr. Cuddihy 10,757 shares valued at $12,500 that were earned in Fiscal 2011 as share-based compensation pursuant to the terms of the initial employment agreement.   There were no stock options exercised for the three months or nine months ended September 30, 2012 or September 30, 2011.

Note 6 – Income Taxes We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided. We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Certain exercises of options and warrants, and restricted stock issued for services that became unrestricted resulted in reductions to taxes currently payable and a corresponding increase to additional-paid-in-capital for prior years. In addition, certain tax benefits for option and warrant exercises totaling $6.3 million are deferred and will be credited to additional-paid-in-capital when our net operating loss carry-forward attributable to these exercises are utilized. Consequently, these net operating loss carryforward will not be available to offset our current income tax expense. As of December 31, 2011, we had net operating loss carry-forwards of approximately $31.6 million for federal purposes that will expire beginning in Fiscal 2020 through 2031. Additionally, there are net operating loss carry-forwards of $20.0 million for state purposes that will expire beginning Fiscal 2018 through 2031. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, we have recorded a full valuation allowance equaling the total deferred tax asset at September 30, 2012 and December 31, 2011. As of September 30, 2012 and December 31, 2011, we have no unrecognized tax benefits. The major jurisdiction for which we file income tax returns is the United States. The Internal Revenue Service (“IRS”) has examined our tax year ended September 30, 2005 and has made no changes to the filed tax returns. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.

Note 7 – Earnings (Loss) Per Share   Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilizes the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at September 30, 2012 and 2011 were 1,293,000 and 1,281,250, respectively.   For the nine months ended September 30, 2012 and 2011, dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the nine months ended September 30, 2012 and 2011, there were 86,328 and 53,517 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation. For the three months ended September 30, 2012, there were 144,943 Common Stock Equivalents, which were in the money, that were included in the earnings per share computation. For the three months ended September 30, 2011, there were zero Common Stock Equivalents which were in the money, that were excluded from the earnings per share computation.     A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Three Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Three Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Nine Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Nine Months Ended</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2011</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Income</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Income</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Loss</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Loss</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Basic earnings (loss) per share</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">1,074</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,836</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">0.07</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">1,110</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">15,113</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">0.07</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(1,543</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,804</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(0.10</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(877</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,901</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(0.06</td> <td style="text-align: left; width: 1%;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Dilutives:</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per share</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,074</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,836</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.07</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,110</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,113</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.07</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,543</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,804</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(0.10</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(877</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,901</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(0.06</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>

Basis of PresentationThe unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the BusinessOur net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines and retail customers’ balance their inventory positions as cold season consumer demand subsides. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Use of EstimatesThe preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates. Our primary product, Cold-EEZEÒlozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE® lozenges we market and distribute Cold-EEZE® Oral Spray, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts® and Kids-EEZE® soft chew children’s OTC cold remedies (“Kids-EEZE® Products”). We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix®”). Each of the Cold-EEZE® Oral Spray products, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts®, Kids-EEZE® Products and Organix® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash EquivalentsWe consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At September 30, 2012 and December 31, 2011, inventory included raw material, work in progress and packaging amounts of $ 1.4 million and $981,000 respectively, and finished goods of $2.0 million and $1.7 million, respectively.

Property, Plant and EquipmentProperty, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - fifteen to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration of RisksFuture revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC drug, personal care or other products in order to continue to compete on a national level and/or international level. Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedyproducts are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States. Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable. We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2012, our cash balance was $ 1.8 million and our bank balance was $2.4 million. Of the total bank balance, $766,000 was covered by federal depository insurance and $1.6 million was uninsured at September 30, 2012. Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large wholesalers, mass merchandisers and multi-outlet pharmacy and chain drug stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Our largest accounts receivable balances are with five customers representing approximately 68.3% and 52.7% of total trade receivable balances at September 30, 2012 and December 31, 2011, respectively. Three of such customers represented approximately 56.2% of total trade receivable balances at September 30,,2012.Two of such customers represented approximately 34.4% of total trade receivable balances at December 31, 2011, respectively. Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 92% and 95% of total revenues for the nine months ended September 30, 2012 and 2011, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and nine months ended September 30, 2012 and 2011, our net sales were principally related to domestic markets. Raw materials used in the production of our products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE® products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable to supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.

Long-lived AssetsWe review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors. Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments  Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of fair value of related party payables, if any, is not practicable due to their related party nature.

Revenue RecognitionSales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history. As of September 30, 2012 and December 31, 2011, we included a provision for sales allowances of $93,000 and $101,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of $37,000 and zero as of September 30, 2012 and December 31, 2011, respectively. Additionally, accrued advertising and other allowances as of September 30, 2012 included $1.3 million for estimated future sales returns and $822,000 for cooperative incentive promotion costs. As of December 31, 2011 accrued advertising and other allowances included $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions.

Shipping and Handling Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock CompensationWe recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended September 30, 2012 and 2011, we charged to operations $45,000 and $125,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the nine months ended September 30, 2012 and 2011, we charged to operations $208,000 and $316,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest EntityOn March 22, 2010, the Company, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.

Advertising and Incentive PromotionsAdvertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense, cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for the three months ended September 30, 2012 and 2011 were $1.3 million and $1.7 million, respectively. Advertising and incentive promotion costs incurred for the nine months ended September 30, 2012 and 2011 were $5.5 million and $3.9 million, respectively. Included in prepaid expenses and other current assets was $947,000 and $1.2 million at September 30, 2012 and December 31, 2011, respectively, relating to prepaid advertising and promotion expenses.

Research and DevelopmentResearch and development costs are charged to operations in the period incurred. Research and development costs for the three months ended September 30, 2012 and 2011 were $165,000 and $198,000, respectively. Research and development costs for the nine months ended September 30, 2012 and 2011 were $1.0 million and $594,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income TaxesWe utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 6). We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively. As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2004 through 2011 remain open to examination by the major taxing jurisdictions to which we are subject. <div> </div>

Recently Issued Accounting StandardsIn June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,” (“ASU 2011-05”) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders’ equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal periods beginning after December 15, 2011. The adoption of ASU 2011-05 did not have a material impact on our consolidated financial position, results of operations or cash flows. In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other Topics” (“ASU 2011-08”) which provides authoritative guidance on testing goodwill for impairment that became effective beginning January 1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of ASU 2011-08 did not have a material impact on our consolidated financial position, results of operations or cash flows.

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2012, as follows (in thousands): <table align="center" style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 1pt solid; text-align: center;">Fiscal Year</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Employment Contracts</td><td style="padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: center; width: 73%;">2012</td><td style="width: 3%;"> </td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 22%;">256</td><td style="text-align: left; width: 1%;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: center;">2013</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,025</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: center;">2014</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,025</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: center;">2015</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">555</td><td style="text-align: left;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: center;">2016</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">-</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: center; padding-bottom: 1pt;">2017</td><td style="padding-bottom: 1pt;"> </td><td style="border-bottom: black 1pt solid; text-align: left;"> </td><td style="border-bottom: black 1pt solid; text-align: right;">-</td><td style="text-align: left; padding-bottom: 1pt;"> </td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: right; padding-bottom: 2.5pt;">Total</td><td style="padding-bottom: 2.5pt;"> </td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">2,861</td><td style="text-align: left; padding-bottom: 2.5pt;"></td></tr></table>

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Three Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Three Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Nine Months Ended</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="10">Nine Months Ended</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2011</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">September 30, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Income</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Income</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Loss</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Loss</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Shares</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">EPS</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Basic earnings (loss) per share</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">1,074</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,836</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">0.07</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">1,110</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">15,113</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">0.07</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(1,543</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,811</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(0.10</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(877</td> <td style="text-align: left; width: 1%;">)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 7%;">14,901</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 7%;">(0.06</td> <td style="text-align: left; width: 1%;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Dilutives:</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in;">Diluted loss per share</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,074</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,836</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.07</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,110</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,113</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.07</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,543</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,811</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(0.10</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(877</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,901</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(0.06</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>

981000

1400000

1700000

2000000

P3Y

P7Y

P15Y

P39Y

P5Y

1800000

2400000

766000

1600000

0.95

0.527

0.344

0.92

0.683

0.562

101000

93000

1700000

1000000

279000

1300000

822000

0.0005

P10Y

0.50

1700000

3900000

1300000

5500000

37000

1440000

2600000

1000000

690000

2000000

3600000

P10Y

750000 690000 0.65 448500 256000 1025000 1025000 555000 0 0 2861000 0.03 0.02 3500000 3500000

0.15 0.50 In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company.

4500000

1800000

No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock.

99000

1449750

41000

122000

900000

250000

15665

40885

10757

13659

17605

12500

37500

12500

1331000

431000

524329

49160

524329

114010

50000 6300000

31600000

20000000

1110000

-877000

1074000

-1543000

15113

14901

14836

14804

0.07

-0.06

0.07

-0.10

1110000

-877000

1074000

-1543000

15113

14901

14836

14804

0.07

-0.06

0.07

-0.10

1281250 1293000

53517

144943

86328

37000

0 0 0 0 0 0 0 0 0 0 0 0 2020 2031 0000868278us-gaap:StateAndLocalJurisdictionMember2012-01-012012-09-30 2018 2031

0.07

-0.10

0.07

-0.06

EX-101.SCH 7 prph-20120930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Investment in Phusion Laboratories, LLC. link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Transactions Affecting Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Investment in Phusion Laboratories LLC (Details Textual) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Earnings (Loss) Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 prph-20120930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 prph-20120930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 prph-20120930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information. Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents (Note 2) Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable (net of $37 and zero, respectively) Accounts Receivable, Net, Current, Total Inventory, Net Inventory, net (Note 2) Inventory, Net, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Finite-Lived Intangible Assets, Net Intangible asset, licensed technology (Note 3) Finite-Lived Intangible Assets, Net, Total Property, Plant and Equipment, Net Property, plant and equipment, net of accumulated depreciation of $3,796 and $3,608, respectively (Note 2) Property, plant and equipment, net of accumulated depreciation of $3,549 and $3,389, respectively (Note 2) Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Assets Assets, Total Total assets Liabilities [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Accrued Royalties, Current Accrued royalties (Note 4) Accrued Marketing Costs, Current Accrued advertising and other allowances Other Liabilities, Current Other current liabilities Other current liabilities Liabilities, Current Total current liabilities Total current liabilities Commitments and Contingencies Commitments and contingencies (Note 4) Stockholders Equity Attributable To Parent [Abstract] STOCKHOLDERS' EQUITY: Common Stock, Value, Issued Common Stock, $.0005 par value; authorized 50,000,000; issued: 20,172,393 and 20,161,636 shares, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid In Capital, Common Stock Additional paid-in-capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Treasury Stock, Value Treasury stock, at cost 5,336,053 and 4,646,053 shares, respectively (Note 5) Treasury Stock, Value, Beginning Balance Treasury Stock, Value, Ending Balance Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively Stockholders Equity Attributable To Parent Total stockholders' equity Total stockholders' equity Balance Balance Liabilities and Stockholders Equity Liabilities and Stockholders' Equity, Total Liabilities and Stockholders' Equity, Total Balance Sheets Parenthetical [Abstract] Balance Sheets Parenthetical [Abstract] Balance Sheets Parenthetical. Allowance For Doubtful Accounts Receivable, Current Allowance for accounts receivable (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Common Stock, Par Or Stated Value Per Share Common Stock, par value (in dollars per share) Common Stock, Shares Authorized Common Stock, shares authorized Common Stock, Shares, Issued Common Stock, shares issued Common Stock, Shares, Issued, Total Treasury Stock, Shares Treasury stock, shares (in shares) Treasury Stock, Shares, Beginning Balance Treasury Stock, Shares, Ending Balance Income Statement [Abstract] Income Statement [Abstract] Sales Revenue, Net Net sales (Note 2) Sales Revenue, Net, Total Cost Of Goods and Services Sold Cost of sales (Note 2) Cost of sales (Note 2) Gross Profit Gross profit Gross profit Operating Expenses [Abstract] Operating expenses: Selling and Marketing Expense Sales and marketing Selling and Marketing Expense, Total General and Administrative Expense Administration General and Administrative Expense, Total Research and Development Expense Research and development Research and development Operating Expenses Operating Expenses, Total Operating Expenses, Total Operating Income (Loss) Income (loss) from operations Income (loss) from operations Interest and Other Income Interest and other income Interest and other income Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income taxes Income Tax Expense (Benefit) Income tax (benefit) (Note 6) Income tax (benefit) (Note 6) Net Income (Loss) Attributable To Parent Net loss Net income (loss) Net Income (Loss) Attributable to Parent Earnings Per Share, Basic and Diluted [Abstract] Basic income (loss) per share: Earnings Per Share, Basic and Diluted Net income (loss) (in dollars per share) Net income (loss) (in dollars per share) Earnings Per Share, Basic, Other Disclosures [Abstract] Weighted average common shares outstanding: Weighted Average Common Shares Outstanding Basic and Diluted Basic and diluted (in shares) Basic and diluted (in shares) The average number of shares issued and outstanding that are used in calculating common stock basic and diluted EPS, determined based on the timing of issuance of shares in the period. Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Retained Earnings [Member] Treasury Stock [Member] Shares, Outstanding Balance (in shares) Balance (in shares) Balance (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition Share-based compensation expense Stock Granted During Period Value Employment Agreement Common stock granted pursuant to employment agreements Value of stock granted pursuant to an employment agreement. Stock Granted During Period Shares Employment Agreement Common stock granted pursuant to employment agreements (in shares) Number of shares granted pursuant to an employment agreement. Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Depreciation, Depletion and Amortization Share-Based Compensation Share-based compensation expense Share-based Compensation, Total Allowance For Loan and Lease Losses, Recoveries Of Bad Debts Bad debt expense Gain (Loss) On Sale Of Property Plant Equipment Gain on sale of asset Gain (Loss) on Sale of Property Plant Equipment, Total Gain on sale of asset Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Accounts Receivable Accounts receivable Accounts receivable Increase (Decrease) In Inventories Inventory Increase (Decrease) in Inventories, Total Inventory Increase (Decrease) In Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) In Accrued Marketing Costs Accrued advertising and other allowances Net change during the period in the amount of Accrued advertising and other allowances at the period end. Accrued advertising and other allowances Increase (Decrease) In Other Operating Assets and Liabilities, Net Other operating assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Other operating assets and liabilities, net Other operating assets and liabilities, net Net Cash Provided By (Used In) Operating Activities Net cash provided by (used in) operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities [Abstract] Cash flows from investing activities: Payments To Acquire Property, Plant, and Equipment Capital expenditures Payments to Acquire Property, Plant, and Equipment, Total Capital expenditures Proceeds From Sale Of Property, Plant, and Equipment Proceeds from the sale of fixed assets Proceeds from the sale of fixed assets Net Cash Provided By (Used In) Investing Activities Net cash flows used in investing activities Net cash flows used in investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] Cash flows from financing activities: Payments For Repurchase Of Equity Purchase of treasury stock Purchase of treasury stock Net Cash Provided By (Used In) Financing Activities Net cash used in financing activities Net cash used in financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Net decrease in cash and cash equivalents Stock Issued Common stock issued in lieu of cash, as payment of accrued compensation Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Investments In and Advances To Affiliates, Schedule Of Investments [Abstract] Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Investments In and Advances To Affiliates, Schedule Of Investments [Text Block] Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Earnings Per Share [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block] Nature Of Operations [Policy Text Block] Nature Of Operations [Policy Text Block] Disclosure of accounting policy for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Use Of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Concentration Risk Disclosure [Policy Text Block] Concentration Risk Disclosure [Policy Text Block] Disclosure of accounting policies for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Advertising and Incentive Promotions [Policy Text Block] Advertising and Incentive Promotions [Policy Text Block] Disclosure of accounting policy for advertising and incentive promotions. Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule Of Future Contingency Obligation [Table Text Block] Schedule Of Future Contingency Obligation [Table Text Block] Tabular disclosure of the contingent obligations of the employment contracts and the purchase commitments of the entity reported over the future periods. Schedule Of Calculation Of Numerator and Denominator In Earnings Per Share [Table Text Block] Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] Component Of Other Operating Cost and Expense, General [Axis] Component of Other Operating Cost and Expense, General [Axis] Component Of Other Operating Cost and Expense, Name [Domain] Component of Other Operating Cost and Expense, Name [Domain] Advertising and Incentive Promotion Costs [Member] Advertising And Incentive Promotion Costs. Property, Plant and Equipment By Type [Axis] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Building and Building Improvements [Member] Machinery and Equipment [Member] Software [Member] Furniture and Fixtures [Member] Concentration Risk By Benchmark [Axis] Concentration Risk by Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Sales Revenue, Goods, Net [Member] Accrued Advertising and Other Allowances [Axis] Accrued Advertising and Other Allowances [Axis] Accrued Advertising And Other Allowances. Accrued Advertising and Other Allowances [Domain] Accrued Advertising and Other Allowances [Domain] Accrued Advertising And Other Allowances. Estimated Future Sales Return [Member] Estimated Future Sales Return. Cooperative Incentive [Member] Cooperative Incentive. Other Advertising and Marketing Promotions [Member] Other Advertising And Marketing Promotions. Award Type [Axis] Award Type [Axis] Share-Based Compensation Arrangements By Share-Based Payment Award, Award Type and Plan Name [Domain] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Stock Options [Member] Major Customers [Axis] Major Customers [Axis] Name Of Major Customer [Domain] Name of Major Customer [Domain] Five Customer [Member] Two Customer [Member] Three Customer [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Limited Liability Company Agreement [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Maximum [Member] Minimum [Member] Inventory, Work In Process and Raw Materials Inventory, Work in Process and Raw Materials Inventory, Finished Goods Inventory, Finished Goods Property, Plant and Equipment, Useful Life Property Plant and Equipment Useful Life Cash Cash Due From Banks Due from Banks Cash, Fdic Insured Amount Cash, FDIC Insured Amount Cash, Uninsured Amount Cash, Uninsured Amount Concentration Risk, Percentage Concentration Risk, Percentage Sales Allowances, Goods Sales Allowances, Goods Accrued Liabilities Accrued Liabilities Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Variable Interest Entity, Qualitative Or Quantitative Information, Ownership Percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Marketing and Advertising Expense Marketing and Advertising Expense Allowance For Doubtful Accounts Receivable Allowance for Doubtful Accounts Receivable Psi Parent [Member] PSI Parent [Member] PSI Parent. Corporate Joint Venture [Member] Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Stock Issued During Period, Value, New Issues Stock Issued During Period, Value, New Issues Payments To Acquire Interest In Joint Venture Payments to Acquire Interest in Joint Venture Treasury Stock Shares Acquired Treasury stock purchase (in shares) Maximum Amount Committed Towards Contributions In Joint Venture Maximum Amount Committed Towards Contributions In Joint Venture Maximum amount committed towards contributions in joint venture Payments To Acquire Intangible Assets Acquisition of product license Acquisition of product license Acquisition of product license Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Useful Life (in years) Common Stock Number Of Share Transferred To Thired Party Common Stock Number Of Share Transferred To Thired Party Equity Redemption ,Number Of Share, Redeem Equity Redemption ,Number Of Share, Redeem The number of share that are redeemed during the period. Equity Redemption Price Per Share Equity Redemption Price Per Share The amount to be paid per share equity by entity upon redemption of securities during the period. Equity Redemption Value Equity Redemption Value The aggregate amount to be paid by the entity upon redemption of the equity share during the period. Estimated Future Obligation [Axis] Estimated Future Obligation [Axis] Estimated Future Obligation. EX-101.PRE 11 prph-20120930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Investment in Phusion Laboratories, LLC.

9 Months Ended

Sep. 30, 2012

Investments In and Advances To Affiliates, Schedule Of Investments [Abstract]

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 3 – Investment in Phusion Laboratories, LLC.

ZIP 14 0001144204-12-062448-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-062448-xbrl.zip M4$L#!!0````(`+-];D'?#Q^%>X0``%-F!``1`!P`<')P:"TR,#$R,#DS,"YX M;6Q55`D``_("I%#R`J10=7@+``$$)0X```0Y`0``[%U[;^,XDO]_@/D.VAPP MN`/BV++\3*=[D4[BGMQV=[))>A[W0(.6:)L[LN0EI22>`_:S7Q4EV9(LV9(M M/Y)H@)EQ))+UJP>+1;)(G?WU>6PJCY0+9EOOC]23VI%"+=TVF#5\?_3MH5?I M'/WUPX\_G/VE4E$^48MRXE!#<06\5Z[^K/SV\>YS4%UIGM1.U).Z\M^J6JVU MJO6:6E=J]5.U=EJO*;=?_E?I3Y5+XI`'3O0_A%*I!`U_)`(:A19D<_43=?Y. M/KFT=7=,+4?Y`L`&#,H^,6>$]*\,YMA<^<5'`/A/ZB>U&"%XT>/,(--CY:O] M2,=]RI5:]U@)`&K:::,+`#-3_871)QJEVCSI()U?J6%1$26E-@)2K=.Z>MIH MSTD]][G)3O&_"NC!$J<3/AF]/QHYSN2T6GUZ>CJ9<'LR`O&8I"].='LLI5KK M:J`GKX;)K#\B-;"U$YL/H61-J^+K/M0/BN-;@\TJA`NWJM[+6=&%II\T65;M M=KM5^7965+"D@M"H6OWMR^=[?43'I,(LX1!+CV!A2[#'RS-A-^IJ>UD-KT10 MP:`33G6TV-0ZW2KA.K=-6AT0W:G0YXE)+`(V->W!WT%#NNU:#I]&Q2:H?C*T M'ZO^2ZF92DVM:.JLFLLY]*:T>O[;A(H&9: M]5\DA7%4#;SCA6TY]-E1[JGNH+N)^`[=?\G` MQ/V"W\_%]YO!=TVM?"$[I:-X6^#KF3.=_ M,P.?@.?CBI1$E/%`-1?7?SOZ4(-_.JU.O=TYJ\8KSQL4=(@.-7A@`$GH;TQG MCH=%,1B\]X8B7X.G8>A''U!,IU$&SJJ);2&1Z@+9:C*GH"]F&R'.I>?!&BB^ M2DT#`YK7GK\-GLSK5R-J6:ZG"U M7MCC";&FYT-.*?)TV#H$;W4:X\A783:^MJ%:4!UW(#B@(>760LH-OY_)U(A5 M"%O#_.UFUC#KM9=4E\:P&ZVNUR/`JVZC1VA?KKYKMPE]2'=L+EZ\AE,X>5.J[KZH@%\]2*&5`7^Q7>-`M5P&_/L-^`_4+,J` MOPSXWZCIEP'_6U!L&?"_9E7#W-%' M:KGTDVT;XBL]\%VOP`)6L1:*=%-Y?%.VX>^`'>AT,+(#MB"#HO>$0UTDOB=\ M*]@M1!PO=_,WQL!N;+Q[&#;>^_TJM,=[6!:^N6.(;0MO26BK!XUS729E@4_5 M*U&@ MASF*O41C?7BR2ULMT%87Y/FF3#6>"8>-,;NXYSHNIWX4#S^MP^Z;TO*S<:^`>H>CO*V1J)1FG68F):QYX!8R MC]_RVX8#)DGYBUA()0+,F$.,5^&*:S8IIW%\2'?/J.-DYMZ.?-LJSO)J&V7B8,;F+G+T;+9<+@'A,&#]@F++F=QK5G5Y_F7?YU\.US;*@Q^O6+GE&89#S@O?RQF&PS76,JMI MYUE-K\0VRC2HTAK*O*G2!LI$J[=G!_'YRX7-)S9^0.0_;68YOP"?+C_P\S*) M)'+KZ9XM9JSD*K69$ M6"LM884E?"'Z"((H/@V_]Z>Z=[CUX)5B%AN[XU=H+DOX+V**.Q-AB&)8EJ5] M%F.?Y+FTSZ+L,RS+TCY7V.='EYF&=\HN^'D]GG#\^AB=I0B\"4^:21*E3WV) M-OMJO>M>;;;TLSELMN=RB^$,#][WV#/^>B&KF;D,,IW--VTAQ=[B-.*TW*\K MUA&!R-'0!1D4?.*WS/A?V[SWI:K4&-L'GG3-]G06T&4,^KQQ+3EZB"VP(E^Z/%S MTMPXRM-#WQ;"2T.U=:W\+Y6*\LUBCG)/=52NHE0J MP?,??[C^E_H_O5]N?Z;/]++9:G=^OZ/_9!]^^W;]+WS\^Q-[U!N-AMYL-O6' M_QM]:)W]?'76^/1)[?U\=JIV>JVFVNO]_$X]??]S\_VGL]:G;NO:;]\#XB)E M%+S`=72P*O_Y6#I]^L&W$_DR`!^\"_[&-A):_'9_N=`<$W:CKK9/X5W^UKZ# M&+_+]?Y9NW(=GWX(%?[JCG&*:?,U22_4QX>7U++'S$IJ-JN`(DU4H^B7*K57)$.[HRY4`?,;$S'#:\$>..#ID`SV$YN"JK^,9Y1P=+[G&#F?CM MB`BJ?"9]<:S`#/WDK)K6).*8O[N0V_'FM670Y[_1:39ZX9Z;VE1`Y\+E>%B[ MQX1.S-\IX5?>;G4V4A7O"F"/3EI3499ZS*3\`AX/;9Z1H?LQ,:&2[F<$6WX,TM1L=Y#:GG=D@:LU:1MH]!NW0SR!QD#U$^T,& MSM8K79!/U9KMJ&:6DRP&7&:_NSZXU#,118U%6BUNT>D$BP"656;U1K.^%C!/ MC(5TKFZMW4TP\'S4,G>G5E-KK*+F1RRW9(KA2H&.I--I)L9&44J;8Q+OGL46]F\BG);:$JA3@4M1F+E%;3+0YECL675FT#E/$D,O#D[M@U<;_\ MD@YPN[L(658:K6[4(:ZF6QS*K+*LM.J-^@8H(SD^A?7+>K,5B]L6Z:R/(O.0 MGQ.%?#JR38-RX65&%>*CU'H]NJ*_2*<(%!ME$.?T*GOA("4Q-F-9.W^UTU1V`V&9OBX^.>^%@K=ZV,!CM!?KA]+:- MDHB+[6VAZ0M$Z5L:ZA86R591+0KA^@MK>1!&0JD)AY9E4B;\-JG,SK2,\S&F M]/PIGZ>N4A:R%M6J=>+K&86`VS7#F5>[VMW6UAD.N8Y;PF^X[+6&C!1O*9=9 M2NLH+Y2_&.*J`=/H$V"IF3B%3*-?(-PTT>\`KI?P=>XZ(YNS/ZF16ZJ)66;- M6JV6.B>/DRP`6:(`MXSL6@BW*'E!F9;:TEI+4'GD-D2474Y0IEW7NEHN1+-# MQCV;7]INWQFXYF)"1X$KE&$OE(?V5D!G=Z!1][DN\$BLXJFDH-ZKP:#6U%*F MZQZE#8#DZ*PY@82_!9:VY1G]\OFJS+I:)[KX'*.0EW@W#_%NMULODGCLF^\K M.&_$$O4*Y7Q5=*AI]4Y6ZKA?=#.0GW[#P)'R1Z93<0^QX^;Z5QN==FRP2".V M`:1<5J$U8_'F5B#ELA4AZBN@TBB":RP`T+;:X5PBG*XAVFJUF%J+WU#2]%+/9%K.?&E:`?U"; M,3^52FP#2/G\@]9N;1]2+O-0:UISUU):-;S58@<1LD$*TA=A1FN,F27/5V'. M8H$&%5L664%Q4W#Y3*NAMG<)+I^1J;'=G9U*;M5P5*NO+;D[*BCA.AXHN(0` MR+3E8DEQ%M>->K"EY#;#E:W._%T3V"Q5VW^7/'G+ M953U1C>ZR+)`(S^`7-;3UF*!>P$`\L7$6LP=%2Z!E?:@Q@Z69$-P;>GVF'Z& M4*J(T:R6(H0YE75`Y#*%2K>F;0-$SA"HO140N4RBHC8;W3PHKH$(I_+\ADQ" M]$IM;A?Q`T])5-;$D.NZ17*93@/!FKJXPCG.[D^(H;R\)Q M4&MLRL)L+R_'U7G%G!U)XZG>;'9"Z4N)M^NMA;J0T7G%!8&94)\;_W"%=^CT MP4X)M&0#??Q`6/C#8G<4\`KF4#\9P[L![X[J]M"2K:2?/\NW$!Y+9-HVXD.3 MSO:"XU*RAW$LKN.,ML.D%^7N7I') M07BMW6ROX#05<'@\RG(@KX!]]&YT,3L+U2V@7'GW<&DF]_U];B^<5"]@B;=3J\?2#E62W`'/5O*&[D&2T(2[M7'%[B(MH!MK"SE2RTD6C6_57KK6B%]6 MGP&@C"832R[>OUE`]VWY%U'G(;L%F*M$V?$CA;PPTT4?N__LUKGNL$=Y=TP!AJO5 M8C%9=NI;P[S2(6C=A?2/-3"#MP@6]W08^3G-=Y-,SE@IZL.RT]X:XI7'7+4B M$'-;I]20.90)$5>Q0E9;T5$V!_'M8FZX)-\7X,:`0A;L+M5[/TO,2B&\- M\FIODY_4HM8/HZF)(=;WX!J=J-+(WC#A\3R5X*!AK!-9A!_E?B64P'"DG_> M#'S[).9L(T!<,J&;-GX0]@&P?333+NU>^'3C3Z;S;J((9VK2]T=CPH?,.E5J M$P?^?7ZG#*#:J:+BWPX;0^^SZ),"PR.QCKT'QXH`_0W>'?TT=-YA6WW\\=5V MJ*(J/Y'QY-V_=>JJ^DX)'9,\"<4>R-_2 MI/"/K_21&.1884(AP*+E#HB.7RCDQ\@PS$^A,NK1P.L$6-]U``!4(_#@D7*! MG]@V%$ZLH6QM9(^I/2'.B.FRUH@2TQDI$VX;K@Y3:V=$'`4O+K0'`\JAIF-+ M.$/OZ@)EXO9-II\HOU)9"OJ5K5!K2(90E%FR*/>/H'NHYH?0D?P$#-)RH,LP'1GR&SC9N_T=4%>X<3D(!MPFGRK]P#^` M`>K>?73F5"HZ9(S'<_,#OQ)8)J8SHL0%C#"H?5`K2-\$";$==@Z^%@HQ#$]P`1!V6!_)PIR M,##)4(S81.ES+`?X+X!XY>KJOZY0JBB20+#XNS(@8V9.3Q4AO]$\=UE@3W/] MU%5?/\%3_(W58Z65<"&DJ]QY3",4VY,OC!V3N0GN`J#R)Q!5AJ8+XD;_8MI_ M0N]%[0.(1VIA']9-9LFN(1S7P$@/M`.>P-6IU+KA\OG@(:![ROD^4GN_+P2*I5\J"KJ``5\Y(@-N#4%6!$=R1FU>*5CM6<"R7!3'^.99Z MYM[]=4(90'=3[-FI29#$HQ02G9L"R,08?/`=)FT36Z";@)@,1CE+!SHC^(&VX8UW`_G=;-F4 MK^@0!5_/`FP91B.O6\`0-@X/^MZ'MV7!<'2`ML'G1(&:C2NABS7#E1"%\,F- M*?$,&!\>*T\PD(]\A-#9PF+PNZ%D`:0.7=JAQHGR$("-12G+XIO33%&-0@1J MPPA$*8,#R2SBI-C1)F#%8.V`Y#B0M-\._CVD4A9R$&F0*<.^.Y<@.!A*"K\SQ*P$#&:8$B3U]3PZFR.D)PQ]XW$2.9V$SD9A8 M;!JS;T>(O=JU"`S8_MD<`\]2RU^^O<,?PF)7SQ#ZX<0%4^F8$!AUA*<)]U?1:0*X%[!;N=L*SF4E"O0>\NH" MQ;`5R\;00#==`V/>BB=@/(+K\.&M.OLT([P;1H\G$60WCDR41S=]X9^A!J] M91)6"6Y<**@?$5M*E0=@@#(NZ#@XBB*KI\YC@9^/P+I)IX`FO;H)N>]R*^D[ M#OG&?JAX5S3/,+REHIL180PV0&G7\T=7RID#Z*0GYK/DTP'R@U$$VG%(S@!! M5YGE2B-O6,:L@CU=G7?M(NE"^>3/$*,+T:0]>&L63+N][?ZD6(LO(5$%.0%R MVC(A_'A%%MDJ9H]WHIT/;%?9\:)D&)>H3Q-[(BY4#OY08.N!%("?@J*4?2ZL M%(#$+8G^*`G?:'G@P1Z-QF09H^,*'PG5V!=;@LUV\5FPYDWF(VQ487!"$9Z@ M`X,DE\5HSE)6L/%YD3E1<]O[AQ8&P&K<7]".#=40ZQY0N[8'G90W%1E(4>XZW,``7_+?T,O7PCD*+P#V&7N)"S-:P'#^$"8N>3 ME&MB(XE*X/!5UY(?`EJ+*,?/"`8\7Y#,#E4.>YL=F$"S,:K!%?J%E%4ON'%( M\47;ZVRJT0TWSJ0!92`AV1T!7N`P(`&`)6,7)EF=X")7*',-!HA$VMNE=Y<= M*U3H?S'3DU,K@/.9HF_,:/$'[[R!'Y,RP3-'DC8W,Z*%".QNI?J<;%TI)F:1 M^6"FB%.$5#05Q^3V*^#0A;GKS-5@,5K91T>M;-6EN(N(K[CHQK.1!R,5EC$= M#`NNHTW@%!;1\.9EYH_91I[@B?I3V37H@PL6WVJ<.5"H%JZ1,5>G7S:HL6#Z M`=(+4Z&B8&E0?F&!^3%GSI4_NJQ$/8,51J,*7:>#5S75FJ+'"B0PWS'R3F(. MJ.YVC,7O;B#8*6/_FT*W'Z."640.6X;3S"6\,1RB<&!_$#+6,25-4M0DSY5` M%MNKR71\10P"?!`-^@@O6BX6OE.PNU3"..Q46H"%)E`REP\IW2'6X5K('U5` MFI;CVF(U*0'H-XR`P:,EYGHF[Z^GR9W M#VLZ`"54Y0&R^@[Z>D!#@T5?L04WD2P=AMBD!I'O'=3BY#)"RXS1!:,"R:/, M!(96>Y<[7Q;^=^_*CTM'3W:)K9DW,B1.Z'3%!;"]$5DVF'.`J--*L..DJB*F M4\$**>&X*9ABK*2+OGM%`A@C75?*LDF1'14+EL8WEP'EU1CAE(!!`8,Q;3P$ MQA:(<@RD>6,%!A@K)[#S23[!^GPT-QU$X,]R)F3SY,Y>R,DRR*\[-BCNJ+@7 M+:M1A$$6BA!8P=_1L2%77E1T!JWYF],Z4#%J_\3@R5X$L8E^*#DXR%>N.369 M,D;I-B@_9E0X-I&:YH:Q:'M:/%H==UV=VI+_*,-+'A[#&UIBH[&/?J!M[Q@U MR=B8,@&9NF&$D5)68($8+AZ?KME2`67G8$UF@`XIBE+0>;1XG`U[E07PZS^1 M_AZ?>E!M`$(*D^&!PQL.R7-!VCYH'&Q0ZQA9/-.!LVJ0S&C[)#E**PA=-5P' MS+:]3W)$Z&2'2CQ&U2.[F"_5&+8PLBAW0EXL`B(\=#C@!Z&4'7@<7A>?P,LC58=!>AC@)_@-U&PZ?/5:_0VD8@5UQA8/Y*MLQLH>ZQWL5?:8"9LBAV:-M9J" MH6X8K+(9SS"GX6*2^3/W0-AGW>#Q!W^&1^O-S^B,)`[Y?\L(ZXN!'SFO(##_ MCL)\R>7DZ;``LP^.;S"*XA`8N&-HY#63/*IY'U>8YUQLKZJS\C=)(ZFD$S1C MU4\D;R9`YGL)\A=.!&]_[U=0F\'J]DZ<_(]J4@F]^?U&,*O0?41;7?2W%7:( M):JQ.-=%W0P"HGK"0;I\X"ON8(:_*E`T>)9]O>A7@/FI[+Q+)%U8_5 M"LH=&>(&$DY!LV@HT?0V/`5GQP%@/-9\?/P_\C,[.A#I!AU1XU'W4*'5'$!G M,)TZT+DS59J3&7W)R9#*T7^EX3)G`+T'D:/A)C-1K-*`QPATB((5$C%O<+&( M;6+#5MECK1CU4F!YUOE2=2-K5S;H5H^M-SRL+8TYL9Z3%/OH"MQORB@%%(1` M_QF(WQ@D=Q22'-0A"7&%>&M+/)X+SB$X/.NC11.I\&O:0A&QO,5\B'1P8OZS;?Y=22 MTH\!%7GOBGH@A:72*0/Y"*S=+4IBJ"Y7D8O0X.2&S;MF57O.55_;NLMZYM<. MQZG1EG[5QK*WD4%L"R@HA41UP[;1LYJQ`IV#X1!BVNN8W.)DJ@VC+$=H.O(7 M!B6),7NO/IU^.J-\6Y/6Y4R#O>G9AP\,>O8G.PO,X#29<5-5=B/M>4=G;WO/`FHIUXM[+H\->I]OM.EXD"CXD%*7DC+E+O#>3WM[9[E;? M[FT?Z"\ZE2&>KLF[]F.GB]8Z'I6M<4:#]FQMY/FS$$\,Q(XO+D,G#2I>?"SQ M<)#VCI8A:N>ATUK'*W-MMV)H`!7:+5*N'(_5]:EY;J,>[?^D'&2>K3&G@B1' MBIH@A9Q]LM$PX"8:8<@>1'99@H90@K6C(TG1F"QY/KA;`-RP4$KR`2-`RA:% MQ"D5#Q$-EE*BLKJ_*+T4O9)C^)TC M66[JUA`5-WIETP[:XF#(XY["DY0A'XJB?C:\=]A?W%' MAA4;8T)7W:*Z!]H@1R%*K;Q5`^%H3W$X8L:1$72D2[J,M;5I^U_Y4:P?)0^S M#U*$WW-S,OE--_SJ9OW36Y60"4K4UPT:ZO M[,,M]W#3*%1(]3\4.*;2)"I68JOW4KRD\#E,)]KMYV397N;HG\/L M("<>SR4;M>R/1?Y;6_63*1=*%Q0X`5<^&+-EKH'O".2V:,2_A-,2J;ELLT^@ M^;!6!MO/&"1EN!*!]%V0*\Q4S MD`0ZF%9)1L)'T+AUS6OB9YD?FJ@2>E)T:Z>68%67A9$UA$:6*#4O`C%]':QD MW_VP0FG0A`J.3A[GU6PG;3=Q'AB-K)-AIG#VP#@YK%@K^-3`3[Y5G]JQ%A'P M'LG;2@ORZ-EG.][+@_U]LI2FE$]SI20-5G-$T'HQXX;-M+S,:`8QDO8-'/AR MF=`#K#W/+V<#-M'Z]+C[2"M9=/JNX0-RTFLL@&.U,,%6D6Z1(VQ1+IQ.Y)MP MSP?XMT!U@=W6.E70N-"NTKC$9QKK#"86\..M)Y4[RLXY1D?4$B,):)8$4 MDYW<1R3L7D[8_:RLGT%GZ\F3E8B-/4G&>C;S;&KRX$510TF, M&13P,TOG09;Z3BVQ!5+\$Y2,,P/-((,'IB-,%8'3GI$*"QH%/(JYA:`SZOC< M&'&(SIH8C+()RT710+'FD[0_4]+)20K-%,6$8DPH`<(C^O"4HK<4S$;.V+%; M`9E^QU,1*Y"4*TT%+V)4(Z^JH;3 M(9R,E27:A&1%VE5E2MS]-*WUQ,+Z]@^W=W\@4/H[VP<_T*8C'LFBL'&655Q< M%=<14!@M8BPEQ>A1`X`JK,'7W]_>N3U4,.,T76F^W;WMO67GNVFYC\Y0-YO= MG[FULYSN8S4TYEID:7#>C;JYR)RCE(MI>[3#._VH[U#85N^*1;-B!7!U@Q]7 M%%/R>3$G3VN6EX1Y@5_FQ&5174+KQN:USU=:$&9TUC'P"OE3*D`7 M)&CGCD`PJ)+F%,QB.%[(HLY@97'6_EIJJ&V<_],IYA:!@K*<'XI M:&28Y80=2;`2I26$)V>YA(L6$1RS)6/*12Z4.Z8 M(7!_CN@[QF`?QC?].4TNMV*JA3JFS.:-=$O_IB2Q1C\X`V4F.TAQ$65".\;JY0-DZ1N=HU7(&Q`"2^7"7 MH^TRX"`5&@#HF.$D;QDL9;>CDWFNOD<83D;3QP1]`4I2TRF!Q@2.RD3G>A-7 M&=L:17+:VY),HT\*8'A2N'$!-VZ(LOI*X%B?#NDA=/&[X,4IJP,9WYCTIV7: M_":Q`6J>`/8'JP@+,.5"I+Y3>TT!QBDCH*0+HJND:6BDV#H.\P2"95+"_UNF MMDJ*QH(S;*T$$V'VFL! MM_I#LDOGD.\0"2L]/%02W6R!:OVRY+RD8_B$KIM"62O=J&-H,3(Z=$+N'"XX MBQ@Q[LR/E>4`6;5@UYK*KB9H$\\Q?2[CF*23?V_+03J.HE>MEZ)@$6!.Q;$M MCK..ZRMEBDC><=`#E3E<93"/1&]PA!!83C:S:<%I\LYU*!@; MF+XTR+2V;P=W)TJX2F'AHW.[#5+9/C4?-M;9(I/U-[45]VB'LBZ,VX#D.,6[ M\=#X$3=SRT`9P8(%WU0KS>BH2@@->WOA(SXK"`-53+F"G(\V&`D1JM[D$F>^ M/*;+G/A`82(G)5:;<)PIW315*]K#@S5?F0.!]J;Q(.:<[D6^\S109[';?F-AT`2=BZ MEV&%EVJNMXC=O9/A=BK#R1BIB!@_N6D8VY)/G%8AG,*@8)<5"C;]R<#)YY`G MWZU,7B;SJ[$)O$"((B8U.$DUP2E)EZ1DWG$:9K"'D/F,AYXCCC'K`E$,4*?3 M2A'2`P=5GY8B2"?]5ZU0V8C7J8UXK1/^Y\TV3Q;%G#J-[E$2E/K[B5S6P;E. MPYC5#-&Y3DSK%-M%"CY8;G5&ZGZ!E4V9#K<.L7;N11O#"-,1RSH9+U/04-C1P&46[T`:?7JW:$FUX(;()@<9MD=I#;V]2U M.G648;UBMJ%*ED6?4Z^A^R3X8U-_(+TN].[+*TO"!$0*G=6*O2O]9<4TT(4= M;DG)'`".#U'[;P0.T;JY2(E3A-W:#[O,2O%K1X>PC&GKUIK4^S!00P@=V-.U M?B'P+8R%:7XP5Q=37T2K.5==%KJEUQC32;&ZT[1-H3,@'GKA6BF M=.TX)E5'Y:(HU;?3&!9!$<%R,`;MB?=0J9]56\3NKS!^^G7$:1&D]_(MH=IY MH@>C&N49;O.W5*$Y59SEQ[XX\YC1!X51A_Z8VB]KV.CW")6]+=PV1LB1VLJ# MZ$6QJHG"90@[*==8J?G_@"D!S4"'S4>RK#1C=HM&3B-DL<(-6E" M603!2*H#&)V%XVXV*C>Y;4L.X].@N.,J(-O=,V$O.1WPU,)B<_S=2D5LW(W= MZ>'I6FMQYZDOBER&]G<+!ZUA`2#N-@9\1I0^67`@AFL'R%8;1I=2MDS#8B`H MJV/,NLY1FCBM''@?IDY(=3I*&>78BHS:T16@XI!H"I5XH_E.B0SKKR4-0F"7 M@Y%2VY<<%1MB?IQ*+MZ1:#S`UF$(A$E*ITLA597XU*_-3JYW%OJ%E,^N%E_G M"E`6GS20T+444][/[#FB3]RC0AQOK,(Y6]*>2R1*ATM=T5OG1Q/H4;O@2!9E"JV*/]@JFQMC5]KCY+7ZTJQ$N9H MEW+!.+^K2R4TU2!OQVD,9MNZ8'I1IO>Y-"0AUZPU1');"6U!,DT`C&50)O-) M(93IW63:4!-LLP):59B6@P+;MI@7<%F[!V99?ZHL);_'*GBLAKF1\FXW!X`X MS=YZ_^=H)^SVNU:_-GT:JD6R#^:'#RG#8KU'<]K5B^! MF1(V\/FE6KKH%,4YQ"R_%!?B@Q4@[N`+W MKA:D1;RQ*=:%ZUB\.1^M(/T.FPF50<^]YWHC-])OCLN!R)CC'=U;'+F0%%K: M/&H\B=.9,IW54)^F3C.V#.,R\T4XD29,+0`Y:I1;W:Y2&I@L[A;EQDZBK!KG MM%&6^=FD7:F)'NJK24@06V_=^QCTYJV+@#)>Y5W:\+B0<1HJL?^"ZH7I>5&+ M[;*\U@LR37')V9YC&!UU<`R).L8L.@OP6G5]M,J\I!22(.46H+DMKY)[_>3M MUF'@^LR(ZES%[=&J$3?I:FJ/9W MLPV::;M-5@^DEX'%0DB69I&*84\ZXY#OH$EB; MITF]7F2]]?3`Y;,"ITJ$4BDW3NLJ9&?F':`IJ=- MU;/.:!4V%=$U(N=\4D>VN7N]O8W:KF/?JP?0U;_ MBFFY>'!.=9+%1XJ/;J3$/DND<328/+C7NAV)=,F=+.>C-)^,L$PR"G+OLS2' M<[G;^<6I=^ZC\[O*V^#P'V.&""S"1V&7@2GL<\O[ZJ"G2;!='[$V%!A6L4]5 M\\XXGNUA',EM)A86]L"?CTJRYC_[`WPIS:C4\_/G$^]54;W,YE\@+0OO5W@3 M+*R%L^OF>#9Q(M"(HJ["I(:B<6\P]=D\*2CUCC5SGH,!X3*_5JI*1)!%K&0,7WBN`G$_!:A(B6WW^+$+S@E_^OY3_+0WN$.;OE@ ME*1Q>CFK;!'[E+[PXOPG3"%"5)L60J!VX0V(TH,1V"OU<0-NIYQN`#K7`C2W MH)3;-J0026X(['A)B3W$S$=KO]LL]_.:3*[0DANYXGX$1%#O=\J-\/K='[PQ M\7P.QFE^(9ILA=RL0%:^ZB#\IO7:M4-V,+T_1FM+VKY?:29E)I4D#A?+OYY^ MG.]'FVE_JL3)]"V!@-8A*+R^X!L>E?O-G$CY_"8>*.!>Y!0W6JJN6&"QR-Q) M_"E=;&LLC9!!NRUUT))4BL&L87SW!A/GL@''W6$C.@MNK?3ME<>Z":@>TY') M"U_7\E7`$S;PUQ2-QS6GTJGQ3IT;I])&BLDZX->XU3*39UFYYDB49Q-RA.\H MTJ<;T&*P<8E):GUP\"(',@.1W_JNTZ[C.65.UB4C/NV*0T_&[-SD.-0]KJD6 M5;KSFYQ2U^TMGF5)%G!F-V4\TF@*57[3"]AXAA:^7O7O+(4O)HKA%<-;61M< M=%1Q)=_0!.LNL*UD&@AH_>U^%;3=[:-%H)UJ3UTDUSI%3GMY*]LT@]?I_%@R M?[1WX-A6VSMVSMO6?':D@(6CHAJ[<`H5X6ZWC*W=Z[[HM8CQ,1C]?\/&_HQK3&"VB?H)YRRM=+?/6_J\W4 M1WXS>H,M@>*V1L;>I,PCGZZ$XK)GN2Z%'G./%YO^U-?6H]$BCJ$Q M/979+OH%N7/!'O'!S#CMZ3(U]B9-%:5QI4Y)'HPIE\;IZDN;_@:3CE/R@7W# M9@ET@C!3R:37F>DI`XUR(G-<#`?>Z(90-[X'O"B-2\V"C/<*[_6,N5DUC';I M2R@MQ0LF;=XZHT0N5G-PH@M]-$K8*U'H=&+3)87+(HW%00NC%6'7SQEJ(@$% M,GBM`!]O_TSY9*MQ.Q[3_P>.2!%+YMEQ,K,^%4Q8`RX3TVET9/,"0AO,V2ZK M>66PYGJ^C6LKLCFG\9CSKK`?AHW<45X>\3SD\2GO*^VOLJCGVT>;F*9_Z6,) M!K:4Q`JI.7[9T/2?QN;62F9\*ZOQP):)(RF=O2O''[_A0-I.M[MG`M&D4O+] M*BA%*+5,??=-/8AXG;AA"(R!R_X#N$T.QULZ$*7.]0VVF^+3W4;W4/>!S`#X MP"E'O9Q[TB\*X.!^%FZFE@@ZU+_*1%E$LOU-#2Z-#M:T&N]]"O]4&UT>7[RO MQ"2BQ.;U MV\J5ZWAXF][JN-G1+KC'%[_HJ2M0BY-J3%>4V5X=[LBBSEV6$366QN-GG5(D MIGEU"J-!B8DV2'R=O1BF:4XMV5_:?S5,5TN;,IHQ^;LP=CL"2ZQV`RBJ]`5Y M=$`$^F&G>61=HF#]@=B@C$M)3<\4X8K4U\6=NG%$Z4644HO''+4<%,62GH,L M4:_).I,:AI'Z?WF=+HM4E$I`&GY0DHBS%@(P54M3%-J*>Z1<*>DEGF-!CKX% MV\85_"$&$XP;JM?7%WY_I3(;(1LLU1T^C$(G#=MVM=$MYI+K+C&W=WLW7[:= M9DX_@.7X[(9<6OJ`C,NZ4!RF!3QH-;YS6.$[I^8BR6I3]7^D:6]`3Z`F/69[3U#Y+RCAYNN(V[GDE+3!F,/C9&I`JA?9 MF1LP\`C'ZKMS[;A%%[@ONL$HV:E!IRG,.40JRS)V1 M:4-C%K9&]*7S5"P""Z3K,4GQUU;7?S$B:]"_`$PT[-%GX-"TXQ2U9/Z>Q$OX(#1@L'D)>R MPK"4I]J@Q3:>B?1E7K8MC+!`E(7L!=$7^_C8Y&O`UZV(VX1V0*4_#\5FW-I_ MXWWA%E_DNA#'0O.JKF/!AX_#@O_VILRW+GU_\O;"UMU85G,NEXA^!9;W/DZ# M;S_^[__\3;]Q:IM%GR;'27@<7A&FOJ;'NAU9?B'-8,^&SM-F-!*I\.&+&O[] MQ0G__?O13Q]_W^UN`3_3AJ(Y)PJBDMF-`44.#926KA0U=/'\/T MDC%+DGJ"T[%\/S=6+IPS>94@U=7*)R"2<^G?EQ,=O" MZ'*'\;A%J'KE7!2@_2^4T<5,X76'>N1LE1/XE@$D8WH2I\!X]5T4P@HKM3+5 MRE?06M)P9A\9+D(]8'G+ME5N_#V@#V58#G1O5UIYG0% M-F/SA7>)(8W8$W8@70BM#2L4RY=P3J6UL^G$1YV]O2[%&,E^,]7>;CHX2C=IHF/S;JT:46E/^W+':2/[!E7;>1QD:]AQ&I>C9<;)E0Z\,.9!_\:5 M`ASZ.@[N/4NMI#"2;QBV1S*/XB:)@@?%=U9+K80_E5SC:W(=ZSQ#*W65]'B. M?,V_3)/@#\@PO?VCFXFF8LI]=Q`UGSWMS,1M[!#U>WN'G3X,+C^@Q*`0#:+O97=[OX^:+L-F0D4UB"G`[(>BRB/P149N\1E'B%:2SRO(Q=7R M&C9%2M^0N.F06%^X1*R%7!M8I8^9!Z6](;@AXMYQ[Q'O&-//.D<6I@XFW#&A M*;&QHY,LN=Q_,20TIZM"=)IRP%@5KZS=FK',PS%ZQ9FEMDT&6T,=>Y\"83$: MZWX3UTF2#M])]0V+YB=X2RL7_PN4IL2P*O?19"PQG0HU>J/.=YJN@J/C+9&: M01E>JJ+>IB+EKKB$;[2,+^1F8..TYX3SL6WL07.#Z,/#Z%R)V'&7VC3O*R=Q ME$U)E;CW0NH(%"SFDM+)B#K95))1YUL^0BUU,X,X$^9F8U.^O,0]8$Z_6%6A18HQXAD'JEB1'M&UK@BJN M>HI_TWT@^7VQUB?'57&OO=QU]!6MC9"6$IFB$[`8;)=Y\8_8=Y/S&RF1IU53` M0AKQDS)LV`'#@"U!J=NY::SB1[%S$TV[<^W.;>(.:@ALU81GJLP%PT-RE0WP M]$NE\Q5J9@::JH8I,B,4>X_EO[18TK,[6L-"%:$C[9),9Q@3KL9?KEXOWDWP MN_U9>Q:J>@)9CU$<.&P7Y2#LR0MJA5EZI+Y'58)\#/)OS]R*0#6;B M4TY;FHC7A4&ZH@R=_H\N_BKSNEE!1N9*YACN<_&2FQO*;+<\NS^\*YV6H'OD MXNPZG:PF<"T_XII?6*\E^PZ7NSK[0+@4IRXTR7];36`3A:JZ1J=R`:ESBA8B MQ:8B^H,\S09617`ZGUP:CFW[ID`ID.7H6,]$C, ME9..HUI2-%E,V7T@=.B(ZQW,.5%8:6/9D\XWU)7&`*[++XRQVKN^I)FZ=)5+ MI/69,Z)-2W)N`I$;SHSM+5F3"3!DKYBJ^$IG1#DHM/O,-:) MN7@#?`$$[A^PV,6FOLD MF1OJ9`&C.?J-$LQQ#[E%)EP:6KEH&+\"]2SP+N,2MH?+/AU60HQ:.M(-N:4A MNU.KLU)W/,XH$UL0Q84_FU(O='[0;EFMYO9T?6`S%G/.LE(T,2FL>]@.C M<*/(GI8Q-E&XH]EK6NH\Y$RNJD`^Z;B\2$^E#HQL^?T$$.YTNP?.%3-3ZV-R MX,Y(@7>R,PEXZ8J>I(Y0D71H\@[0K\Y+8J1BXP'L:5'-%^<&KQR=I$Q-W4:+ MWQ+#CS1_\4RLT*P,U36P34S!U-/-=+NO\W:EYIN.8>+I&&\]`4%WJ:.HND$- ML7U[-7W]-F7.3PPYH.SH!Q0L&J8QW8OQBD0(Z&I`M/SUVT?'Q&*B0.Z`V&++M&7?7W3Y M\P3K_OFS`U:F@2#-')"LT31("[#RWKG/AOI9`9(?@4>QDY'7FY#K/PH%L]4L M)+F5&V='@]S?O\OLZR`' MB,9"W9D8F@"[#0F$,>#[8"`UD12*M,O1MB;@8:QMQ7$0=J`.YL]W7 M8'[%ZM05J.N\>GLBT"#4,QNOU6HF\74:SXJ#.L3=Z1SN]^Y$8!>1*(JB^UDSNF8]J$&,[P40^X=]1;0/2XOL3K?4Y)OM*;G+CNQL1\(^T&U@$> MRH20VB'*EYV`B*(;7),4:]9M;1)U`\YQ?V<>:@(3>MY>NTZ-NTQ+&7XVIX0C MR>,(O5[_!S>YEVHHRX)*DCBWR<%;1]_-7H&$\W2I<$GGY6!!XSB"(RGM0("4 MI;V^3F>7K[(_,[&4J*0:3)0Q';1(XI&4O2X/I5H%9;E#67&$D/0AXT^+; ME]&5]I"ZVXR;..HKT_2%KS1F)7U<5Z]6-A#')8CX.#9?^81[@X(7-/^51AUE M6U$I!-DJ9DYI9@,):MWS^FC:,^K M>U;=R@(#!H5**>_>%-KB:#2^Z8GN7GN!K7N!79+ZE3FGOGY&"]NH5WK2^)?* M/%;A_*9%NV8E[2H/MB&,[^#-OF!O;H^I['?M; M^-04M4C):];*+LJ*O#:7[KTC:^2>5$9;NDKY!HMT*BH*YN3'5%-J,+!=L<_L MSJJ0S$E50BV7$*0I1934-S+H/)I(5-R&KH-T8[9I`JC[&"YL!0A/SWW;:Z/0 M<[>X-5_7QBT/E?0P)<&$!5><#S9S.Z)KVO4M M.,EJ]7LS[W8#QX)4?++Z"-M'?$>80:>CTS2AD)(F=:G7W!6?6*]*V@("=TU>H)L*V#$$M8G$'$JC8Z(FS#FU26C''8V]G3U*& MZ@K(]5B>34"QYU*W6!DQC.(ZLYM5_, MA<+.O:C4D"1'7HBWMDGG*\WQ7H5@[-$%0"I.IZ^)_92)@-#`$^8+1GO;AS5% MBS%EV8A.34NK2B2FJ(D=Y/)ZN@(KU\C`*I-WWDCGL?$UD=6;!#2#X]PD*=<] MZAST#5:V7*OXJKCG.QB5QM!B!UV4B]SJ[NSWFT"RF M:L1JXM$:N66BA1&Y;`@.]V9^U(?E_U*C6JL>6J!VI: M9U8MMY=-N-W`V/_.Z6;#^F:5KCA5D6H0;Q=[_9G3O@V&`J7+GD;B/+@!#AW' M"Z^KHNVX1!/H#F[:1B6SKG9<"_S=H&`M2D_K7,ZW(EBN)M%I M5"5ZNYW]_M$*_.Q:?>QZ]C< M:./GZI:11'CN1=P`D,(-U%;@=H1>JR92X\0K8\ZH,3O<6X(L=+?%08.!/EE@H"_/ MHN_(6YWV'Z!,P$&G-WN]O0[B0,XL\S]?GJ[ M-%[TMX3!USOH['?[:^72JYW"1^Z&/Z#W!X;:?75^VZ8 M+?,%/0*%]^NV=U*"?C^"_?VO;-N-?#';/QE%:@B+IZ)\T-_.V*'*!5/TF^UQ M*[]U3+6F,IG@3I$0][/2H>0C#B7KZYJL4FRCSM*%T3/-%W_*#-020R%EUW1* M9'?I]5S497TOF?5U3/Q>[D:#0]^P+_&6G$E!UYMA284I-X]%BE&,6]^N9MH7 MAI7+D4&O!H1>\EO<\5]"S7,\2O/9V,^E^.-5_S6VC"!G3>C/#`>0.>_*6UWL M\@6CV,UU?]]P*AQIK]LY/.PO8+4.6P5R] M5)@AT,V%%-24@_Z!!G$>`FM,RIHJ-;2]Z\"XGN]>M]DPNFRE7;3.)S9._^M^?2D;=?JV)9.UJG9HX MVI0TN4?9G>VU/NVU/H]YK<^#MF[=P$/7WMCSU[NQYY%WW\8<@Q/9R,K8D=0R MV[(OX4ER=^N\#XJU7_)%J`RSQF0GBL,>[[0N_YA>)WBX"2$].,=SSW` M^LH=3D*[KNWPE+,0/@LO2@'*\!F/Y(5=`VDTY%B69I0 MVR-MVN(=1=R\?0L`H_Z`=<'!H18+7_5FX1,M7`M)%\_5PBGT#`2Z]+VW[,9* M0^H'*RFH6E0""JV7Z9H<#FSI<=,2\X8.N+L]IZ4,NW;53M>S-RC!J+4+FZPK;"DH7^YTG>L\Z004U$-D":BLJ7=8`^F)*R:K M7*BUG+JRPB7#B^.EBRXEMOV7RGFWB7&?>MU_\-AY&Q5:P*0 MV(?7?TF('UX4K(7CB*>8JHS!_"^HU)<*J$=RI'+URNF7BTKX''/2^<(SU%K* MS%R4ML!`[_9I!^!KU(L2Z*U-!'&B(.!AU6KY.JI=P+;/]2C"*F^^?PV@;KS& M;;51=%(5YS4U?,B.]\6ZXR\WMP;78C^#Z&S[Z&3*J_%QE%^B'VFQGPT'% MV:!A]UY]!L[]VH,U>+2(QRK1VQQ'V'L_CP)R.3*"8D*0;2XNS4:I>`:MD4CN M\7&N]T*-'P5B75;HR@TW"5=V,%LP*MS2;N:FR.*4591@IU@D9&=6^\&"*`2<)S256=)7(@"IHX&&PMZBNVQN4LRVL_W9H9A)+W>?( M`E2BQL5QHRE1H6S()K5+W+.;WG'Z`E^S?Q8K#O9&]EYGYVC71%KATR'\?[]^ M'_O"8_M\&(..T:QTJWU'CM.5:MIY(O)SG^\Y'%19CWTNY(1I[)/+`0SJKS=? M1(MXP45IU$@/`BJNYT5T3*IWRNWOJI[^RGYRM8O*MOEH>Y#7ZDR(6?#%5&@@ M%M&67;Z4]_'TQ!_M`@&UU.*WJ$0A%DUJ>)V3^JU/QBVIY$Q\N-_9W>&ZVOYN MI]\[6`A'/3"F58S,5)K!:VK6<4-9W]W\_`K#LMA@^2(!M<;0X.)$.F[C7@+P&PE`O.\]`2S0D>Y6JOI?47,)*\6513>RV MOJT+P,9AZ\V%`G/%.<4.LLW M%`G/%.6"$8PK*AJ+@F6*\92LM6WGV"&_9 M2LM6GC_.-XVMW,_%*,M">4/RYK*8JM^==B\[Y.8KVY:8]N5M9JO>,'>PPG2] M3O=@[T$7N#I>GP[Q[C;M':BXUSGQN=P]:VCU-VO4ZO5ZW M)=Y3YY]](./NAB_UZ9"QY9\M[9:<[E6OT]][V)/W^OD1[3'USFYK/CS5L]?= M?F#=Y1D>O8>FV>'!P\JZ9TBR1^261]VE\[A:;KEA)P_4S(=UL=QP].[C+O+U MD_P!-]&#,H"'/!WW,-?3AKXERT9"WY)E(Z%OR;*1T+=DV4CH6[)L)/0M6382 M^I8L&PE]2Y:-A+XERT9"WY)E(Z%_IF1YW(3*#]*^+7_;;IXGN;"G#7U+EHV$ MOB7+1D+?DF4CH6_)LI'0MV392.A;LFPD]"U9-A+ZEBP;"7U+EHV$OB7+1D+_ M3,ER/YX[/Y%B753XCK?>OSETLNEU@,J M]/`.I]6O<&H&\Z$=Q32K%Z;E(%9W\5LOW;QV12A6W.UWO/[IP6GRO#;!O8.S MZFZXXS52[79X#CSA;M>IM'O@.>R!.UYKU6Z"YR47[G@]5KL=G@-/:.5"NP?N M>EW7'8FR]&4TSXOX&R,JTO],U9"WIGXD4N--U M9JT4>!:ECAY63-*$\91 MHO+\@\J#+**F+,=)>!P$:9D4,-,YO!Q$*C<3>0$`#Q^^J.'?7YSPW[\?_?3Q M]]WNUH6:;.UT>SLO?D3X)TU8_*/,BV@X>^>-_>PR@B^Z0-;NY/L[#Y'RUNOA MYR(:J]Q+U-3+TK&?=/B+CI>K+!I:9`_T'Q'^08OSTJ'G+H_P&!E3/1? MUT-9"2IUM_L84[HCY%]'RBL3OPPCC"T!-F'PG/\22L&'893X21#Y,4`'7XQA M_MP;^5?*&RB5>)-,38#ZH12?I>!SE.:#>>\4,Z'!GI_ONXN.)^=1[]]KS)Q/85[B_O2*]&0J8,5,` MKP(.X"5I`6\$<1DJ#];IA5$>Q&E>`MGA0;_PQL@1X+%L3&@8`.CJOV6$^,(U M-\ZR%HP*HGY)B+07.'I>0<,_CH_/73QL>[@;<+#QQ$]F.-S:ML9@!CLU\2_I M"5I(6A8>#4XXS>%S'#)V?%HW3/-'F01X;GCA:9G=/'='B('`X^J!/$0(H%B1 M=I#2RL_P1Y@!!SQ.DA(&^*(F:59X,-4G(!2A]4($: M#U3F[?8Z'O"6WK9WREA.)U&"D,*&M.OLT([P0SS`C)D$!LAS/YO1Z+XW]*,, MD618A-[1"Q8Z2?,('^M4'X`!RKB@XY!.8'=0-RO":^6QP,]'WC!.IX`FO3IX M/$I#W"TA'`%XJN.0;^R'BG=%\PQZD&*4*47S@3Q0WAA8T"@7G%W@'F6D=0EI M.Q[L"#HW&AL1;&:9/X*I[1Q`)STQGR6?#I`?C")U!6.G5RH3=)59KC3RAB6@ M'CMSWX!/.!L>&:P1<_.-E]T72@_3Q.8IIAIA&HT MK%6`[?8X5>*."SB#4YPHT'-\9'JXM4!?BW!W""\D7CF$]^G`GWT]`&;& M*IS!0VE8!D6^[9V460:`Q;,./6C'BY)A7"I@P,3&B%N5@S]44*"T@)^"HI3S M("P7@,2M"\B;E!F(HEQIN>'!7H[&<,Q`@;M2,3X2JC'^B$<)I]7P8!59,*+Y M@4UH1BCTX`DZ,$AR"9R10(+Q,B&9@@/"B\R)EMO>/[30`);D_N*!DA(JX"\H M17*'(>`P]N3".G_R824`E.(E(F9#Q(EE6&,X]H+:*$?4Y307R(S_EI4G638# MKJ;*1\Y,\*?TU]`/BC0#8ORF'$&GOB-0-(;&\"C*0H_Q5F:`@O^6?@9BVQN! MM(5_"+O$K9RM$:=`%!(E"!<0.Y^`4&-A$(#8R6EXV([?%+$>'-X/*1DHQ\\( M!CQ?D&P/50Y[&]`&N`&:C4'.5.D7EID60A52?`'0DE(TE4S%Q)GMI$&:%[SM M'$%?X#`@*8!UJ[S0JQ-3!281G3 MP;#@.EH'3F$1#6]>9OZ8QDLG>*+^5'8-^N#F%1&R'&=WK9]?(^*@`1`1+<\I?6$(::#;`]&#]T&@^UZG<5<6TIM>QO@@\=(PLD,XX M:K<=K6OG[CX`@H_];\I3ABQTTG.@//D&B)_'*/0)Z8"SRJ! M+([\011;V\/J__@@TAO`I=VWX!TZVQXJ:$9]682%)E`REYT0AT+>ZS`?9'.P M#E2L^'W:_*SU;8.I!$>>K06V84@$9.E51%832J6!CR=S`-HL\U'`>)F)>@DL M)9TBF\C=,Y<.0*D"C0DY=L6/W=!'8,+,G_[EWY<>FHQ2ZQ-0]&OA($6:DJ7!^XUX@,&4`) MR0JM\X(I``J/Z1WF!^!DKL+=8QX"=3V(&UN>C=>D@`G^6,R&; M)W?V0DZ&0'[=L4&I-?#11H15C&#N-,,T6D=^`SY8RW+9?D7T:T7?G-:!BE'9 M)SY-YB%(/Q]I7FA52%US:C)E;-!MT&',J'!L(C7-#6/1YK/H\QUW79W:DO\H MPTL>'I;I:\&+MCT:$-O>,2J$L;%<`K)LPPC82<9Z*!##Q>/V(S/BFFOV-H#L M'*Q)DX<#-4;S6.1ZQSL!0;?U\>/_]['1H3GTQV`\OO7RV1@DHK5H\G)B5[;3 MDY7I;^M>3_=[^3M._P3=&@$L"V#5?R+I/3[PH)P`@'_"R<43,RYC%E^LKX/. MP*8S:EFX^6-:RQ6JS2EL"5B4$JU-]'42&J65@:XB#^J3G`XZU&#@ ML&^H>EH7LZ0:KQ8>%N4:S8;[1WC><+A7T6MF)Z"[FZ=(KL:@*;%#:#P!30JA MZL#C\+S^!K@9K3H*T)L`/\%OHB+3YZO7Z%?%+`BYQ4$ MYM]1F"^YG#P=%F"XP>D-1E$<`N]V3(6\9E1'-3_C"O.@NB%$\';W_L5]&6PF[T3,$U`7K(@<`%ES]#W M&\&L0O<1K6U1W5;8(9:HQF9<%W4[JY!6HYR0M"P&K)D;^!D<,N?8ULXG,QMF MCJBH7%YFZI(85`G?H#S0!UL(ZAC[>`@)K'+"^K%QRRS@:XZ<)J\Y<)1XMNU= MB/W?]%PFMBEJ?:Q1H+H<#7$#":>@6324:#P;GH*SXP`P'BL]/OX?>90=]8?4 M@HYH\*AVJ-`J#:`N"(=A]\Q4:4YF5"4QBUGE&,P,7.8,H/T?.1CK9J]KD%\`OKP M<1+B/Q]!?P>]')=U=]_H&NUDA,US@'MD]>PW9:0^Q1/0Q07R-0;1'(4DZ'1T M07Q;8W10&.\M>N;%(9^B8RS/*ZJSZZ1D#9LL%F67O^V=U+XQZ@(]BKH^;[N0 MMBX9DU=\)-"?EB9JIG?JL$Q"-B28<9";C8Q95EZ^R[$DA1YC(_(>FF_`#TJ" MD0[I""S9+3A!X]IR%7GQ#$X:=^=2>]#=M*=:F[BW?7I[=[V!S?M5V[C>!@:: M+9B@SA$Y#<-%KV;&JF\.&G^HD*SDDB;[:AAE.4+3D;\P<$@LU7OUZ?33&1C` MJ=XGJ+&9:<`&9/X.5E\\^Y,M?#,X369\2Y5M1IO94:6-[Z`2RL.189?Y@S@" MZ0?6Y7'1&.M*&L*&KK-$SA+(!G^*>QE0YL<@!]+L&QX?]IX'=E!,(,)C+X\.>YUNM^OX?LCSGU`HD<#U+E.,^N'K.]O=ZMN] M[0/]1:"<&7L==EJ$?!14D/H1X%$C+1@L.M>A0@7@/(M[T9:[M2W3"H^*Y14J0XU2R MOA?'Q5AFDQ0=Z+#]G='$18E<0&9KS'(@`9"BQD9!8)]L*0QMB4X1LI./O8H@ MYDNP2G3,)AJ3Q88]M1X8551_V MX#`BI0QT-HX#E%K%JD:4T:SA@,",8Q/HRI;\%&ORTNZ^\J-8/TH^7A]$`K]W MJ4CE-ZDRU3BF,9')P0QO58(6'">X1%<6BB0)FHB=M`XH-P!U.X4RF6V0XRUB*O"?$I;A>G4\?CJO9?DG8H>0$ MD_77H0'_"39U.O%!1@3>^$Y_7$4+VF@\K5`;=IN"0 MX'%>S132=@_G4-'(.I%D"F<.;97#BK6!CPW\Y%OUL1UKT0#/D:2GM"!GFGVV MX[T\V-\G2V=*R2A72G)--2<$11;35=C.`EV(9A`C9]_`@2^7"3W`"O'\>AY] M![G:DBA!F[*IOBXZ=MK`1*[#$R/EL^@CP).XU9M;,I6U.3:"Z*&4I?S%F`GUDB M#[+4#]E*(N9H@!3G`J6_S$`;R."!Z0B3,^"H9Z2R@A8!CV)2'NB(.BPV1ARB MIR4&&VO"PE`TSA$R!=3V/(15F;2`9HIBQBZF<`#A$7UX0M&'"58@Y\C8K8#< MON.IB!5&2C*C.&**Z9V7OG9B4-*;7]2((8G!.>P*6"2F0NCP(OK+1VP^8L`4 MP$O'4=!QU5VCICI^=)-N+,`[:9V<6Q'',+Y6Q3$E2!PRXJ,L15%T M"!=C#8DV(1F%=E69$B\[36O]H["^_T#%$8#%^:@H$T#@"JLP=??W]ZY%50=XK9?I^E*T^WN;>\M.]U-JVTY_;6V MATTXH]P:JY4QPR+#@I-<.`E!&XA-2=<2%UQ,UZ,=WN1'?8>Z!@)MP"Q7=`## M-.WMXXHR2MXK9N)IS="2N$LNZ?$=`3[PRYP8+*I):,W87/#Y*@;"C,[4!38A M?W)$9%%2<^[(`H,J]IP+=^$('4LY@Y7%F>Z?;EFV83"85G+NIZJV$YR,NA!. M+NS'0-P1K=FD`?GB>/MSM+9#G<_MI#37S&^.9K`/"`X6;:8$TY71@,[AR0#% M\8DH[FX\`>2/I!M>HK0E+5_/"5(O44Z=U0HY#!7`M+8EY]_WT&\<*\[U`3E) M6X(R+R+<\1=<\<6N)W$(@&[F<7R&POV\2^&PAYB&JBB9$T:3.CT::N:&3)1. M%F3QS5H8Q]!-(BZH,>@2AUU+TT^(F8!\-O-2VBLN0`]LM`FJZ4`EQB1^;WO_ M3*>8R`5ZR7!^*6A7F.6$'4EG$ETEA"=GN81X%A$T6C$_D3NDOJ\?@57<.5F*=)O#W+X`70R/SX;/@Y32X_8W7-,>78/A77,H*] M%5-5$`.^@5[EWY2DAXCI+.%QCDG*QHCM.B2?G(XLE?!$Z.^C)&LL`<%=Z='> M)K/'T8&#*`O*<5ZP0J3K_IPC4PO,BSTC\^'N15-DP"$DU.?1P<)9TC)8RIY# M)W5;?8\PM(N6C`G``I2D=5,:B@GKE(E.EB9N,;8U?>1SMR6,1C\4P/`$4#T) MK%2*5FHK@>-Z.J2'T$/O@D<]=2-2SE/0!?ZTS)C?I.,-%E0'S0D6^PLPY4*D MO@=*A;D`X^3A4V8#T55R(312;"&$>0+!,CG5_RU36RW$&98Y1\]H7)&Q#*T6 M$Q0>QYV*Q4M*$BW\"$YS_DX$.`V$5E9:B/;R#E\"+O2'Y&C.(=\A$I9*>*CX MN9'[:KVO)):D8_B$7IA"6:/;J%AH`#(Z=%KK'"XX%Q<%IF\N:FM3D>;DG5;W`(DFRD2C0?&C^@'V`A)CMG^OBGUF=$Q ME>@7:!3TB,]"?Z"**5=;\['VL?LXJ-+DUF:>/`:CH^1-05F5E)IL(FFF?-&4 M?&AG#19,90X$SEERAL0]PL;`5A'1)C%/C>`S5GY2/G>*/1;^E/2L*)F46HO$ MJ"4/Y[RK'4,XI#F/;[W/%-3K==RZTW0`)&%+7885/JHYWB)6]TZ&VZD,)V.D M(E[\Y*9AI.`+,WK8_Q3""0P*]CZA4-.?#)Q\!GGRWY!#O[F,=XZ`3B\+`NDL38\ M(6G4[`A,65JLD)&2P`X.KAN1Y>562Z2*%530D,UP8QF;NTJZH/M^0@7%CYW, M8#G&4B?>91%2TOZ%M6=$V5.Q"P5RSP%]`YG`A6E%X1@HE23N*>B"Y'*(O(TZD(`T[392D8J<4'^'!)JP8P19_2]644\6I@.S),X\9 MS5,$1.B/P6JV]4;T>X1JY19N&2-<24'F0?2B6*E%H3:$791KK-2\A[B%I6!S M`4@.:@0^Z@B585L9-(\R\6RH4+J@T%&;J_NBPLSHFGF$2[`#ELTLQ9Q%$@-] M@P4NOT>"6,>N'$`:F0`D_D+=UBC-C%"3)I1Z`+CB>@!&9^$XJXUR3T[?DF/_ M-"CNN`K(=O=,V,=.ASNUL-BL?K>J\`IXWO%@Y: MPP)`W&T,^(PHQ[+@$`Y7"Y!5.(PNI<28AL404E;'F'6\HR1Q.B[P/DR=0.QT ME#+*L4$8-8DK0+4BL10J\65SLY,,:Z4E=T)@EX.14I.5'!4J8GR<3BX^F&@\ MP(9>"(1)3`FO)_9/T6? MN)6$N/=8=72VI#V72)0.EZ6B3]#G)`#,;VT>F&7]J;*4W"NKX+$6':\4IS;T1VG6OQ9.:O#QLK>]:Q+PG,XC MUML\KR&]!,9(B\/GE^JBHA,4Y]:Y_%)P":6 M14KUO6P=74SO`#_2P(.4P&0/;=)I!2;K.#PF)X^"YB^@C:38@X/=GIJ;8>%5 M[.>"_`&[K7?'/\!49IN$-WBH(;$5&)>9+P*'5%OJH,?!IMPJ:Y5ZOV1QER8W[!)EU?"H#=#,SR;=/DW0 ML1AEU/.#A*MU^[W'GNU;%P'EO,T5&+05>"F#5T-";,,U@LRO6?) M3Y]C]!V5:HRD.M8I6OY3/POUZ2OSDC)*@I0[:.:VJ`IK&6QOMF>@!J[)^444 MYY(FE_:F'X5.\A;M2?HGT<,@@[O;($;[R!?%?>N6!IWPLS1%M:>:[8%,.YTY MX``D<.UP)&FR9;\A@\;G@#I4KY?V,W43[ MK[<9LLIV5]]5%D2Y^)0Y/*0W7#7^7@(>!R69A4DJ5C9EC4N*A*YIM>F:U&1% MUEO/$EP^.7"J1%:%W%K3=(M^N==W-.Z=?I/&3=JZPY8:>8EIP6>:R53=\XQ6 M85%1GI=BUTE3BNH^`A0D[G)73(5GWKF/+NPJ8X.3?XP9);`('Z5)L%V?<3:4&!6Q3[5P#OCB'<2>_]&Z/S!.S`,+.Q'/Q^59)I_]@?X4II1 M>>?GSR?>*URE,^>_0$P6WJ_P)MA7"V?7+>ELLD6@$:6(U-0=%$QA@ZG/YDE! MJ7>L.?,<#`B7^;5222H"O@*D)`1IJ]DHT`[G=R07N;.I"3@%]6UYR1AK@,U6)N+MO%/"_?HU]-&1#*)LP6UYWK;7J93/H77[_[@C8GAT8EVB5]-`>`UB%HNK[@&QXEU:9R M+\3\)AXHX%[DWC;JJ:Y:8)G(W$F\*=T%XF1)V6!Z6!Q;UP98B:?:0W)N_!H; M:/D=U]PQ!FK/@KV!`J8.]C7NJ,QD-%8NX!&=TX3=X#N*=NF&J1AP6V*26C\8 MO#J`+"?D5+[K[.IX3I&0=72(:[?B"),Q.S>2G8H+]H;.3W>! M;26-6D#K;_>KH.UN'RT"[53[OR*Y<"AR.J%;J:!9HTZ-]=CO%NB]BW4M$'%YS\[RA:=&U-_\T!TMN M/$#5!I%8G/;5_[Z!&@K#Y@%P:A,UD=^,QF#+C+C]C['1*._&I^N'N%Q8[O1@ M[ZL)9[$AI3/?_.^+KMS0&UVB=OBDTV&"V\Q=V2XVUA58+0_"/=7HSL;A84R) M`U);E$$T#RK[QOXO9P3=F8/7]$`G!7LPQ&O>8R,$=$/@N`R4%]6R* MZJK,VOUS>GXG+63^#78_@"F?Z5Z%[+.2?*9(,@4QTSW#.DK?;2J*EG%)D/:[[KUNO^_RI]+UBFF[EA9K8@T@)5GP83!R:"D#X MTDCM[D:TF_NBV%2F'JX>C19QL(EIJ`]FQL--EW:Q]V6J*($I M=4K>8$RYG$Q7-]K$+YATG)+/Z!LV&*#3@SDZ)K',3$^Y5Y0-F.-B.$)%-U:Z M@3#@0VE<:O9CO#UXSV3,'9=AM$M?8DXI7GAH,\49)7*!EX,374RC4<)6?*&3 M:$U3$2X[-'8&+8Q6A#TO9ZB!!.3UY[4"?+SU,^63A<;=:TR['#@>12PY5\?) MS/H@,%4+.$Q,)]&1R0L(;3!G>XSFE<&:Z^4VK`W'IIS$8TXXPOX1-L1%V6C$ MZY"WI[RGM&_'HIUOPFQBEOZECP4/V&T1*Y#F^&1#6WH:F[L0F?&MC,;#6B:. MA'3VK1Q]_(8C3CO=[IZ)UI(:R3>`H/2@G"KUW3?5%X,9E\!1@PT8`Y?]!W": M'(ZV-.M)G0L&;+?![44T#*.K!A++MVYGXV:ESE7\?E93YS;0+$U2/!1.G<13 MR9CYHI!5`)K1I;!]A\!7T,.)RKXJ^.+$^]K M.HD"#YYY_;9R.3@>[J:W.F[.L`ON\<4O>NH*U.*V&M/]6K;_A3NRJ'F7940M ME_%X6C<5B7!>G<+(2F(\]Q*H9K^&:4)32X&73EH-T]72DXS&3!XP#(*.P#JK MW4*)JGY!/AX0CW[8:1Y9)^Y;#R'V^N)23M.'1+@F]4IQIVX<47K[I-0J,4<- M",6TY+@@R]1KLNZEAF&D]EY>IYL.%<7D2?,/2A)_UG(`IFMIB@)=<=^1*R5= MMG,L4=$W-EL?O3]$Q[QQ3/7Z^G+JKU1X(F2#I;K#AU'H)"?;3C&Z6UMRW87; M]A[JYHNAT\RIQ6]%N656UI7B,"K@.ZOQFL,*KSDU-Q]66XS_(TU#KKN`37I& MFY283WXS1SELX"AB,.4ZX;Y@[4TS$,!\8<'B%3#5&] M?LW<_H#'-E;?G9G@D`XES<4.](SC9,R!OL$PMKYEY^ M+I=9Y-XK:%AFT:A<7H+:8TO/,&U(-D MB_K13G+UUM-_K0*(%Z@XSO$B@^3R[R^Z_'F".33\V0"5:1`H,`;HU2@:I$61 MCJUI4X3Z20&0'X`',178ZP%,=+P$IS(*KU-W-4?RD9F4>6_PF_\`R0E)13@_ MC4!KYH$9&A'<].YM0$0\`\:`.#LTS4=*0=7A,PWR"17@!=+M;#UPORFR>7H, M`.1+L.:3$+="FKWU_D\0#(=!\,Y;GE0-Z_1DKQWL_L!OX'%:N!AY6#^[!.K= M*6,U+,R$/1GCY5*O4@FE>7=G1P/;W[_]S'6<5O\WH8P MC%UZL]?I[O37-=N#[F2-RKV_,BK7N2?G87\D1/;[3WM'SO.H1T+DUA/6EZ.B_>%O$T!)5X M8[.Y9J(NUDY6'-(AYT[G<+]W!Y*Z2U](RC=D7[!E>EOKLE*M;%X_$?<%/'XV M_!F;\F!]`67Q8)?,!#^=)A_]#/U-^;G*+M#Q_&3LUF,*OB4!M=-V+ANQ=UEQ M0W#NPX,+C6JLUQ.C@A2.M_H,9GBVS=#G6- MF=!D[.[7;3A<*_A__V.5_^:>[6\0,%-O$55NCUWU0*U@`6_0F@'BQ@5/A([1#?WXC7J2G6U.U95\!-4].%)7;^GRB;T7[^B![A MAU]FB[CGB[B?HZ3%V_/`FR@JF\%L;S89[F6ZNSDE5Z"_"8A:&'>[G4H^Q\Z& MXN@O3)+>AN+H+TR2]I1L'$DVZY2T8FT]L;9E(./4O0U%PC/%.7ER\@U%PC/% M^,M86L;R5\!YRU@>&.&?T[S=XBU;>>8X;]E*RU:>.<9;MM*R ME06NGEOFS:SJ!7KOYU%`C48QQ\)[A?7)KVW8?UE,U1-B[V6'W)R'N\2T+V\S M6S5I^&"%Z7J=[L'>@RYP=;P^'>+=;=H[4'&O<[B[O^%+?3ID?.`SV-WN'K2T M>YJTZW5ZO6Y+O*?./_M`QMT-7^K3(6/+/UO:+3G=JUZGO_>P)^_U\R/:8^J= MRV=_N!=9=G>/0>FF:'!P\KZYXAR1Z16QYU6V[Y5$\>J)D/ZV*Y MX>@M[9A=HCCUJ9<-.,6I#\0`'O)TW,-<3QOZEBP;"7U+EHV$OB7+1D+?DF4C MH6_)LI'0MV392.A;LFPD]"U9-A+ZEBP;"7U+EHV$_IF2Y7$3*C]$,5T5D+]M M-\^37-C3AKXERT9"WY)E(Z%OR;*1T+=DV4CH6[)L)/0M6382^I8L&PE]2Y:- MA+XERT9"WY)E(Z%_IF2YCXP[/.MM=;=[46+=E+C*MQY_N?1BJ?&`"CV\P6GU"YR:P7QH1S'-ZH5I.8C57?S6 M2[>N71&*%??Z'2]_>G":/*]-<._@K+H;[GB)5+L=G@-/N-ME*NT>>`Y[X(Z7 M6K6;X'G)A3M>CM5NA^?`$UJYT.Z!NU[6=4>B+'T5S?,B_L;)@SM>^M7R@F?! M"^YV>5C+"IXR[>]T"5E+^FYTF5DK!9X%)[C;I6CWRPHJ89,WA0^+Q<]_ M>U/F6Y>^/WE[$8Q46,;J;'CBQT$9^]A%Y6SXJ(!K#VW]_T7WQX]%AK]OMVA4M->]:`>UN7:@)`KJS&-"M M_HL?>WO=[II`_10E40Z4^T>:AG=&(L%VL`BVRE1W`V991.UT5P8&<#=163$[ MC_VD``Q^_&\93<;PTB^Y&I;QYVBH&B$[^NFC"]?O"\=Y/_LZFZCC[U'^^T4Z M+*:P]W]2XX'*7OQXOOL?"^H2@#P6W#_YP2A*5#9S?^=%_/[%3R[E*4#QN!P_ MT\7YWRN+.W@:BWM?1C%*"?A9_WDZGF3IE<('\QMIV.L_TW76R+E[]#36^:D$ M*5J4F8+?/T7?\:_<+.(.M#KQ\]%:)-5AC0'CP.Y$'TKU*4O'[_WDVWHX?ETT MNA/45_CIP^G):9(#TL+C<5J"@G1'"$"+.-C?GUOPW#QU0'X!56B-8!#F]QLP M7YNG`D::!+`=,M+;OD3Y-U#,\`O_4O66V*Z]W^<&>#][KY)@-/:S;RSM_%CE M7Q0(X%*1V/U9"5]U5C(!Z-RE[+SXL;M]U'>6<0V<=UK/I_]\=+6?J[#'8<4NIFSEK@63%2F86`R/PQ+P#B0H6?2E25QWX"MJ`*^!OTXG%*#7]O M0@'LZIV#HT='@,/S'FJC[VX`W6^S[-ML=*#RX<[.'9=+#LWW?J["DW0\44E. M@N`XR]#>9`O./G+NS_"KXZF?A=)[^JPL\L)/T&K]3:$3&58+BP7Q\?$[2)(H M5^=9%#1;D3>8";\#1GZGR=U5[Z$(@T4[>O8#K6$.;8.;IQRL/.47-?8C=#(C[.MB=C9- M0'L911.K:C2NC;4:Y*/``G%YW=\_JTL_YE'HV'R.QE%A]_L,5^DGL^-+4(JL M+^PFU;?OG*"E07;7:5@T'#/GK'_\CBAO7MQNU21=47Y?/^$=03M:!;3=HX<$ M;7=9O:Y1&#P@UFX`K=^_-6A&<'Q*LP]I.2B&93QO,"REEW2OE2VN6%EJSGN" M\GH3XI&A7-+&V#VHBNF5(;THTN#;:9Z#8.-/Z:>E;*$Y M'GJ>1^=^UL0LJ5(KK]ML>WO5K;L<:$LLYE<_+M5]K:7)_UIW.RX%5\5]SA(S M_YH>!_\MH\Q(C=/D7VF4%+_"CR!P[G\I<_;.DI"YB_F:*3\OLQEA@:DG[X;7 MBF?'KWK'K;5_5%W$-1`AX)-L,GHKT1!V$H/X!WT`%(*O*2HQ.>DFT:`D768- M-#E)LTD*6KIR1UIJJVGZW`GFF[8>*'41$WC/%?%[<[/K1>X6S]+-\+G+@8C MW(7Z##9/6'MLQ3C4*NNIJM"J-9',;;BMD7%:HQ60&5M_%K-7Y@AK`L6`N70/:; M3M]9/_`+C54R+_;["U90@6HA["1^[@7F&K;W]@[["[%-4%@8JUZ:LT$<79)I M^:&$@RX^AT]1'OCQ?Y2?+>DM63@J>X;&DS@EIJ)-SAO]8%N[P'K[^\X>6@WN M)=?[*ON])==J`%XR05>*%A8^)16:"%>!=>D#.'PR:].@WKRT1^6:A_N]);:B683UBYT-OZ0S/RYF MGY0Z]Z/P+"$?_F>5YR?HUO"3#RHL`U)O5[:L&]UWW5T!\W9`-*X!@,G+&!TR M#[>,G89EK`2'68F$`00'QTE8&68MN;.[?=>BN6'"=0"VK&MM9<"T`<`N[],D M5-]1,R9K/\M9#[H`D^S;-9&,:YU_S:HA*EQ.#&/)V:W=R]F.U;UB%/ZOZ7NE M3>6OJ8YB?$$/_JH!\\:]VM,J[>W!:#QV'T#U0J/X+&&'*&F=HN*_G^D!X'2O M;27];L.I6PT,:Q7Z^0@/9NT!#(LL!^N/IXE7C)2'^3N%EPX]WPM@3#CON:=D M4/P:GZ&A/3$Z9//6,Z\D9_K#Z%'+Q8C/_'ZW1^\@4K4,`HB/_92'<_0HTG@ MI`,SYDBY41J',-K8G\'$P0C#15Z:Z%F':4:?`B(U=W2JC;2MK=!K<+*6.&3% M#,R/K_PH1N?IIS3[![R[;*`6D='!TL8J$>9X^ND5:P'-PJ`=1`MSC*D4QZ4W2*4R"S"B&'V,_ST%0 MPT=:F#[F:\/P/>4F\$ZY9V:`R61'Z]G9BU:P3O3\JG*,YR75K$M`E,4HS:(_%P2TUB?ED!';4?U`<55D`]V]1,3HUXOCC]R`ND1'-+09K M8<_3O,A4`1BE%9/B7N3O9U^C`LN6[3`%^KWMX^'1PO_.L<-_K'O0/UHS[ MVS(TGH5G/TUXYN6J,6\OMGJ[^_VC-3#C)M@W""FWE%6]@_VUY!W?B)UK$I'^ MHE*J2:WL+YN\=32NT/Q,!U93*^'30_F1ETX/L]CO:V-9QD]]-.JW@)]C= M[:W5O]*PAG6BZ%.:#17U/+@CBI8747MKQE##$M:)(?+3FI&7EV)WP%!_9V]W M9QTZSN(E;!R&;JGO[!WU]M>XES8$4]3<CFKZZ!0P3C+UY4]'Q-F07%"(VX,$O7J MO_K?N6Y$0PW/,@T`HM]\Q$>AVO^OFD=T*C$KSL/H`!K&?8<^_V]W75!7^OJ4(VA.ND2M]GR M"P*+O9[3=&NE^=<+^.+MOB!'Y:C;VPC`%V_U!8`?[NYO!."+M_DBP+M[:P"\ MWK[[ENS[F@J_KA,R;)SM=N!>QCHV=9^5)^=8\,,I"HL@6#?P M]Z(L/!3P]Z(P/`[FUZ0T+`-\73+&.,-V'`K%6-*U) MB7!@(N^1.(;0!3>?V+^49^2&/KH[AY@?(+ZJ:V=;(TS7M[SJ[4ACW>5@,LGA M21&%B+[H2EVHH,RHBR6[-56([?'1#UH6'G_YNOW?P)'%4#VC='XZP M)&9O]TDBJ1ZRN3\D'>[O[AS>)XZ M#S^HP5(ER3?83@O:!"XW_;T#?X/9<4V?PZ47`$OX?[>VO$]I6B1IH3R@)-5. M;FWAZN(H^?9V*+]]A@_>=_JJF$W4WU\`P"H!6K^0;[,4[Y`;%<7D[9LWT^ET M^_L@B[?3[/+-3K>[^P9_?H,/OL"AW\R-;:-0<[M*)Y#5]M#B9DTKV9\F[+32 MO,N#2^^LPU98&E":<75\KDN-7`74N8Y<:Z#^2J?H\:B_HK'U*-2_7:^-1Z7^ M2MZ_^Z;^JIOUD<%=E@WYC2MRZEQ)VCGTPD^ M23J!S1P']38K/F#_A66XU8\[W1T-STJCKP33QR1 MM[J]+70\UW\S:`R=1X^V=KMV"OY%?]:3O*F0&&C^_]S3P;CU#H&7#S?I/-UA M(;<]AM5MB>^PK0O;)BDQ=8^'`T8'#,YU?=^;DW9E2-:_C+4X=C=@'>L(+6S` M,M82CKC5.H2%X7_AX_\/4$L#!!0````(`+-];D%JBU4P#`@``.=:```5`!P` M<')P:"TR,#$R,#DS,%]C86PN>&UL550)``/R`J10\@*D4'5X"P`!!"4.```$ M.0$``-U<6W/B-A1^[TS_@TM?:["!;!)/TPXAR4YFV$TFR6[[UA'V(6C66%0R M$/;7]\B8=,&V;+.[0M[)0Q*CHW/YI'.3S.]_OLQ":PE<4!9=M-RVT[(@\EE` MH^>+UH>G&_NL]>6UKEZKA>[]SK M]35S[7IN#QGKYWKF]4^U<^TYN*#T<^WA@JK#]2.%%>QR/6F?23Y/B_W-XO:V MC-YXW;[7[^E@A+ORI-:N+&:4YP#<_G8K.EX?UTK7&GQ_5JZ'6Q!QTL(*%>OU M-+'JRS6OA56WZSE]3:ST:85N&1>[!E88=WJ>6\L_'<@*5[K[1JY`#:P0J!// M<72P0CZG7O]$$ZLSW,5Z6$FL:B4&7\6J7H0\E!5&*WU8M_/WN]&C/X49 ML6DD8A+Y_U/):?+HW//S\T[R*0X5U!,)_8CY)$ZRXE*YK,(1\C][.\R6CVRW M:_?<]HL(6M(&G(7P`!,K8>_%ZSEXZD M_O4Q)C%(A.XF-S1"12D)[YF@4N9A2(1(4&M9DL.'A]L=->:(DA"B3OS5,Y^;=CGZPCWT=^ MP'<5)-S?\L`_,[#O;HUT1$EB,!\"QW,5J M=R%02#:7`I"P9:V`/D]C_$@[A`/?9PL4]@%\0,''(;R'N,*Z4Y&9#YA:ZQ2G MKDDXW49+E(WQ-0JJP&5GF/DX[&J5VKUGDMWO.7$C0"JBA',"Y@/ M$!,:07!->(1A0V`<6"'WB0,2"KRLYOYS! MC8`F3\GRF&D?L:S$(KA6""TE-2/!4:JUCYHBTRD+6TU3-6]D13??V3M=_>/G MG[8_W^;`^#;RV0P./!M.B34<`Z><-/>JWW(FQ#UG$V6(^W*4[F[Z(PE!/,`2 MH@6H>X?[(X]ZQ)%CV,RFV=?,Q)-:64+?3=XR%B0>`?B2^B`><:LKBXQ"(M-! M4>E;[M%L_0#=S8$3V>Q(#\I4!T_9L9JK:@AQSF\B+0%8:2 MD"7G3N5PJ>F:`%:)YN:5JJ^:;5*]$<:B*K[ZB]$FP)(5/K.+OHRRAA<\-=3* M69@5$P*=BPP3R4K+:W><7AG_9WR#@`Q9A%9=H&%3"[-(7,*$<=B,>R(O(*Y? MT!6CN6E$^/H6(17O&7X:Q8AVF,`7`P>AOJ3V_;@><07G`IZ]\?8=+6Y>%O.J M1KI5+S&NJRO<(HIF`)NC:5775-A^^3;-%WDY^29D*W$;!92#'Q_8A\G.HZ$E MDV6JN;:3UX-1!HRE2XJ:7*X_"'D![#42#7S,3I-NG=K35YU$=^UZ:+`Z8@NA M/B3[6W9/:1.;/E%PB7XO&+*9#!IEB^,1S=[4M( MZN1-3??#X;ECE!3(4\.!W+NQ?=`>W=+^<(!FC).">O9MPFNV]I1/\N7(W@S. M@:H6>4/1JF>B%+!SD_*AK/#)U>)7W=-;AV4OK5:>I*%`'V*NUW+4**];8`,9 M+L37-D+R)M'\KAQ9R\14/+&!CUDJA\+WR13:U9CDN$W-FD!FWK6K8:SRWHKV M\QF4U@<(DCY\3I52%>P:LS0;[3KF,N]TOL``Z5>^?)W?RIOD.'[KAO$'F"^X M+[OI=Y/2R[YJ.O/6JP*N(N]48!(#'5+^M\C<`ZG M@U\Y(S/\_L-W-$>NEZ_HHG]`<^0Z$?,N*0W"D*WD-\FA!QLQ(H\T1E);V5>5 MMY5]M@39GKF;7)+@"L;J+SJI/UG#2ZU#S%?Y.VR*S^I?OYT/'_T'4$L#!!0` M```(`+-];D$882+)7B0``+L_`@`5`!P`<')P:"TR,#$R,#DS,%]D968N>&UL M550)``/R`J10\@*D4'5X"P`!!"4.```$.0$``.T]V7+;.I;O4S7_X$F_MF-K M<197W^F2%Z7=X\0N6[FW^XE%DY"%#D6J`5*V^NL'($5*E(B-(@C0Y4I5HDA8 MSH+EG(.S_.6OK_/@:`D0AE'XVX?>Q],/1R#T(A^&S[]]^#D9'W_Y\-?__>__ M^LO_'!__X^+A]N@J\I(Y"..C[Z3-%`+_Z`7&LZ/K_QQ?^S".T-'OV5A'9*B/ MO8^?CIY61U=N[$Z0Z_W"1^2'/X`?`NR[JS\?_8B68/X$T-'IYS\?]4][_:/3 M_OG9Y_/3+T?WWX^.CVM/W/]XNC_Q&,&=6;^N9^WUSX=?S_O]=F<][9T/OIX/ MABW/VC_O#J.H`Z`WSK7AZ/B1KI7\TTC]5[YQL0<*G M5J8BB`T&+4TUI&N^E:GZ_?/3LY:F&M(5V,I4Y%AN9RIR[PS.>TKG4\VIR$KO M?:(KL(6I"*/.SD]/VYB*S//Y?'C6TE1?R"YN9RK**R7!X*"IU&[(NE.1VZI7 M$@$"&/YZ;_6XPC$]\.#]9MSEQ@X#,1&$XCU<+\-L'#.>+`.3?S1"8 M,E',YZ>0GU&8_T1'.SD`&O(9A'3='/M@ZB9!W"!L^V,W!&DT=V&H!]!LZ(/@ M3(`N&,`(.\Y`D<%X@W"&?5Z(=`&T;QJ-$MLQXPA2D'2#3X M`BUFQ_38//TZ.$U'R<_C4>A?AS&,5S?A-$+S](CZ<+2+'85J@:+%C!P[@?N$ M/WK1_"1%CSO.@3`^QFX,Z.!WTS$,R=D+W>`^PI".?1FX&*<7B0JTDB,>"/>% M&]"+XG$&0(SO743FFX$8>FZ@`BMGE.;H>A.2^4!-$JX['PC-913Z9)\!GWS` M44#4X!CXQ2SX;OH81]ZO613X1$*X_G="UI@*O'6&;XZ^ERZ>C8/H!=^$/D3` MBVN2>G^<0V%,YG,7K0CZ\#DDJ]YSR1[VO"@AFSA\OB>$\B#`5R!V88`GX#5. MW``K`5]K@@.QN@F7`,>49#?A_2RAA_>M^Q0A-XX0F>TV\`[`2'WP@W?&?`[3 M"3$Y7LGZI90#X1;=U#:"<#3M\-8AN\*H!\(_06Z(78]>!G@TG9)=1F;:/QX. MP*7F#`?O"GI.3]S7@_C`&>5`^*Y=%!(ZX-L(XWN`'F?DLJNQP'G#Z(.P#BEE MADLA)HH'#%/IY):`5P*:5Y`JJW1JA26$T%U:F+ MGU)I-<''SZZ[.*&4.P%!C/-O4EH>G_;6BNJ?UE\[Q?U&D`,WY"/.9R$P@R"= MVV$W=DXS(IF`>.(^;58-#]JTH=/;9><(E6$FVD(^VEIQ4-+$IRB:2Y`KGS(2 M`'L4(7(8_?:!]$@P@21:4)BI^)HI(^<>.87)`KP.TFYD%X%G^F'S>Q`1B>NW M#S%*0$TF8>!]?(Z6)SZ`&7_(AUVVD*^<;!4_@&>(8W*ZQC_<>15C6$V=O@[6 M5"K1]9C$`3QG4V^/3VV0_)+`C=R`"*3@]?_`BDOSG;;.H#-$WX<\IWJ_9:I? M)HCJ@&.(B0KX3^"BZ]"_(J@P",]J[@P[0'L.\#GY!T86_1@&`%T22)XCQ%_R MI9;.60>(7@UW3N]AR_0FHC+U&GE2@(/+/J*F(2_F,*G< MT'K#%Q/LILU>]4E/7V7IFQ3YAS[<+-T@?:6*+UV$5D2'^-T-$MZVD>IOU%BV M3_QJ)LEBPMQJK>^:["D:/P`/$'#)0?`#Q&NS$V\/<;H9M:S),DJ`@#U[B[ZV MAV3L%8&/PY#M9D:M;+(,V`&X:6MR?8+?([!PH7_]NJ#N,F0SW\4S@#*TQ!M# MHK=1`YTL>^3P:-H(?>CM+W%PE3`P::*3/JEV(&[:$%V?YF-*-'`+E\"_"6,W M?(;D&,W`Y1]6_(Y&[7BR7!&BT+1%^Y`#+5H`%*_N`S?S=R""R8(*G7PF\;H9 MM0;*'V% M*`#>'O$J%[SOW165NN55C7('LP9"%I7YNL8^!C:I@2@!_D.T<@.*E11;JGHX M/9-JNC)?6"C8H_^M@?SNHE^`>LE>1EA*SN5T<3HX?1,ZN]J[.&@8(]NJ,24*F1,*NQJ_*B&WAZ5D1/$P+,/LWLY/=O=;"21 ML&>[[,=A2`C-[$Y.SW:_'#D<[-I$:WN=GW M83;UO0O]F_#27<#8#;9@YLEHPLY.WZP?4`UVR2%ECWS]0..-0N#GL4A$X$SF M24"C8Z\(T3W(._7$G9V^6A:[Z@5!]$*7^#A"5U'R%$^38-\A1\+(J3).=QS]%+&R1Y8N28H+ M!#R8QM.3SP%("1[ZHWF$8OB?]'OF`RW?KMW(%-:'WFI`V!Z1?4L;)/?;'4H) MXJ>2;)X'0LZHP>IM?72O&B[VB/9[H8*C))Y%"/YG(^7P.;;;R_J08#D<[!'U M]^"\P3A1XT[6P_I`8C'\]CAAE53V#$I9*T76VOIP8C[L`F^KML.AUBG[WM6I M=W6J^^K4HQL`HADL09@`OD_G3LO.J$3[<-NC]%"/E+OIMRCR4ZL20$OH`?P8 M!?PKE]6I,XH)%P5[5(UOB":70]&4^Y"SU:HSJD,99GM4A#NB@+K4N6$=/"+C M<\OLTQGU@(>!/=6MX>;<&LY-1%8%+<<8]PL/$&J>";R`D MF`74LN//"5TI5C%<`C&G!#V-ZA`UV"5&QQXQX`%@0"A"HW^OB*`21*G53@6VIF-^E+AP1[8]NR( MW"GH&Z\?\W334XLU9?S"S05'JO"CS]#"\K3%Z;F[\3'C>EYAIU&3F"D=- M@&G5J+OIYKU M#@X'*H_PO+,K_]..:U&=ZIKOSD?OSD=OP/DH1R=;U43R M6$1AFN3@%4JML*I^>AR3.`6S.2PMV"1@)P,/:P2L'?BN2M77JQ2BJO::7I`9 M->$Y7&%1FZ'O,'!Y:\QQKL#430(]\N6&2>M)6N)2@90UW"JY.'\O"58B9^ZL MM5&_&>9FJ.9*-?C6\&(W6X&0'=4=C/J9*7*$B8$]5CE&%A`A<[C]C'IF*O)( MA(@]GC!;T3-"]NRU->JMK,B2*N#M\8(Y-&=&=Y-L;?F%F3^X9.H_,MM:7R2/ M![D])U+-YVW;2^8QP;;G$!KY_TIPEJ-P$C&NL'3M/+FIK6M.?212X]P#('L9 MPQBL`T&R:G0/P(N>,V:($C/IGKH[*;S;H$03KH:,][ST@/]&R[,#_RI!U"*< M@I'.?3U?!-&*XC9Z1@`PDCW4&L?^DH&UT6K"\TB16]D-T0"[F`/9[Q-6'R_+ MHIUI.;)Q$+W@&W+9(^#%[V\/[V\/;^#MH;K:7K8_B8A%#5?@"F3_2CS_UQFN M,R'4-9&S1S.C]?D(\/ZGPWQYY,5S*UGA1'\RHI:,N\Y@* MB#KRUAA\ZVF')DV']>@MHSP.[6%+26NA*D?HP;2HY@;<2=3F>YFJW1J8F#UXF6S9^B`RU>QW,5O]LE<-, M`MBSI;>SGMY&+EU_MU2N?P6>^`43E0,X_8S^U:DB9$[^-DCVK'7W+HB;JUMN>YK]AE)\Y[8?.(A1JFA:+2?1R-)=W/E98^4',9NU0--FY"%KC_@C;S]LY%G$ M;%'R MCOP@9K-?U&16->?5D+9&*2)0>@#X::1TA7RU.A MD8/>;.WA1EFNAK3U5_P8AF[H-73%@+T]2R&_J,81>@"+!'G4 MX?-N*HP4XO8S6_JX)DOX%SD33VON;GFT&]G,9HLI-\IC-:3MN;A53K*&W%/- M%F5N]NA6Q=L>ZULUY".RBA%:D04KBHF2ZN_TNY(I5!H=>Z[=-/HC*R?8XS!J MNYG3[TK=Q%VH!1NGG:B59#YWT>IN^@B?0SB%'E7)-KG%H@!ZY'R_HAD0`CPA MDR1N@-_#6=[#6=Y".$N>R>!NNO/F$*4E"=8IR?.J./S\6NJ#=2CI5BWDK-$` M)*'_XVPT3'@IM,+S5Z*WIG@BZ7M7DB&*W"SA9_]&;(Z9 MEER?^KEJ7_;-BP0&?G8UY!]OY@L4+;-1F.Y#N(='RE[;LO':!J_N`@(N51N:#2FZB#&[.%ACXEZ MG"!"RP0!@M,8OM)/XC.0W(?UVL+D#HS>8N M^B6TZO&[:HI0TF3$$^-BSS;;AS:'5<(ZP^^J*QI)P28GP0E9)N[C9HVDH9>' MEJ@$>IEIGSJP'[\HSC+.Z&(VEDQJ*U4SCH>0-8RBSK8$PB4($_`MBGS\`XC% M?'8GL_%D!S"+CY(]0O[8A2AUR;A8%1__!@$BE)JM;@G\HB=(N0$TQ8QI$5GD M,;)'VBP`_9[6\^%06,K490XQ-P%BA>?M9,7TB+7$RL" M/\PUCN&0[P0CZFY@)&FR(#7RTFE#-&1S(H"P!7J25*=R>!%YB*F.8B?QKB$NJB-KSB#!Z M<9$OX0M6:J-,5G@U3HTX=) M*9=<'=/IBNJ3MJKLLY=AXM2$O#4:]MM83)98;`RO*OOL-VE@WMV"?^>S&QN. M"-6U]QF+HA)]:UAYX094HGF<`1#?TFDH+?B7/ZN+IL!2+7(`#P=!<33#S!&> MQ>Q.3E^/E53Z>N9279Y1&VRLWD:'<),]!CIQ)*)RRR[1-W M%]R&I1!]A#4L5=2F<`O2PRVB9G%C?T5*&W,S"1 M!*YRQ588'`U1\1^G43IH4P,+51/[@OW\EM MA2#-ILFE^= M0FM/4<*K!-`R2Q=N^(MW2FTW_"[4]KJYT(8RO;BYO0AHNYX_F-#F` M8)GOM7>&7U,S09@:G*C0K@[7EAWTO=<`\0_<)] M!KP:#[QNSM"DFXH2=P18-/UT<$"L1.HL\S<0^.,(T8"HVRA\OH5+X!=QO%<0 MTX3]9*%Q^*8TCC,TJ=2K,%(9+7MLBP6D>SCLUF;DL%5^$.?,I-5`A:=J.&W4 M4N,<3>,5-^%;(JVTJKESUA6[`0OZ@A_F[01IB31JOR7+YRI*GF*B?.4YHOBZ M*+.;<]85FX$(BX)/YDT'ZUC(_"$.`IQ[BH;^#W)39__A76Y2`SAG73$@R.-3 M<-&\$4$8\<(*>%F'K=PE,8[=D&9J_@/`YUE,+H`E0$0DNWXETAG$Y/B''K=J M4SL0.&==,86T2)!B(9HWMZ0H/8FQ?E+&^@%0%J65/,*T7&/B!A.`YGW1HFP7 M&N>L*\8C0\0I%JMY(U7U%E4^Y)RSKIBIV/`77#%OJ"H>7*@&F1D)``9HR:U& MS.[DG'7%;,7'H>"0>?/5[RZ"U*7H)HP!`CC.'+[N7D*`\`PN-O8<#L.DQW#. MNF+84D*I8*=Y,U>1N81(N%LY3=819%QG%%Y'YZPKABPQ'@6WS)NNRO%]1>*: MU%QS*=36)'H[G[IBK))$9O-.;YQY]$`G!*$UJ*]H[L-="@8WKM(&#>VT\Q(G>:JY5>F(`-4C=2;19C(#\\@A)XH M:\Q^4ST%D1NB8B6X]OB27T9H004R\/>($.!WPNY$HJ`CIY>F"L>',D,.HQ_@)?T)[ZT*C.`T0*W:A*B)#KV;"T&R*E3 MU@$<+/9S]AFGEZ92N!HVEP"))N)*&#OJAM+%#5)/`?B4 MT&$G$?4RP()S3J&WKNJV#>\>>62:B"IA\&,=KYU%3=#]#.,8^&LXMD'#PIOH MH/',%D*5YMDAZ%D4C^)B^B9#_Z'QDDMR1I.;=A1?N@BMB+B4"DH\E4RFO]EJ MJ:KQ0U+HV!.J4B4=N>$S?"*W;?H>JB@IEOIJJH_:DI"XAXH]82@TI#P&:;S% M#J!2@=LRW76506V>=[+8-!)T(I;O?R04M;MI*@U-D!OB*4"(GNV3&96+[ET4 MKR3D>ZEQS%:WK"/?2Z/52$P*JY`;V>/QZ@'X8)Z.60**?@WF+`Y)=-54R[)I MIDABTDC,B20?4L_T>X!2$&0Y4.JDJU:E9MKOX=!(C(@DU5E2&KNQF8*%!U.Y M@%T4^-"*HTDF]:=B!Q4:BA#@M8?)NV?)NV>)4<\2N3JH=T\!?.:5 M!Q)WZH!GB102K=6>W3U? M!%&JZN M='I.#V))WKTC[BT*V&A\H6="H'Z&>(%\.`4`E]8$939QY0Q44AM!G,X>+Q5 M!EE2>:C?A6E"S5N`\25-_N&&5\!/O-1M MCR54U1O-B*E16>"JC9M&D]8V3$3"PF2M$"&K(08J#=@->^0AZ&DTA*VS:ZY7 M528M;V!C,DO0K1N62#$2`FM7*\I,ZLOE9FMA-)T"C\*7NGS-HH!`AS-OC'?% MYEVQ>7N*#:T:1$M-"_29[68=4F-VP+9&.,[A$DK$Y8:F]91=C?AJ9!INQ]_?I9D$RBU,JH9K"_1JLDREUX]1*0?'LJ)N"FE5&Q7)J` M)7@UJDM7$!')+4)8CI2,YD;E:BF:L@&W)Y:?'#AI:`0CS?8?,)[=A#Y<0I]( MTM>O7I#0G-I[R>'IV\)]A&,$8H)TFJ`;A(0Q,;Y836`<$$5O,XQ`@#$%DA[_ M!"W"DD$2V9-&9`]"BO8#T1A3]7`&%Y-(D,:KYDB:W":D93N3W*]>C^H$M$;0 M-+B*+!%5W\!RLL\)^'(&P?3Z%7A)#)<$ERGT`!*G#V/W,NH85&-_5W.6CZ`^ MH3V=]X[%&85G-H@16X769N0CNETY>F1EOKVVFM" MWIJK]6TL)DN$/\.KRC[![0$0$19Z,?#3=T6AR%;9WG""*%TG0/728%+`'IY2 MQ`77?M%&4RHH+5=^">@FPE$:I+=XYVQ:Z4KB)'VYE@G)(?8&7KM6MR*U+;E] MU,ENWX7QG9!NGLR%#"BU,YOY:G M]5E#`EK;HP\ED;"41VDBHAS.RPC'WT$\BZ29Q>AN?^XK56SLL9*4(,Z!79LX3%AS.7W;\UEI15UGIOLKX)%3BT!S0V-!7<1,9;_7T.G; M;E1BP]U(,OJ&U-?,C0=OKQ>>KEK1W.EWQ5#$@EYG4OH'L"32GL]?W:5&SL!V MBTTUS(TDF3=\W:1__0YP7%1G[.FX:2JF<09=,>\TC;4H?7X7UDUFW+H)<8R2 MU._B+IX!-)FYX?IF385Q?!-F>.M84XH@.`/;35(F*%*LQ4.,6+:O1;H%:76C M#.U)%+O!V(5(5%[-#$#.P'9SFWGZ%*OV$'-=DRG1`7@$:$EDK6J:_(C"98I2 MBCY.$=K^G;[V_(CB?X+X`7C1:1$*9]`50V?+1"D6I0;[:<.H MC)Z?$7@FE.1IO.U,[`P[8>=MA0[%"K+`=DP%M.S`O4I08:I,0?T!7M)?^&D> M)?H[P\Y8>V71*5C883-NR=XR"OWKUP6@X6Z3B'[5YB.T+`C.\,V;<6M0I%B+ M&GP1F\&#\Q*@819G:+L151/2Q4+0X,AX*+3E=:QK(91G<8:V6R0U(5TL!//^ ME:,@'7S;-KJ-)84]Q#R51VX`9VB[;5(=GX*+AU@H;7_HH`*7R4>-K?F=H>V6 MU=;)42Q!\_99;3AG]^'TR[@#C#KMA\VZ?+)B[.^.ILRJ,]B6<1 MHDBW$#]0S.4,NV)-UH)ZL8PLL#)7VQ\RJ*N1_X8B7,-"(QS2&7;&_GL`A@7O MS8=)<]$XP!:W,X!S9KLA5AV?@HOF#:KW*/(`\/&8H+XM3>7/"+R#7=C7.>N* M(54*E8)M%AA1*8P/8)$@CY9GJEAPHHW'[>R<=<9P*85+P;D.>XYN/S;K=%6N MFLN*W5,3\L5B,F_E/!3# MLON)\+IJ?C;GK"OV2DW(;Y(\M>A73L!C5#B5ZN>:O74A?J_9:V_-WF*!KRWI\4J0AKRZ0X?J^#(1L"9[\#Z$PAH0 MK"ZFJ_RRB2W+'/LJ_S;*'DORG#?')_ORGZ<'PRCT;\D4P=\3!+$//0J+,#VW MH*?1JL.\G<*YN;C8Z"MOE@#4*"/-^MF).N7102 M>#$%.*\+L+8KO=N3WNU);\">5*#SZ('013`2F),JVW?(FL2"WQ[M=PW7SQ`O M@`>G$/CBBJ*L/J;-24QJ,YC#P>.M,L@2@U)SG++/H/0#Q)GUA5[C1>KZ2;3U MJC6+`@(KOG`Q5[U5',FHP4GE4E/'RQX#QD[6D'*\P5;8MHBW2N-8;YVJBY4] MYHI<]L[E;A'_*MMWQKC$@MZ>"F3R9\05#)*8ZV^O/%9G#$9U,&O"#*'U+%V# MNG=HJ)^FK)&LMR_5QZN)>F5Z3E3Q/F7TL-[<)(:?7WF,_K&`,Z,G'"/7XY6T M$O7L-)\V^#=0M8SUTDFG@DOP"+P$$1J1[;OV?]Z!B9O%37$4N[E2BR[ZBG\) M(4G!J,V9K/=;X,B:#@U4XSITKQR\3=X$/S;4$)2V,OV6\>XC^_ZF\1;?-+** M%S3((`II!E'9MXVJ?EU\XV#@88UA=@<^H1F]LKTU;QPL:C-$7@8N;XTYMKUO M-,*E)M\XQ!%'%(BE&U!HF2ZPPCY&WR*8B[U"K!(@H8_B:S=-/`HKZI2R2,[M M9/TK@10*]CSUC,(8^GM2]_6K%R1$'J893^@22^+4D^ANNBN'C^:T.CWG"&MD M_,X\.32%K>#)J$*Y.:'P/!$-A?SG_P%02P,$%`````@`LWUN0VFUWU7:7 M[1T8AX%*8E9RK)1R)&5UY_SZXT-O2A2I1Y!97>)Y_^1(OK#;SB(OT(M7[[[[X=V+']'M MS^CD9'3'KYZ]D#N^2DBKU[=YKR]?O7OS]MVK5["]OGCY[O7;=Z_?`/?ZZMW+ MU[1C^%Y_?/?F!_!>7[^@`@7?ZVLJ4":]_DKP9]SL];MG/[)^[O9M97GYNNCH M^W>OWKQ[\QJB(ZJ5WQEI97]'70;@Y9M"%5^\>T-EY14Z7;ZKE^^H"M)Y`NF* M,O;Z-5!7;YC,@W3UZM6[%]\!=?6&22!(5]0LPW1%UYW7[UX:V:>175%)?_D] MDT"`KNA$???NQ0N(KF@_/[Q[\SU05S]2+8;IBLV5D6,PJ2NS%7)L5W2U>MEP M`4(2_7'OI1A1'S1*__VK39;MWCU__OGSYV=?[I/P69P\/'_UXL7KYT7#KT3+ M=U]2TFC]^771]N7S__[Y_2=_@[?>"8G2S(O\"HJAZ8)[^?;MV^?\5]HT)>]2 M#O\^]KV,>\6#=*'>%NRODZ+9"?OJY.6KD]+=O\L. M._SO7Z5DNPL9V?R[38+7W32$2?*P3Y_OTY,'S]L))*%WC\,"U5?/_X06H.XMX_[E]W7JWK-N91+;0_FV M@4L`41HA*+S%"8F#RV@>$HBFN00+1^P./& MMH2#&E-JJ/&X,:T@9Z0UD^DT'LAJ!-DZPCZ_I_TW*,-?,AP%S/R);QFDPI8+ M&\C6`+XTQ7X#6<@6@SAI\KE+=IL3MK:]>/OZ!>>$??/78N4\C:C:9R0[7$?K M.-GRQ>3T/LWH%C(K$''2.?J_ZL,^_U/!=(/&!*?Q/O&Q$<-BW)O$>/<&Q+#% ME4*RXR(LNT]I+[SDWA>/$E/\Y#K/2E>+FX.3%R$%R[_^*UU),\RHNO/N*W-9T_Z> MA@"JWDMB6U3*!NAWW@1>C%$**U5-?B*QRWBW()UU&\37]F.K(:-78AIS6 M255(`&N&>#O[`CN=9"N2*PE%K_2V)<)4@E/L/WN('Y\'F`CAI1_:,DN_^JNP M[!_Q`V$&/-LNJ]K;%$!>%62VISY?=ZMVB#6$EM;9"8:0U2%A*"1U0!*6 ME=-SJAF)%U[3[\(Z'\VP\MHC%++` M=DO$4A)[OD\2VN$527TO_`OVDLLHN*#6O4=H>YL#R:V"W+88Y$V1:(M88[KC M"=B]KA5;NQ#I4%($"AU01Z0DF6M[Q4)<7).>WN($[7M;;8$M;QM(GML&&^& MBG;VC.XLY,+:VTXQD*UMEPPL)9]WB<<"K3X=MO>Q--XY\DC`RU8ZH" MA/52U2STN7\<"G&P%1*`J`9IT8,%X0?8N]40LPY7=UC&EM*.XMCXCJ+MT8-& M$R");Y'5>WS/?KTGX#U=15Z?>:VV09(SMJ$ MM2>R_!VQ!C8D;1J%4++6.<%U8>N:W:5M6AF#HMC(=[<%MG)M0GO-B6AH=?L^ M-\W0UK!3*+K,8I=$+"VQXJ1`]'Q%O^NZCE*W!Y;<+H)[)2$_QLD%@C>W*<%S MTPXMR;W"TB7-?9("(]'L[$M?GJO65J2Y3NR0//`C241ZZ[4BQ)"#],MR6 M#@O1`C?K*Q)YD4^H1L4I&8AP,P*W$5&@9J?_POYFC4I`5$!:C'.;C;'8D#$K MT0D:0M@;KS`L@7!:=9JF.$LU]*?5$%!3)!*E31AOX(#H#U/ZZ=/EW2>;`MP] MWVU1[9QL.*$\]]+-:12P?R[_OB>/7DBU)CW-SKTD.9#HX5W)?23>?/9!UR!HF\^Q!E&K[Z=G:.L]M`# M8,T MY$8VLFW?30PDH"_B^_&>TO$1^YC2=!_B#SC+HSA4GHD*#-)/49,O^0)Y?1-A[L?_R^L?N";]`R?QBC9(=]C/R",.#Y:,^]QS MU&/(03TZ#:V1_+MAE8%3^^OHD78;)P=*@T+-&\T`U;I%7EM$RI^Y8-C267TB MF6;:=;",!M0!!>N2S[9"=0@GG`+=)GCGD>#RRPY'*:;K^DVVP8G8PPTOGSK0 M@.JFQTQ;:'(HE(/Q18<#(@%I?5&=QA868"GG*^9\^7ETKL=1V-0/`_%KJXV^ M[$&?B&FXG;8T9$AH')'X(3*Y71\08R"G<`9*X<_PAEP\JTIT12*2X??4U0^N MHXP.)J$^IB!)[>4-``*JV2`+;3$1`"<<`E4@Y0IDT3TTYJ5&/I?W%0J)SVQT M@#+L;Z(XC!\.N1_YVI(?N<0$.>!NZJE.6]VU]`;2)8UW.,D.MW0">%*$O^_) MCMU]J;5?"0;JA"K)E]TTT7R%.(!(:U&`6%7\T8SL2D9PQ4A^JN/Y_GZ[#UFR M'A3@78)](M*1\!.?U0]OO^>`]./W+WYL'OM8WGK:&([OWKPMAN/UCV^AAL/@ M)F!V85^AL_(>X,P+63H\>[<`"W!WR9\&]+$&N_4:-K/RGFO0QD)OM@9W6?#; MJ]Y]E=WME&*[M\R-HL$&JG?GY,J.2;U5`I?]]\2[)R')"-:)O^EJ#:@5W<2V MY[O6RH%P'$V:KT_/KM]?WUU??D*G'R[0I[N;\__\\\W[B\N/G[Y&E__UR_7= M7VS*KD),VH+<+R/PE[BWWH'=*^E?W[8`+%S<2B3W7@?F+>V?L1E3OA,M[=Z^ MCA]H!_;G:@'ONVGME&Y0K4SV./@8'[R0F0R$@-7+'J([Y(6U1&53%S33 MD/:D:)IO"M](FT)@*5<)3(>8*Z0%7,Y_]I(_<$8W:>=QJG67HP*#E_@^\OM$ MIVR/.(`KPF_*AA=0_!E)&2/51:<7AO%GMM&VNX/0$*P>I5!)%9QF\)O5FH,X MK!1]$(#ZT$]T6X;$97^MJ74E,*6]N%\,*Q`[7MH"A$-JZH"@MY54+>563@.& M5=.N5FK)ADNJJ$5P\Y;?NA;.2[.E`XL!W7-`[5CR'Y)M>?A[%)S'$5NH<>13 MDA3ZIX*"?%:D)%YZUU"U%N]4ZNVMO1Z:Q()?;^_$ODE#GJ3'&(/"!/G(.O;_ MV,1A@).470QE!ZVGU;U`H`^J%:3+KXVKQDBT1J=9EI#[?<9?,-S%Z-;C5M7^ M.;899QW'U^_L/ID>$BGYH?2`/,$N#WENN,%'I^VFP`M!B\PNTUEE[LM?(5ZG M*=V@VK3]1E3_R[,7+UY\AW9>@AX9P+\B;Y]MXH3\`P?HNQ`8,+[SU2'`=G7L[0@6Z1I?JW'88&/+T5H<5 MZ?"S!$(,"EU'*(=;-;*M6CO+G<@4>]]Q0J(37\#9-%2SS`_IF1^G[-C"G+IC MYO2MAW0XKVLZX$SA1YQY),+!I9K%]^)`X(WJ^_?B+^ZS@?R`^;OK+[6&#\_3IFQ*6RHC=1X'IIUR`'% MKOIKV6.IWN+U#G()N=;TF^?VVM)KFVU>T1A=S=B]DIET%>/._4OO57Q::_HU M?RN863I6=HUH@R5.BW3K*]@4*NW>O^G?NUE]$Q4%1J9N$-32:ZD>-E1/I]AJ MV6$6'0B?FH.;KW-VK#Y9A.7)UGLQE0JI'H\I]$?'%NR2W89K^(NWKU]P_6;? M_#4WAI\V&+,',6Q)W^",^%ZH"#+1A030;GTF>I8!)*!0`\QB@,GQ,13DQ2AX M@@4PCI[9T&=#E2G4V4Q?`.]YBV<<5W%R$>_OL_4^E-.0:CS5,<(#>?MKR*!T M4U#`(XH`%1A09PI:V^][9F-U35GUNA((DP@%<1AZ26KW&=P8J96N&D>(+.B3 MN>IXO,I>0S^'F)/;L02D@NDF0 M`!4WC:S>J*AQ[T"$_&C&RFCY^KK)"MB(:SCKKZ4TI5`1N#P@@E:4BA.0GI;/ M$_2428*RHT0=Q*ME3`"@"L(!A3%F0MQ*UYZ4.*(9?:*DT(@>.;*H">*%A(D6 MY!`V-:`D6D?Z'7I-941]+O9D&>)-GT!-&'@'[EX&Q'Y08QLR;RD\45"BT-2N MUK8"%$MBAT+'1$,G0A2':4X;FLG<-O'1GNP4FQHRJ M`WYKC\1*`8*=X@JYJTRSF_5/<1SP$"6Q9CD`8A#V=IBF/,1K)[1R`<)A=Y5#8B]O+`=D'DYG?TKB-+U-XK7R M]7*]%:!6-HEK2P+_%8F?;>F<#H6[92C44JWQ]$%J4(<0ME5&ED#`W+QT[^JQ MK&]Y(52=>B#],)#Y>16$2\EBB[9%D5X72H2,8Z`HQVLUK]J@T$B9;@F!Q?VFRK[2ZG]3:1SJS>=2BUNJSYUE)MKK;U=[EVM,V<1_Y/DZU]*W6VH;& M-8CM%XG\IO@;UM!:)D8]H@M20T8J8B*%8@$81[9**\U/N!4EE"6[5PTEL8:, M.,DPG4KVT()7>1*D*'2Q!P`TWJ2'9%E&1$/N*8DZ7**MO6"3,92+$G]D&+.GIN*F-')G>!TG6+2[\[[@]/(+ MW1#'24`B+SE<9WB;?J`#1"'I8(7\1Z1%67 MJ.H3B4X+]X!WNT*-CA'O>86:?:.B<[M!S%HPHR@C.&V'VZWJ%YV MA^PMJ9309HW2F.\\SG"$U5$/?1#@YJ2+Z![1I4V+?2'Z)F]M;2-@3#W5,?3- M?4YU'MSSO:6HI(6(A[<8O2+?K>U]\@ZGJ1]PIK4W;[8#U,HV@5WAKLVEV:V, MJ3KTLR70CN+I4$?J"[6M%-,3Q2#K$P-($]&I:VW#T*5H<.:@*!10O!L_\U+B MLY-[$N[I+&D$8^EB`#0A^DRUI:JL$5&F/U@A#BWNQ@2\`[%;XSD4W#14O$J( M8#6HRU`4VWID)H?.:-AXS7)(H\9JDJ/JH[,N:F84@5G5X?AQR"",-`1N&`!^ M!GE!4I\._C[1BGHVPV/;."@8U#85J_QTOX;&U;77@-W?,'G8,#?"HQUZ#QCY M(K%#_N0]WF=IYO&7UNXMQT-BJZ6+`S([(@2<@ M@\K%/9;57FG,$97E+H4TUG#97[YG9;SB)LC=^B6332B7\2/F2RLI^5RLW6UP M:32C_?:>+@WLL6(]B8^XH:P);;;Q,D0;H'V*>5U7WPM]EK60_5A87I8:`MU+ M`W=Y^VF%`ISA9,LK"-(6]/\I`#5@*"-;AH(2P'KF&9UKQ(@V(B^'O13JD^QA M(ZOZ%&,(61\JSW]PLY:+.&BX6'KPH%6D]!B2"TL5V2QNUEWE5!QPHZ:S%J\[ MZY`XDL##2!;E+5'(E96\CS]CYIPH-$)N:R?78TFH*MD@^ETTLRH@ MO:.K2"S8&%K`JA)!0)@[[(6W'@FNHW-O1ZCW/R@4:CC(^@\##,AOZHKVB`&< M7$Z6CFHG1"-!2CK$P^:4DHI%VZRE.7VD)ZYQV$2FYLGHJT MULJ:!ZY!;E%9SY$\MFZ1K%-H>!Z"07HF[5YZ=`W24?W;/LW8!BJ]BWL< M'DXE/_ADVRL6`XXJ!SQ/WGQRQH^NZWVO4-E[D6(1B?Y1C0!KM=7@QU0,E#CC M]VL(BY17=K*`N>DNM,HQ M.631H^R#WIU/$'CI>GV\M(,^2$:UW%R.0P3Z7-F>UZS40E^L"#3H[H&\8)BK5WZ(J M!5J%S0'-GH5USO::+Z_U;&,L@W8);O4=QGA9[GAI/$Z0+=U(L,/"R"`=G7G"3V;HYQ"S#RSY^39.,O*/ MSA.;VGAK@0.:($UVVKI0!UNA$E`DN*^!VC(),[#%>?&6Y$7K;?C"$S1[2F>S M-#'`X@=I64T,1=M2&E@)X$"TL_9%\5`TF@P`'9+617)W\(`<96$U.$V?3 M'6[I]/"'<+N>R`-#!)`5R719DLIB4<#BY.$F0@R::5@!CS@"5&*P5J5L$G\L MM(`Q%J^11Z705K';.>8HSNC:IQZFN`!#8;M3YK'5F2I;O'ZZAVWEJ^Q[1^V#J)S_,-_4OD5ZF=A#)5 M$Y5:0^+=D]#^J:BYG';DBS834IM*>.K[\3[*F(.$R2-+P&ND?AW@5A6ODQU- ME2M@407LCJ9I,59RD"S`@=EJO!P'=HU!O[X,FX%>9;%I`*ZC1^H.Q&QK9*3Y M=3BK*M]D0%/7:T#NZ/@0)^+7@[6Z#Y,'GC0&WO)^8;;QMVN0.O1WV!+)RNN" M#W+K'48[(`6L$]Y'Q8BIZY%#NF.3AEDJ:=\M1/M(\S1N,H@\&<[9J>ESXH8/ MU=)W?0>JJ>P3GH5U=I'L.8*+KR`]I.1E)\\E.4PO>+BP-)#TO%\L1@^GQ^KH$`\U:LRUQ9Y;+TM MTQAVK*D["LC+ZGAP)&?!7=KT69IOL$=LAF:G\73-S.98/=]EP]T^^J(R:W:^ MVX?$[OEN/VNZY[M<%FM1M=5)Z/OJ)'3%XG3=<08-V!;\#9WTKEC0K"L.X\1) M)98F=:HWZ?JD-OF[6WQN)S!I^9YBP-YJW%.HC:V+K\`4BXD!$B=???5X?(:/ M--Q_XM7GV9H]I;!6E',&+HL"%SI\N?F`K<_&&.N@=1O#CD;3N5Z:JI#9MSEJ M5@UM3XG,K0=BL[#>?FE*2EX=>=.V*G#J569P[-[=\T[=ZKEB8 M*Q)YD3_3V8P*F7V+HV;5T/*4R([B;,:,]?;9S+KDU>VS&0U9UE3884&&/YNY MBI./>$?E9N.EU'<151XUCF.ZX2R

XML 17 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents (Note 2)	$ 1,815	$ 5,541
Accounts receivable (net of $37 and zero, respectively)	4,172	3,219
Inventory, net (Note 2)	3,414	2,688
Prepaid expenses and other current assets	1,104	1,747
Total current assets	10,505	13,195
Intangible asset, licensed technology (Note 3)	3,577	3,577
Property, plant and equipment, net of accumulated depreciation of $3,796 and $3,608, respectively (Note 2)	2,452	2,307
Total assets	16,534	19,079
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	537	885
Accrued royalties (Note 4)	3,524	3,524
Accrued advertising and other allowances	2,143	2,959
Other current liabilities	439	485
Total current liabilities	6,643	7,853
Commitments and contingencies (Note 4)	0	0
STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000; issued: 20,172,393 and 20,161,636 shares, respectively	10	10
Additional paid-in-capital	41,760	41,552
Accumulated deficit	(6,242)	(4,699)
Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively	(25,637)	(25,637)
Total stockholders' equity	9,891	11,226
Liabilities and Stockholders' Equity, Total	$ 16,534	$ 19,079

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (1,543)	$ (877)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	188	297
Share-based compensation expense	208	316
Bad debt expense	37	0
Gain on sale of asset	0	(28)
Changes in operating assets and liabilities:
Accounts receivable	(990)	402
Inventory	(726)	(1,836)
Accounts payable	(348)	237
Accrued advertising and other allowances	(816)	(605)
Other operating assets and liabilities, net	597	(951)
Net cash used in operating activities	(3,393)	(3,045)
Cash flows from investing activities:
Capital expenditures	(333)	(288)
Proceeds from the sale of fixed assets	0	166
Net cash flows used in investing activities	(333)	(122)
Cash flows from financing activities:
Purchase of treasury stock	0	(449)
Net cash used in financing activities	0	(449)
Net decrease in cash and cash equivalents	(3,726)	(3,616)
Cash and cash equivalents at beginning of period	5,541	8,232
Cash and cash equivalents at end of period	1,815	4,616
Common stock issued in lieu of cash, as payment of accrued compensation	$ 0	$ 294

XML 19 R22.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011
Deferred Tax Assets Benefits For Option and Warrant Exercises	$ 6.3
Deferred Tax Assets, Operating Loss Carryforwards, Domestic		31.6
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 20.0
Operating Loss Carry Forwards Expiration Start Date	2020
Operating Loss Carry Forwards Expiration End Date	2031
State and Local Jurisdiction [Member]
Operating Loss Carry Forwards Expiration Start Date	2018
Operating Loss Carry Forwards Expiration End Date	2031

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

+ References+ Details

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References+ Details

XML 20 R24.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Details Textual) (USD $)	3 Months Ended		9 Months Ended
Earnings (Loss) Per Share (Details Textual) (USD $)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Warrants and Options Outstanding	1,293,000	1,281,250	1,293,000	1,281,250
Common Stock Equivalents [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	144,943	0	86,328	53,517

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 22 R7.htm IDEA: XBRL DOCUMENT

Organization and Business

9 Months Ended

Sep. 30, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Organization and Business

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

XML 23 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets [Parenthetical] (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Allowance for accounts receivable (in dollars)	$ 37	$ 0
Accumulated depreciation (in dollars)	$ 3,796	$ 3,608
Common Stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common Stock, shares authorized	50,000,000	50,000,000
Common Stock, shares issued	20,172,393	20,161,636
Treasury stock, shares (in shares)	5,336,053	5,336,053

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References+ Details

XML 24 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		1 Months Ended	3 Months Ended		9 Months Ended							9 Months Ended	12 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2010 Limited Liability Company Agreement [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2011 Stock Options [Member]	Sep. 30, 2012 Stock Options [Member]	Sep. 30, 2011 Stock Options [Member]	Sep. 30, 2012 Estimated Future Sales Return [Member]	Dec. 31, 2011 Estimated Future Sales Return [Member]	Sep. 30, 2012 Cooperative Incentive [Member]	Dec. 31, 2011 Cooperative Incentive [Member]	Dec. 31, 2011 Other Advertising and Marketing Promotions [Member]	Sep. 30, 2012 Accounts Receivable [Member] Five Customer [Member]	Dec. 31, 2011 Accounts Receivable [Member] Five Customer [Member]	Dec. 31, 2011 Accounts Receivable [Member] Two Customer [Member]	Sep. 30, 2012 Accounts Receivable [Member] Three Customer [Member]	Sep. 30, 2012 Sales Revenue, Goods, Net [Member]	Sep. 30, 2011 Sales Revenue, Goods, Net [Member]	Sep. 30, 2012 Building and Building Improvements [Member] Maximum [Member]	Sep. 30, 2012 Building and Building Improvements [Member] Minimum [Member]	Sep. 30, 2012 Machinery and Equipment [Member] Maximum [Member]	Sep. 30, 2012 Machinery and Equipment [Member] Minimum [Member]	Sep. 30, 2012 Software [Member]	Sep. 30, 2012 Furniture and Fixtures [Member]	Sep. 30, 2012 Advertising and Incentive Promotion Costs [Member]	Dec. 31, 2011 Advertising and Incentive Promotion Costs [Member]
Inventory, Work in Process and Raw Materials	$ 1,400,000		$ 1,400,000		$ 981,000
Inventory, Finished Goods	2,000,000		2,000,000		1,700,000
Property Plant and Equipment Useful Life																							39 years	15 years	7 years	3 years	3 years	5 years
Cash	1,800,000		1,800,000
Due from Banks	2,400,000		2,400,000
Cash, FDIC Insured Amount	766,000		766,000
Cash, Uninsured Amount	1,600,000		1,600,000
Concentration Risk, Percentage																	68.30%	52.70%	34.40%	56.20%	92.00%	95.00%
Sales Allowances, Goods			93,000		101,000
Accrued Liabilities												1,300,000	1,700,000	822,000	1,000,000	279,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.0005		$ 0.0005
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			10 years
Share-based compensation expense			208,000	316,000				45,000	125,000	208,000	316,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage							50.00%
Marketing and Advertising Expense	1,300,000	1,700,000	5,500,000	3,900,000
Prepaid expenses and other current assets	1,104,000		1,104,000		1,747,000																								947,000	1,200,000
Research and development	165,000	198,000	1,055,000	594,000
Allowance for Doubtful Accounts Receivable	$ 37,000		$ 37,000		$ 0	$ 0

XML 25 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012	Nov. 13, 2012
Entity Registrant Name	ProPhase Labs, Inc.
Entity Central Index Key	0000868278
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	prph
Entity Common Stock, Shares Outstanding		14,836,340
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2012
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2012

XML 26 R18.htm IDEA: XBRL DOCUMENT

Investment in Phusion Laboratories LLC (Details Textual) (USD $)					1 Months Ended	9 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010	Sep. 30, 2011 PSI Parent [Member]	Sep. 30, 2012 PSI Parent [Member]	Sep. 30, 2012 Corporate Joint Venture [Member]
Stock Issued During Period, Shares, New Issues						1,440,000
Stock Issued During Period, Value, New Issues						$ 2,600,000
Payments to Acquire Interest in Joint Venture						1,000,000
Treasury stock purchase (in shares)					690,000
Maximum Amount Committed Towards Contributions In Joint Venture							2,000,000
Cash and Cash Equivalents, At Carrying Value	1,815,000	5,541,000	4,616,000	8,232,000			388,000
Acquisition of product license							3,600,000
Finite-Lived Intangible Assets, Useful Life (in years)							10 years
Common Stock Number Of Share Transferred To Thired Party					750,000
Equity Redemption ,Number Of Share, Redeem					690,000
Equity Redemption Price Per Share					$ 0.65
Equity Redemption Value					$ 448,500

XML 27 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net sales (Note 2)	$ 5,415	$ 5,083	$ 13,328	$ 9,992
Cost of sales (Note 2)	2,016	1,487	4,763	3,508
Gross profit	3,399	3,596	8,565	6,484
Operating expenses:
Sales and marketing	1,035	1,158	5,032	3,376
Administration	1,126	1,134	4,027	3,417
Research and development	165	198	1,055	594
Operating Expenses, Total	2,326	2,490	10,114	7,387
Income (loss) from operations	1,073	1,106	(1,549)	(903)
Interest and other income	1	4	6	26
Income (loss) before income taxes	1,074	1,110	(1,543)	(877)
Income tax (benefit) (Note 6)	0	0	0	0
Net income (loss)	$ 1,074	$ 1,110	$ (1,543)	$ (877)
Basic income (loss) per share:
Net income (loss) (in dollars per share)	$ 0.07	$ 0.07	$ (0.10)	$ (0.06)
Diluted income (loss) per share:
Net income (loss)	$ 0.07	$ 0.07	$ (0.10)	$ (0.06)
Weighted average common shares outstanding:
Basic and diluted (in shares)	14,836	15,113	14,804	14,901

XML 28 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Income Tax Disclosure [Text Block]

Note 6 – Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

XML 29 R11.htm IDEA: XBRL DOCUMENT

Transactions Affecting Stockholders' Equity

9 Months Ended

Sep. 30, 2012

Stockholders Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 5 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

The 1997 Option Plan

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 (the “2010 Equity Compensation Plan”). The 2010 Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued is equal to 900,000 shares plus up to 900,000 shares that are authorized for issuance, Issued Options (defined below) but unissued under the 1997 Plan, an aggregate of 1.8 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made; however, as of March 31, 2010, there remained 1,449,750 shares subject to vested options that were authorized for issuance (the “Issued Options”) but were unissued under the 1997 Plan. As of September 30, 2012, 1,331,000 of the Issued Options under the 1997 Plan expired unexercised or were terminated (the “Expired Options”). As a consequence, these options are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Equity Compensation Plan and the remaining 431,000 options are deemed cancelled. For the three months and nine months ended September 30, 2012, no options were granted pursuant to the 2010 Equity Compensation Plan. For the three months and nine months ended September 30, 2011, we granted 524,329 options, to employees pursuant to the 2010 Equity Compensation Plan. At September, 30, 2012, there are 13,659 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

The 2010 Directors’ Equity Compensation Plan

Stock Option Exercises and Other Grants

Pursuant to the terms of Robert V. Cuddihy, Jr.’s, our Chief Operating Officer and Chief Financial Officer, initial employment agreement dated August 19, 2009 which terminated effective January 1, 2012, Mr. Cuddihy received an annual grant of shares of Common Stock that is equal to $50,000, payable quarterly,promptly following the close of each quarter calculated based on the average closing price of our Common Stock for the last five (5) trading days of the quarter. For the three months and nine months ended September 30, 2011 Mr. Cuddihy earned 15,665 shares and 40,885 shares, respectively, valued at $12,500 and $37,500, respectively, as share-based compensation. In January 2012, we issued to Mr. Cuddihy 10,757 shares valued at $12,500 that were earned in Fiscal 2011 as share-based compensation pursuant to the terms of the initial employment agreement.

There were no stock options exercised for the three months or nine months ended September 30, 2012 or September 30, 2011.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

XML 30 R23.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Basic earnings (loss) per share - Income	$ 1,074	$ 1,110	$ (1,543)	$ (877)
Basic earnings (loss) per share - Share (in shares)	14,836	15,113	14,804	14,901
Basic earnings (loss) per share - EPS (in dollars per share)	$ 0.07	$ 0.07	$ (0.10)	$ (0.06)
Dilutives:
Diluted Options - Income	0	0	0	0
Diluted Options - Share (in shares)	0	0	0	0
Diluted Options - Earnings Per Share (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Diluted loss per share - Income	$ 1,074	$ 1,110	$ (1,543)	$ (877)
Diluted loss per share - Share (in shares)	14,836	15,113	14,804	14,901
Diluted loss per share - EPS (in dollars per share)	$ 0.07	$ 0.07	$ (0.10)	$ (0.06)

XML 31 R19.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) (Employment Contracts [Member], USD $) In Thousands, unless otherwise specified	Sep. 30, 2012
Employment Contracts [Member]
2012	$ 256
2013	1,025
2014	1,025
2015	555
2016	0
2017	0
Total	$ 2,861

XML 32 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Contingency Obligation [Table Text Block]

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2012, as follows (in thousands):

Fiscal Year	Employment Contracts
2012	$	256
2013		1,025
2014		1,025
2015		555
2016		-
2017		-
Total	$	2,861

XML 33 R13.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 7 – Earnings (Loss) Per Share

	Three Months Ended						Three Months Ended						Nine Months Ended								Nine Months Ended
	September 30, 2012						September 30, 2011						September 30, 2012								September 30, 2011
	Income		Shares		EPS		Income		Shares		EPS		Loss			Shares		EPS			Loss			Shares		EPS
Basic earnings (loss) per share	$	1,074		14,836	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,804	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

Dilutives:
Options		-		-		-		-		-		-		-			-		-			-			-		-

Diluted loss per share	$	1,074		14,836	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,804	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 34 R14.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2012
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block]	*Basis of Presentation* The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2011. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of operating results that may be achieved over the course of the full year.
Nature Of Operations [Policy Text Block]	*Seasonality of the Business* Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines and retail customers’ balance their inventory positions as cold season consumer demand subsides. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates. Our primary product, Cold-EEZE^Òlozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® lozenges we market and distribute Cold-EEZE^®Oral Spray, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts® and Kids-EEZE^® soft chew children’s OTC cold remedies (“Kids-EEZE^® Products”). We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Oral Spray products, Cold-EEZE® Cold Remedy Daytime/Nighttime QuickMelts®, Kids-EEZE^® Products and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.
Inventory, Policy [Policy Text Block]	*Inventory Valuation* Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At September 30, 2012 and December 31, 2011, inventory included raw material, work in progress and packaging amounts of $ 1.4 million and $981,000 respectively, and finished goods of $2.0 million and $1.7 million, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	*Property, Plant and Equipment* Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - fifteen to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.
Concentration Risk Disclosure [Policy Text Block]	*Concentration of Risks* Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC drug, personal care or other products in order to continue to compete on a national level and/or international level. Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedyproducts are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States. Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable. We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2012, our cash balance was $ 1.8 million and our bank balance was $2.4 million. Of the total bank balance, $766,000 was covered by federal depository insurance and $1.6 million was uninsured at September 30, 2012. Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large wholesalers, mass merchandisers and multi-outlet pharmacy and chain drug stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. Our largest accounts receivable balances are with five customers representing approximately 68.3% and 52.7% of total trade receivable balances at September 30, 2012 and December 31, 2011, respectively. Three of such customers represented approximately 56.2% of total trade receivable balances at September 30,,2012.Two of such customers represented approximately 34.4% of total trade receivable balances at December 31, 2011, respectively. Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 92% and 95% of total revenues for the nine months ended September 30, 2012 and 2011, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and nine months ended September 30, 2012 and 2011, our net sales were principally related to domestic markets. Raw materials used in the production of our products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE^® products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable to supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	*Long-lived Assets* We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors. Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.
Fair Value of Financial Instruments, Policy [Policy Text Block]	*Fair Value of Financial Instruments* Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments. Determination of fair value of related party payables, if any, is not practicable due to their related party nature.
Revenue Recognition, Policy [Policy Text Block]	*Revenue Recognition* Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history. As of September 30, 2012 and December 31, 2011, we included a provision for sales allowances of $93,000 and $101,000, respectively, which are reported as a reduction to account receivables. We also included an estimate of the uncollectability of our accounts receivable as an allowance for doubtful accounts of $37,000 and zero as of September 30, 2012 and December 31, 2011, respectively. Additionally, accrued advertising and other allowances as of September 30, 2012 included $1.3 million for estimated future sales returns and $822,000 for cooperative incentive promotion costs. As of December 31, 2011 accrued advertising and other allowances included $1.7 million for estimated future sales returns, $1.0 million for cooperative incentive promotion costs and $279,000 for certain other advertising and marketing promotions.
Shipping and Handling Cost, Policy [Policy Text Block]	*Shipping and Handling* Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.
Compensation Related Costs, Policy [Policy Text Block]	*Stock Compensation* We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period. Stock and stock options for the purchase of our common stock, $0.0005 par value (“Common Stock”), have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 5). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended September 30, 2012 and 2011, we charged to operations $45,000 and $125,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the nine months ended September 30, 2012 and 2011, we charged to operations $208,000 and $316,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	*Variable Interest Entity* On March 22, 2010, the Company, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.
Advertising and Incentive Promotions [Policy Text Block]	*Advertising and Incentive Promotions* Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of media advertising, presented as part of sales and marketing expense, cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and free product, which is accounted for as part of cost of sales. Advertising and incentive promotion costs incurred for the three months ended September 30, 2012 and 2011 were $1.3 million and $1.7 million, respectively. Advertising and incentive promotion costs incurred for the nine months ended September 30, 2012 and 2011 were $5.5 million and $3.9 million, respectively. Included in prepaid expenses and other current assets was $947,000 and $1.2 million at September 30, 2012 and December 31, 2011, respectively, relating to prepaid advertising and promotion expenses.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended September 30, 2012 and 2011 were $165,000 and $198,000, respectively. Research and development costs for the nine months ended September 30, 2012 and 2011 were $1.0 million and $594,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.
Income Tax, Policy [Policy Text Block]	*Income Taxes* We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 6). We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively. As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2004 through 2011 remain open to examination by the major taxing jurisdictions to which we are subject.
New Accounting Pronouncements, Policy [Policy Text Block]	*Recently Issued Accounting Standards* In June 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-05, “Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income,” (“ASU 2011-05”) which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders’ equity. Instead, comprehensive income must be presented in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 is effective for fiscal periods beginning after December 15, 2011. The adoption of ASU 2011-05 did not have a material impact on our consolidated financial position, results of operations or cash flows. In September 2011, the FASB issued Accounting Standards Update No. 2011-08, “Intangibles – Goodwill and Other Topics” (“ASU 2011-08”) which provides authoritative guidance on testing goodwill for impairment that became effective beginning January 1, 2012, with earlier adoption permitted. The revised standard is intended to reduce the cost and complexity of the annual goodwill impairment test by providing entities an option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under ASU 2011-08, an entity would not be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The amendments include a number of events and circumstances for an entity to consider in conducting the qualitative assessment. The adoption of ASU 2011-08 did not have a material impact on our consolidated financial position, results of operations or cash flows.

XML 35 R16.htm IDEA: XBRL DOCUMENT

Earnings (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

	Three Months Ended						Three Months Ended						Nine Months Ended								Nine Months Ended
	September 30, 2012						September 30, 2011						September 30, 2012								September 30, 2011
	Income		Shares		EPS		Income		Shares		EPS		Loss			Shares		EPS			Loss			Shares		EPS
Basic earnings (loss) per share	$	1,074		14,836	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,811	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

Dilutives:
Options		-		-		-		-		-		-		-			-		-			-			-		-

Diluted loss per share	$	1,074		14,836	$	0.07	$	1,110		15,113	$	0.07	$	(1,543	)		14,811	$	(0.10	)	$	(877	)		14,901	$	(0.06	)

XML 36 R21.htm IDEA: XBRL DOCUMENT

Transactions Affecting Stockholders' Equity (Details Textual) (USD $)	9 Months Ended	3 Months Ended	9 Months Ended				3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011 Chief Operating Officer and Chief Financial Officer [Member]	Sep. 30, 2012 Chief Operating Officer and Chief Financial Officer [Member]	Sep. 30, 2011 Chief Operating Officer and Chief Financial Officer [Member]	Sep. 30, 2012 Plan 1997 [Member]	Mar. 31, 2010 Plan 1997 [Member]	Sep. 30, 2012 Plan 2010 [Member]	Sep. 30, 2011 Plan 2010 [Member]	Sep. 30, 2012 Plan 2010 [Member]	Sep. 30, 2011 Plan 2010 [Member]	Sep. 30, 2012 Directors Plan 2010 [Member]	Sep. 30, 2011 Directors Plan 2010 [Member]	Sep. 30, 2012 Directors Plan 2010 [Member]	Sep. 30, 2011 Directors Plan 2010 [Member]
Option Indexed to Issuer's Equity, Strike Price	$ 45
Minimum Percentage Of Common Stock To Be Acquired To Exercise Rights	15.00%
Percentage Of Discount On Market Value Of Share By Exercise Of Rights	50.00%
Cash Less Exercise Of Right Terms	In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company.
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant					4,500,000		1,800,000		1,800,000
Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms	No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					99,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						1,449,750
Allocated Share-based Compensation Expense												$ 41,000		$ 122,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							900,000		900,000		250,000		250,000
Stock Issued During Period, Shares, Share-based Compensation, Gross		15,665	10,757	40,885
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period									13,659				17,605
Stock Issued During Period, Value, Share-based Compensation, Gross		12,500	12,500	37,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period					1,331,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period									431,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							0	524,329	0	524,329	0	49,160	0	114,010
Common Stock Value Issued For Payable			$ 50,000

XML 37 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (USD $) In Thousands, except Share data	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2011	$ 10	$ 41,552	$ (4,699)	$ (25,637)	$ 11,226
Balance (in shares) at Dec. 31, 2011	14,825,583
Net loss	0	0	(1,543)	0	(1,543)
Share-based compensation expense	0	115	0	0	115
Common stock granted pursuant to employment agreements	0	93	0	0	93
Common stock granted pursuant to employment agreements (in shares)	10,757
Balance at Sep. 30, 2012	$ 10	$ 41,760	$ (6,242)	$ (25,637)	$ 9,891
Balance (in shares) at Sep. 30, 2012	14,836,340

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A91

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 39

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References+ Details

XML 38 R10.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 4 – Commitments and Contingencies

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2012, as follows (in thousands):

Fiscal Year	Employment Contracts
2012	$	256
2013		1,025
2014		1,025
2015		555
2016		-
2017		-
Total	$	2,861

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies (Details Textual) (USD $) In Millions, unless otherwise specified	Sep. 30, 2012	Dec. 31, 2011
Percentage Of Royalty Fee Paid On Sales Less Certian Deductions	3.00%
Percentage Of Consulting Fee Paid On Sales Less Certian Deductions	2.00%
Accrued Royalty and Consulting Fees	$ 3.5	$ 3.5